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 Obesity is associated with a worse breast cancer prognosis, particularly in 
estrogen receptor alpha (ER) positive, postmenopausal patients. It has also been 
correlated with elevated levels of inflammation, which can stimulate adipose tissue 
aromatase expression and subsequent estrogen production. Given that obese 
patients have a lower response rate to aromatase inhibitor treatment and greater 
mammary tissue aromatase levels, it was hypothesized that obesity promotes ER 
positive postmenopausal breast cancer progression in part via an inflammation-
induced increase in mammary tissue aromatase expression and ER activity. 
These studies utilized an in vitro model of obesity in which cultured cells were 
exposed to postmenopausal breast cancer patients’ serum samples, pooled by 
body mass index category (Obese (OB): ≥30.0 kg/m2; Normal weight (N): 18.5-
24.9 kg/m2). OB versus N patient sera induced greater breast cancer cell (BCC) 
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aromatase expression, as well as higher ER activity and cell viability in the 
presence of testosterone, the substrate for aromatase. Pre-adipocytes exposed to 
OB versus N patient sera also indirectly stimulated greater BCC aromatase 
expression, ER activity, and viability. A retrospective review of breast cancer 
patient data demonstrated that daily use of non-steroidal anti-inflammatory drugs, 
which inhibit cyclooxygenase-2 (COX-2) activity, is associated with reduced ER 
positive breast cancer recurrence in obese and overweight women. The 
mechanisms mediating this effect were examined using the same in vitro model. 
Exposure to OB versus N patient sera stimulated greater macrophage and BCC 
COX-2 expression and prostaglandin E2 production, leading to enhanced pre-
adipocyte aromatase expression. These OB patient sera-induced effects were 
further linked with greater BCC ER activity, proliferation, and migration in the 
presence of testosterone, and these differences were eliminated or reduced with 
aromatase inhibition. Based on these findings, prospective studies designed to 
examine the clinical benefit of NSAID use in obese ER positive postmenopausal 
breast cancer patients are warranted. Additional obesity-associated mechanisms 
that may also promote breast cancer progression were also explored, including 
enhanced cross-talk between non-genomic ER and growth factor signaling 
pathways, reduced estrogen receptor beta expression, and resistance to 
chemotherapy. Finally, the impact of obesity on tumor incidence and 
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characteristics in the MMTV-Wnt1 mouse model of mammary carcinogenesis was 
explored. 
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Chapter 1: Introduction 
 
1.1 Breast Cancer Prevalence and Mortality 
Breast cancer is the most common form of cancer in females, accounting for 
almost one out of every three cancers diagnosed in United States women. Based 
on current incidence rates, the National Cancer Institute estimates that 12.4% of 
women born in the United States today will develop breast cancer at some point in 
their lives (1).  Rates of both in situ and invasive breast cancer have surged over 
the last 30 years (1), largely due to improved detection with the growth of wide-
spread mammography screening (2). However, increases in the prevalence of 
some breast cancer risk factors, including obesity, may have also contributed to 
this trend (3-6). In contrast with this rise in incidence, breast cancer mortality has 
been decreasing, with a 2.2% decline per year between 1990 and 2007 (1). This 
improvement has also been attributed to increased early detection with 
mammography (7-9), though a recent study found that such screening does not 
promote breast cancer survival (10). Advancements in the treatment of breast 
cancer are a likely additional driver of the decline in mortality.  
While numerous factors contribute to an individual woman’s breast cancer 
risk, the strongest risk factor is age. Consequently, breast cancer is more prevalent 
among postmenopausal women, with the highest incidence rates found among 
women 75-79 years of age (1). However, younger women tend to have more 
aggressive tumors and lower survival rates (11). Postmenopausal women are most 
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likely to develop the luminal A subtype of breast cancer (12), which expresses both 
estrogen receptor alpha (ER) and the progesterone receptor (PR). Luminal A 
cancers, the least aggressive of the four major breast cancer subtypes, are 
associated with a favorable prognosis, largely because they tend to respond well 
to endocrine therapies targeting estrogen production or ER itself (13). Patients 
with tumors that do not express ER/PR have a 1.5 to 2-fold higher risk of mortality 
(14). Listed in order of increasing aggressiveness, the other subtypes are luminal 
B (ER positive, PR negative), HER2 receptor over-expressing (ER/PR positive 
or negative), and triple negative (ER, PR, and HER2 negative) (13). While HER2 
over-expressing tumors are still considered to be more aggressive than Luminal A 
or B, the prognosis for women with this breast cancer subtype has greatly 
improved in recent years with the introduction of drugs that specifically target the 
HER2 receptor (15). In contrast, triple negative breast cancers continue to be 
associated with a negative prognosis due to the lack of druggable targets in these 
tumors. While patients with luminal A cancers do tend to have the best prognoses, 
there are additional factors that can contribute to a poor breast cancer outcome, 
including obesity.   
1.2 The Obesity Epidemic  
Multiple measures of adiposity can be employed in order to define obesity, 
including waist to hip circumference ratio and body fat percentage. The latter may 
be assessed by skin caliper measurements, dual-energy x-ray absorptiometry, 
bioelectrical impendence, hydrostatic weighing, or air-displacement 
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plethysmography. However, body mass index (BMI) is typically used by 
organizations that track obesity trends, like the United States’ Centers for Disease 
Control and Prevention and the World Health Organization, because of its relative 
ease of collection. BMI is defined as the ratio of an individual’s mass in kilograms 
divided by her height in meters squared (kg/m2). The resulting values are used to 
characterize individuals as underweight (<18.5 kg/m2), normal weight (18.5-24.9 
kg/m2), overweight (25.0-29.9 kg/m2), or obese (≥30 kg/m2). Certain individuals, 
particularly those with a large amount of lean muscle mass, may be misclassified 
by these BMI categories. However, for the majority of people, BMI is strongly 
correlated with body fat percentage as well as chronic disease risk and mortality 
(16). 
Regardless of the measure used, there is little doubt that obesity has become 
a significant global health problem over the past 30 years. In the United States, the 
adult obesity rate has risen over that time period to a current rate of 35.7% (17). 
Similar trends are evident around the world and are no longer unique to wealthy, 
industrialized countries (18). The rise in obesity rates is alarming given the 
association between excess adiposity and an increased incidence of and mortality 
from numerous chronic diseases, including certain types of cancer.    
1.3 Obesity and Breast Cancer 
In postmenopausal women, obesity increases breast cancer risk by 
approximately 40% (3-5). While most research has indicated that obesity actually 
protects premenopausal women from breast cancer, two recent studies suggest 
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that the interaction may be more complex, differing with presence of other risk 
factors (6). A large body of evidence has established that obesity is also associated 
with a worse breast cancer prognosis for both pre- and postmenopausal women. 
One prospective study found that the breast cancer mortality rate escalates with 
each successive increase in BMI category, (19). Another study showed a 
significantly greater risk for disease recurrence within 10 years of diagnosis in 
breast cancer patients who were obese at the time of treatment in comparison to 
non-obese patients (20).  These effects could be due to later diagnosis in the obese 
population, resulting in more advanced disease at the time of diagnosis.  This 
hypothesis was initially supported by data from a large cohort of patients followed 
for a 20 year period; Majed et al. (21) reported that the obese patients presented 
with more advanced tumors, suggesting that diagnosis had been delayed.  
However, the authors ultimately found that multivariate statistical analysis 
demonstrated an independent effect of obesity on breast cancer prognosis, 
regardless of tumor stage at time of diagnosis. Survival analysis revealed 
increased metastatic recurrence as well as decreased disease-free interval and 
overall survival in the obese patient population. Additional studies have produced 
similar findings supporting the link between obesity and a worse prognosis (22, 
23).  
While obesity has been shown to negatively impact breast cancer outcome 
for both pre- and postmenopausal patients, the most prominent effects are seen in 
ER positive postmenopausal patients, a finding confirmed by a recent 
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retrospective analysis of the German BRENDA-cohort (24). Obesity has been 
hypothesized to negatively impact outcomes in this patient population by 
promoting adipose tissue expression of aromatase, the rate-limiting enzyme in the 
production of estradiol from testosterone. Due to an abundance of this aromatase-
expressing tissue, obese postmenopausal women typically have higher levels of 
circulating estradiol (25-27), and researchers have posited that this may contribute 
to the observed increase in breast cancer risk, recurrence, and mortality in this 
population. 
1.4 Aromatase, Obesity, and Breast Cancer 
1.4.1 Aromatase Expression and Regulation 
Aromatase is a member of the cytochrome P450 superfamily of enzymes that 
is localized in the endoplasmic reticulum of estrogen-producing cells. It is an 
enzyme complex composed of two polypeptides: aromatase cytochrome P450, the 
product of the CYP19A1 gene, and NADPH-cytochrome P450 reductase, a 
flavoprotein that is ubiquitously distributed in most cells. In premenopausal women, 
ovarian granulosa cells are the primary site of aromatase expression, while the 
adipose (specifically immature adipose fibroblasts, also called pre-adipocytes) is 
the principal aromatase-expressing tissue following menopause. Aromatase is 
also expressed at low levels in the placenta, bone, skin, brain, blood vessels, 
testicular Leydig cells, and the breast (28).   
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Aromatase expression is regulated by multiple partially-tissue specific 
promoters (29). Ovarian aromatase expression is induced by follicle stimulating 
hormone through the potent PII promoter (28), while aromatase levels in disease-
free adipose tissue are governed by the relatively weak I.4 promoter, which 
requires combined stimulation by a glucocorticoid plus a class I cytokine like 
interleukin 6 (IL-6) or tumor necrosis factor alpha (TNF). However, in the 
presence of the pro-inflammatory eicosanoid prostaglandin E2 (PGE2), pre-
adipocytes will utilize the stronger I.3 and PII aromatase promoters. Breast cancer 
cells can also express aromatase via these promoters, but the mechanisms by 
which they are regulated differ from pre-adipocytes and remain poorly understood 
(28, 29).  
It is known that paracrine interactions between these two cell types contribute 
to a substantial increase in local breast tissue aromatase expression and estrogen 
production with the development of breast cancer. Malignant breast epithelial cells 
secrete a large quantity of cytokines, including TNF and interleukin-11, which 
inhibit the differentiation of pre-adipocytes into mature adipocytes. This promotes 
the desmoplastic reaction, an expansion in the population of adipose fibroblasts 
that creates a dense population of these aromatase expressing, estrogen-
producing cells around the tumor (28, 29). In addition, the pre-adipocytes are 
stimulated to express higher amounts of aromatase via the I.3 and PII promoters 
by breast cancer cell-derived PGE2. Pre-adipocyte aromatase expression is also 
induced by additional unknown factors that the breast cancer cells produce (30). 
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While PGE2 is known to be independently capable of stimulating aromatase 
expression in pre-adipocytes, the other breast cancer cell secretory products make 
significant contributions to this paracrine effect. In fact, stimulation of pre-adipocyte 
aromatase expression via MCF-7 breast cancer cell conditioned media exposure 
persists with inhibition of the cancer cells’ COX-2 activity, clearly showing that 
these other factors can independently promote pre-adipocyte aromatase 
expression (30, 31). The pro-angiogenic tumor environment also encourages the 
proliferation of endothelial cells that express aromatase via the I.7 promoter and 
contribute to estrogen production within the tumor microenvironment. Finally, the 
cancer cells themselves express additional aromatase via the I.3 and PII 
promoters (28, 29). The result of these paracrine interactions is a 5-fold elevation 
in aromatase expression in the tumor and associated adipose tissue in comparison 
to disease-free tissue. There is a corresponding increase in breast tumor estradiol 
levels, which can be up to 10-fold higher than systemic serum concentrations, 
suggesting that this estrogen is being produced locally and not taken up from 
circulation (32). In support of the hypothesis that paracrine interactions between 
the tumor and adipose tissue contribute to this local production, O’Neill et al. [33] 
demonstrated in their analysis of 12 breast samples that the highest aromatase 
activity is consistently found in the tumor-containing breast quadrant in comparison 
to the adjacent and distal quadrants.  
1.4.2 Aromatase and Obesity 
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These findings suggest that an obesity-associated elevation in systemic 
estrogen levels will probably not have a significant impact on breast tumor ER 
activity, given that a much larger local source of estrogen is already available in 
the tumor microenvironment and adjacent adipose tissue. However, aromatase 
and estrogen may still be key factors in the link between obesity and poor 
prognosis in ER positive, postmenopausal breast cancer patients. Obesity is 
associated with increased circulating levels of several growth factors, cytokines, 
and adipokines that may enhance the paracrine interactions described above, 
resulting in a further elevation in local aromatase levels and estrogen production.  
For example, serum concentrations of IL-6 and TNF are generally increased with 
obesity (34), and these cytokines have been shown to promote PGE2 production 
in multiple cell types via their effects on cyclooxygenase-2 (COX-2) expression 
(35-37). In addition, obesity is accompanied by elevated levels of free insulin-like 
growth factor (IGF-1) (38, 39), which can directly regulate the expression of 
aromatase in breast cancer epithelial cells.  IGF-1 treatment in vitro increases 
aromatase expression in both MCF-7 and MDA-MB-231 breast cancer cells (40).   
Recent studies by Dannenberg et al. confirmed the presence of elevated 
aromatase expression in the breast tissue of overweight and obese women with 
and without breast cancer. Crucially, they demonstrated high congruence between 
aromatase levels, obesity, and local breast tissue inflammation, as measured by 
the number of crown-like structures (CLS-B). CLS-B are inflammatory foci 
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composed of a necrotic adipocyte surrounded by macrophages, which produce 
excess amounts of several pro-inflammatory mediators, including PGE2 (41-43).  
In addition to promoting an increased number of these CLS-B, obesity is 
associated with another factor that may further enhance PGE2 production in 
adipose-infiltrating macrophages. Saturated fatty acids can promote COX-2 
expression and PGE2 secretion by cultured macrophages (43, 44),   and the 
increased lipolysis that accompanies obesity results in a higher concentration of 
circulating free fatty acids (45-47). Consequently, the obesity-associated elevation 
in breast tissue aromatase levels may also be due to free fatty acid-induced 
macrophage PGE2 production. Overall, this obesity-induced local breast 
aromatase expression and estrogen production may be a significant contributor to 
the worse outcome observed in obese postmenopausal patients with ER positive 
breast cancer.   
1.4.3 Obesity and Response to Aromatase Inhibitors 
This hypothesis is supported by an analysis of data from the ATAC trial by 
Sestak et al. (48), which found that obese breast cancer patients receiving the 
aromatase inhibitor anastrozole had a significantly greater risk of recurrence.   In 
agreement with these findings, Schmid et al. (49) demonstrated that obese 
patients have a reduced response rate to another aromatase inhibitor, letrozole, in 
comparison to lean (11 vs 35%).  The ATAC trial also showed that while anatrozole 
treatment resulted in significantly greater recurrence-free survival in comparison 
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to the selective erstrogen receptor modulator tamoxifen, this advantage was lost 
in the obese cohort (48).  In addition, while three extra years of anastrozole 
treatment has been shown to decrease normal weight patients’ risk of disease 
recurrence and death by half, overweight and obese patients did not benefit from 
this treatment (50). Furthermore, plasma estradiol and estrone sulfate levels in 
obese patients remain significantly elevated in comparison to non-obese patients 
following letrozole treatment (51), suggesting that this reduced response rate is 
related to suboptimal inhibition of obesity-associated aromatase activity. It is 
possible that an adjustment in the aromatase inhibitor dosage, which is prescribed 
at a fixed amount, may improve obese patient prognosis.  However, that inference 
is confounded by two phase III clinical trials of anastrozole that found no overall 
benefit from a 10 mg dose (versus 1 mg), indicating that an increased dosage may 
not be effective in overcoming obesity-induced resistance to aromatase inhibitors 
(52, 53).  
1.5 Obesity and Endocrine Resistance 
As discussed above, obese breast cancer patients do not respond as well as 
lean patients to aromatase inhibitor treatment. This resistance to aromatase 
inhibitor therapy may be mediated by increased local aromatase expression alone, 
but it is likely due to the activation of multiple signaling pathways. In general, 
endocrine therapy resistance can develop through a number of different 
mechanisms.  Frequently, aberrant signaling from growth factor receptors, 
particularly the insulin-like growth factor 1 receptor (IGF-1R) and the HER family 
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of receptors, is responsible.  These receptors can engage in bidirectional crosstalk 
with ER, leading to increased nongenomic ERactivity, ligand-independent 
activation of ER, and dysregulated cell cycle and apoptotic signaling.  
Nongenomic ER activity results in the activation of the MAPK and PI3K/Akt 
signaling pathways, and these can in turn activate ER via phosphorylation, 
leading to enhanced genomic ER activity (54, 55).   
Over the past decade, a number of researchers have successfully 
characterized several of the nongenomic interactions that occur between ER and 
other signaling molecules in the cytoplasm.  For example, Song et al. (56, 57) 
discovered that, in the presence of estradiol, ER undergoes translocation to the 
plasma membrane and complexes with IGF-1R and the adaptor protein Shc, 
resulting in MAPK pathway activation.  Down-regulation of IGF-1R prevents ER 
translocation to the membrane, suggesting that IGF-1R signaling is necessary for 
nongenomic ER activity.  Ligand-bound ER can also directly bind Src as well as 
p85, the regulatory subunit of PI3K, resulting in Akt activation downstream (58, 
59).  In addition, p85 can bind IGF-1R, leading to speculation that ER may 
complex with both of these molecules upon activation by estradiol (60, 61).    The 
receptor for leptin, an obesity-associated adipokine, has also been shown to 
crosstalk with IGF-1R, resulting in greater IGF-1R activation and an upregulation 
of Akt and ERK1/2 phosphorylation (62).  This interaction could potentially 
enhance IGF-1R/ER crosstalk.  Activated Akt and ERK1/2 can in turn activate 
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ER via phosphorylation at serine 167 and 118, respectively, within the receptor’s 
AF-1 domain, leading to enhanced genomic ER activity (63, 64).    
Obesity is typically accompanied by elevated circulating levels of insulin, 
bioavailable IGF-1 and leptin, as well as a series of pro-inflammatory cytokines 
(34, 38, 39, 65).  All of these obesity-associated circulating factors are able to 
activate the PI3K/Akt and/or MAPK pathways, potentially increasing the ER 
crosstalk pathways described above and leading to endocrine resistance and 
breast cancer progression (66-70). In fact, the metabolic alterations associated 
with obesity, including changes in insulin and insulin-like growth factor binding 
protein 1 (IGFBP-1) serum levels (which result in increased circulating free IGF-1 
levels), are significantly correlated with breast cancer recurrence and mortality 
(71).  High serum concentrations of pro-inflammatory cytokines and leptin have 
been similarly linked to a worse breast cancer outcome (72-74).  In addition, 
because obesity enhances local breast tissue aromatase expression and 
aromatase inhibitors fail to effectively suppress estrogen production in many obese 
patients, more estradiol is also available in the tumor microenvironment to activate 
these nongenomic ER signaling pathways. Overall, obesity creates a complex 
metabolic imbalance accompanied by chronic inflammation, enriching the blood 
with a number of signaling molecules that may promote breast cancer progression 
and adversely affect outcome.   
1.6 Dissertation Objectives 
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Given that obesity rates are climbing globally and have exceeded a third of 
the adult population in the United States, it is expected that the incidence and 
severity of many obesity-associated diseases will also continue to rise, including 
breast cancer. Obesity negatively impacts breast cancer prognosis across all ages 
and breast cancer subtypes. Consequently, while breast cancer mortality rates 
have improved in recent years, the obesity epidemic may be mitigating the positive 
impact of treatment advancements and other factors on survival rates. In addition, 
obesity rates in the United States are highest among older women, and it is in this 
postmenopausal population that the strongest link between obesity and a poor 
breast cancer prognosis is seen. Thus, this project was designed to expand our 
understanding of the mechanisms by which obesity promotes postmenopausal 
ER positive breast cancer, with a focus on examining the role of obesity-induced 
local aromatase expression and estrogen production.  
We hypothesized that obesity promotes postmenopausal breast cancer 
progression by enhancing local estrogen production via an inflammatory cytokine-
induced elevation in aromatase expression and activity in the mammary stroma 
and epithelium. An in vitro model of obesity (Illustration 1.1) was designed that 
utilized serum samples from postmenopausal breast cancer patients pooled by 
BMI category (normal weight: 18.5-24.9 kg/m2; obese: ≥30 kg/m2). Various 
cultured cells, including breast cancer cells, pre-adipocytes, and macrophages, 
were exposed to the pooled sera alone and in co-culture in order to mimic the 
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impact of obesity on the tumor microenvironment. We examined the direct impact 
of obese patient sera on breast cancer cell and pre-adipocyte aromatase 
expression as well as the ability of the obese patient sera to promote pre-
adipocyte, breast cancer cell, and macrophage production of aromatase-
promoting factors like IL-6 and PGE2. Through elucidation of the signaling 
pathways responsible for the obesity-associated elevation in local aromatase 
expression, our ultimate goal was to identify a more effective chemotherapeutic 
regimen for postmenopausal, ER positive breast cancer patients. 
 
Illustration 1.1 An in vitro model of obesity and the tumor microenvironment 
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Studies examining the role of docetaxel resistance and a HER2-mediated 
reduction in ER expression in the obesity-breast cancer progression link were 
also initiated, along with an investigation of the obesity’s impact on tumor incidence 
and characteristics in the MMTV-Wnt1 mouse model of mammary carcinogenesis. 
Preliminary results from these studies are presented here.  
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Chapter 2: Breast cancer cell aromatase expression is stimulated by 
obesity-associated PI3K/Akt, MAPK, and interleukin-6 signaling 
 
2.1 Introduction 
According to the United States Centers for Disease Control and Prevention, 
over a third of U.S. women are currently obese, defined as a body mass index 
(BMI) ≥30 kg/m2 (17). This indicates that there is a substantial need for better 
understanding of the mechanisms linking obesity with various chronic diseases, 
including breast cancer. In postmenopausal women, epidemiological studies have 
shown that obesity increases the risk of developing breast cancer, with one study 
demonstrating a 41% elevation in risk between the lowest and highest BMI 
quintiles (3, 75). It has also been established that obesity is associated with a 
worse breast cancer prognosis for both pre- and postmenopausal women. One 
prospective study found that the mortality rate due to breast cancer was amplified 
with each successive increase in BMI category (19).  Other research has shown a 
significantly greater risk for disease recurrence within 10 years of diagnosis in 
breast cancer patients who were obese at the time of treatment in comparison to 
non-obese patients (20). One mechanism for this negative effect may be reduced 
response to endocrine therapy (22), as researchers have found that obese 
postmenopausal patients’ response rate to the aromatase inhibitor letrozole is 
significantly lower in comparison to lean patients’ (11% vs 35%) (49).   
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The key enzyme responsible for the conversion of androgens to estrogens is 
aromatase, encoded by the CYP19A1 gene (28). Following menopause, the 
primary site of aromatase activity shifts from the ovarian granulosa cells to the 
adipose tissue (76). The majority of breast tumors in obese postmenopausal 
women are estrogen receptor alpha (ER) positive, suggesting that elevated 
estrogen synthesis by the adipose tissue may be the primary mediator of breast 
tumorigenesis in this population (77).   This is supported by a recent study 
demonstrating that free plasma estradiol levels rise by approximately 20% for each 
5 kg/m2 increase in BMI among postmenopausal women (78).  However, 
aromatization of androgens into biologically active estradiol also occurs in the 
breast tissue, indicating that elevated local estrogen production may also be a 
factor in the increased breast cancer risk and worse prognosis seen in the obese 
postmenopausal population.  In fact, examination of breast carcinoma tissue 
samples has revealed estradiol concentrations ten-fold greater than circulating 
plasma levels and two times the concentration found in normal breast tissue.  This 
is correlated with a four to five-fold increase in aromatase expression within the 
breast tumor (32). Taken together, this data has led many researchers to 
hypothesize that factors associated with obesity may be driving local aromatase 
expression and activity even higher, thereby promoting greater local estrogen 
production and activity.  However, the specific mechanisms by which this occurs 
are not clearly understood.   
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The current study examined the impact of obesity-associated circulating factors 
on the expression of aromatase in breast cancer cells, utilizing an in vitro model of 
obesity. Systemic obesity-associated factors were shown to both directly and 
indirectly enhance breast cancer cell aromatase expression, resulting in 
subsequent increases in ER activity and cell viability. Through better 
understanding of the mechanisms mediating these effects, an improved 
chemotherapeutic regimen for the obese postmenopausal population may be 
developed. 
 
2.2 Materials and Methods 
2.2.1 Serum Samples 
Serum was collected from 25 postmenopausal breast cancer patients under 
an IRB approved biorepository collection protocol at the Cancer Therapy and 
Research Center of University of Texas Health Science Center at San Antonio. 
The collection and use of these biological samples was conducted in accordance 
with the Declaration of Helsinki and good clinical practice. Informed consent was 
obtained prior to participation, and all samples and data were de-identified prior to 
release to maintain patient confidentiality. BMI was calculated, and serum was 
pooled according to the BMI category of the patient (normal weight (N): 18.5-24.9 
kg/m2; obese (OB): ≥30.0 kg/m2). The free IGF-1 concentration of each patient’s 
serum sample was measured using the MILLIPLEX MAP Human IGF-1 Single 
Plex Metabolism Assay, while the MILLIPLEX MAP Human Serum Adipokine 
19 
 
Panel A and B kits were used to assess patient serum concentrations of insulin, 
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), leptin, and adiponectin 
(EMD Millipore, Billerica, MA). 
2.2.2 Cell Lines and Reagents 
MCF-7 breast cancer cells (ATCC) were maintained in IMEM (GIBCO Life 
Technologies) supplemented with 10% fetal bovine serum (FBS). Pre-adipocytes 
isolated from women undergoing elective surgical procedures were a generous gift 
from Dr. Rong Li, UTHSCSA, and have been described previously (79). They were 
maintained in DMEM/F12 1:1 media (GIBCO Life Technologies) plus 10% FBS. 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent) was 
purchased from Sigma-Aldrich (St. Louis, MO).  Testosterone, anastrozole, LY 
294,002, and PD 98,059 were also obtained from Sigma-Aldrich. The Akt II 
inhibitor and IL-6 depleting antibody were produced by EMD Millipore (Billerica, 
MA). The primary antibodies for pAkt (s473), tAkt, pERK1/2, and tERK1/2 were 
purchased from Cell Signaling (Beverly, MA).   
2.2.3 Pre-adipocyte Conditioned Media 
Pre-adipocyte conditioned media (CM) was generated by seeding 2x105 pre-
adipocytes per well in 6-well plates, allowing them to grow to confluence, then 
serum-starving the cells for 18 hours. The pre-adipocytes were then exposed to a 
2% concentration of the pooled N or OB sera in serum-free media (SFM) for three 
hours, the sera removed and cells washed once with phosphate buffered saline 
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(PBS) followed by incubation in SFM for 24 hours. Over the course of this 24 hours, 
the cells release various factors into the SFM, enriching it into CM, which was then 
collected and stored at -20°C for subsequent in vitro assays. 
2.2.4 Quantitative RT-PCR 
MCF-7 cell CYP19A1 (aromatase) mRNA levels were assessed following a 
24-hour incubation in 2% N or OB patient sera (in SFM) or pre-adipocyte CM. The 
MCF-7 cells were serum-starved for 18 hours prior to sera or CM exposure. To 
assess the role of the PI3K, Akt and MAPK signaling in the sera’s effects on 
aromatase expression, the MCF-7 cells were pre-treated with LY 294,002, Akt II 
inhibitor, and PD 98,059 for one hour prior to as well as during sera exposure. The 
pre-adipocyte CM was incubated with an IL-6 depleting antibody for one hour prior 
to its addition to the MCF-7 cells in order to examine the impact of pre-adipocyte-
secreted IL-6 on MCF-7 cell aromatase expression. Total RNA was isolated using 
TRIzol reagent (Invitrogen) and reverse transcribed with Promega’s ImProm II 
Reverse Transcription System. The primer sequences are as follows: CYP19A1: 
forward, 5’-GCCGAATCGAGAGCTGTAAT-3’; reverse, 5’-GAGAATTCATGCGA 
GTCTGGA-3’. 
2.2.5 ERE Luciferase Assay 
A luciferase reporter gene driven by a 3X ERE-tk promoter was utilized to 
measure ER transcriptional activity.  Transient transfections were performed in 
triplicate wells three times.  MCF-7 cells were seeded at a density of 1.5 x 104 in 
24 well plates and concurrently transfected with the ERE luciferase and renilla 
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plasmids after 24 hours of growth using Fugene 6 from Promega (Madison, WI) at 
a 1:3 ratio.  The cells were serum-starved for six hours the following day, then 
exposed for 48 hours to 2% patient sera in SFM or pre-adipocyte CM +/- 
testosterone (100 nM) +/- anastrozole (1 uM).  Luciferase activity was then 
measured using Promega’s Dual Luciferase Reporter Assay System, with the 
fluorescence read on a FLUOstar Omega Spectrometer (BMG Labtech, 
Offenberg, Germany).   Relative ER activity was calculated by dividing each 
fluorescence value (standardized to renilla) by the value for cells grown in N patient 
sera or CM with testosterone. 
2.2.6 MTT Assay 
MCF-7 cells were seeded at a density of 8x103 in 96 well plates.  After 24 
hours of growth in the 10% FBS media, the cells were exposed to 2% patient sera 
in SFM or pre-adipocyte CM +/- testosterone (100 nM) +/- anastrozole (1 uM) for 
48 hours.  MTT reagent in PBS (5 mg/ml) was then added to each well to a final 
concentration of 0.5 mg/ml.  After two hours of incubation at 37°C, the media was 
removed and 50 ul DMSO added to each well to lyse the cells.  Absorbance was 
read at 570 nm on a FLUOstar Omega Spectrometer (BMG Labtech, Offenberg, 
Germany).  Relative cell viability was calculated by dividing each absorbance value 
by the absorbance for cells grown in N patient sera or CM with testosterone.   
2.2.7 Western Blot Analysis 
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The MCF-7 cells were grown to 80% confluence, then serum-starved for 18 
hours and exposed to 2% patient sera in SFM for 15 minutes or one hour.  Kinase 
lysis buffer was used for protein extraction.  Protein content of the lysates was 
measured using the BCA Protein Assay kit from Thermo Scientific Pierce 
(Rockford, IL).  Images were acquired using a Syngene G:BOX Chemi (Frederick, 
MD).  Relative protein levels were calculated by first standardizing phosphorylated 
protein to total protein levels for each experimental condition, then dividing the 
standardized protein level for each condition by that of cells grown in N patient 
sera.  Data from at least three independent experiments was compiled for each 
protein to calculate the average protein level, standard error of the mean and 
statistical significance, with one representative image for each protein shown. 
2.2.8 Statistical analysis 
Differences between cells exposed to two different experimental conditions 
were measured using Student’s t test. Two-way ANOVA was used for experiments 
with two independent variables. A p value of <0.05 was considered significant.   
 
2.3 Results 
2.3.1 Patient Characteristics 
Table 2.1 describes the postmenopausal breast cancer patients that provided 
the sera utilized in this study, which was pooled into two groups by BMI category, 
obese (OB) and normal weight (N).  There was no significant difference in the 
average patient age between groups.  The average patient BMI in the OB group 
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was significantly higher than the N group (p<0.01), and this was accompanied by 
significantly higher levels of IL-6 (p<0.05), TNF (p<0.05), and leptin (p<0.01), as 
well as lower levels of adiponectin (p<0.05).  In addition, the OB group’s serum 
insulin levels were almost five-fold greater, a difference that approached 
significance (p=0.10), but there was no difference in free IGF-1 concentration.  
Sixty percent of the patients in the OB group were Hispanic, while the N group was 
predominantly white.  Diabetes and hypercholesterolemia were found in at least 
25% of the patients in the OB group, but were not present in the N group.  Those 
diagnosed with these conditions had all been prescribed metformin and statins, 
respectively, two drugs with possible anti-cancer effects (80-85).  The majority of 
patients in both groups were receiving either aromatase inhibitor or tamoxifen 
treatment.  
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Table 2.1 Patient Characteristics   
     Obese    Normal weight  
Number of patients   20    5 
Average Age (years)  59.7 (6.28)   59.5 (4.76) 
Average BMI (kg/m2)  36.6 (5.04)**   21.1 (2.17) 
Average Serum Concentrations 
Free IGF-1 (ng/ml)  4.92 (0.925)   5.43 (1.80) 
Insulin (pg/ml)  742.9 (156.8)  157.4 (44.1) 
Interleukin 6 (pg/ml)  4.6 (0.58)*   1.6 (0.29) 
TNF- (pg/ml)  7.1 (0.51)*   4.6 (0.19) 
Leptin (ng/ml)  36.6 (4.67)**   6.40 (3.86) 
Adiponectin (ug/ml)  54.5 (6.55)*   97.5 (32.0)  
   
Ethnicity/Race 
Hispanic 12     0 
White 6     3 
African-American 2     0 
Asian 0     1 
Not Available     0     1 
Confounding Conditions 
Diabetes 5     0 
Hypercholesterolemia 8     0 
Hypertension 14     1 
Medications 
Aromatase Inhibitor 9     1 
Tamoxifen 5     2 
Chemotherapy    6     2 
Metformin 5     0 
Statin 8     0 
(Standard error of the mean); *, p<0.05; **, p<0.01 in comparison to normal weight 
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2.3.2 Obesity-associated circulating factors stimulate breast cancer cell 
aromatase expression 
In order to examine the direct impact of obesity-associated circulating factors 
on breast cancer cell aromatase expression, MCF-7 cells were cultured in pooled 
serum from obese (OB) or normal weight (N) postmenopausal breast cancer 
patients.  MCF-7 cell aromatase expression was 43% higher (p<0.05) after a 24 
hour incubation in OB versus N patient sera (Figure 2.1a). When the cells were 
simultaneously exposed to sera and testosterone, the substrate for aromatase, 
ER activity was 2.5 fold greater (p<0.05) under OB versus N conditions. In 
contrast, there was no difference in ERactivity when the cells were exposed to 
OB versus N patient sera alone. This indicates that any variance between the OB 
and N sera in estradiol concentration was not sufficient to induce a difference in 
breast cancer cell ER activity. It also suggests that MCF-7 cell-produced estradiol 
is responsible for the difference in ER activity seen with the addition of 
testosterone. In support of this conclusion, aromatase inhibition with anastrozole 
during sera and testosterone exposure eliminated the difference between the OB 
and N patient sera conditions (Figure 2.1b). To examine whether this OB patient 
sera-induced aromatase expression and ER activity could promote breast cancer 
progression, MCF-7 cell viability was measured. There was a non-significant 
difference in viability when the cells were exposed to OB versus N patient sera 
alone, but the addition of testosterone resulted in OB patient sera-induced viability 
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a 
levels that were significantly elevated in comparison to N. Aromatase inhibition 
again eliminated the difference between the OB and N plus testosterone conditions 
(Figure 2.1c).  
 
 
Figure 2.1 Obesity-associated circulating factors promote breast cancer cell 
aromatase expression, ER activity, and viability. (a) Aromatase expression in 
MCF-7 cells exposed to 2% obese (OB) or normal weight (N) patient sera for 24 
hours. (b) ER activity, measured by ERE luciferase, in MCF-7 cells cultured in 
2% OB or N patient sera +/- vehicle, testosterone, and/or anastrozole for 48 hours. 
(c) MCF-7 cell viability, assessed by MTT assay, following culture in the same 
conditions as (b) for 48 hours. **, p<0.01; different letters indicate significant 
differences, p<0.05. 
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2.3.3 Akt and MAPK pathway signaling mediates the effects of obese patient 
sera on breast cancer cell aromatase expression 
Obesity is associated with elevated levels of numerous growth factors, 
adipokines, and inflammatory cytokines that can activate the Akt and MAPK 
signaling pathways, which could mediate the effects of the OB patient sera on 
breast cancer cell aromatase expression (34, 38-39, 65-70). To investigate this 
hypothesis, activation of these two pathways was first examined by western blot 
analysis. MCF-7 cells exposed to OB patient sera for 15 minutes and 1 hour had 
2-fold (p<0.01) and 55% (p<0.05) higher levels of pAkt (ser473), respectively, in 
comparison to cells incubated in N patient sera. pERK1/2 levels were 79% and 
33% greater (p<0.05) after Ob versus N patient sera exposure for the same time 
periods (Figure 2.2a). The role of these pathways in OB sera-induced aromatase 
expression was examined using three inhibitors: LY 294,002 (LY, a PI3K inhibitor), 
Akt II inhibitor (AktII), and PD 98,059 (PD, a MEK inhibitor). MCF-7 cell treatment 
with AktII or PD significantly inhibited OB sera-induced aromatase expression, 
bringing it down to the level of the N sera condition. Intriguingly, all three inhibitors 
significantly increased MCF-7 cell aromatase expression when combined with N 
patient sera exposure (Figure 2.2b).   
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Figure 2.2 Obesity-associated systemic factors stimulate breast cancer cell 
aromatase expression via Akt and MAPK signaling pathways. (a) MCF-7 cells 
were exposed to 2% obese (OB) or normal weight (N) patient sera for 15 min or 1 
hr; pAkt (ser473) and pERK1/2 protein levels were then measured by western blot 
and standardized to tAkt and tERK1/2 protein levels, respectively. Densitometry 
data from at least three independent experiments were compiled for each protein 
and cell line to calculate the average protein level, standard error of the mean and 
statistical significance, with one representative image for each protein shown. (b) 
Aromatase expression in MCF-7 cells exposed to 2% OB or N patient sera +/- 
vehicle, LY 294,002, Akt II inhibitor (AktII), or PD 98,059 for 24 hr. *, p<0.05; **, 
p<0.01; different letters indicate significant differences, p<0.05. 
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2.3.4 Obesity-associated systemic factors indirectly promote breast cancer 
cell aromatase expression via stimulation of pre-adipocyte interleukin-6 
production 
Researchers have previously established that aromatase expression is 
upregulated in breast cancer cells that have been co-cultured with patient-derived 
intra-tumoral stromal cells (86).  Adipose fibroblasts, also known as pre-
adipocytes, are one type of stromal cell found within breast tumors and the 
adjacent mammary tissue. These cells are known to produce inflammatory factors, 
including interleukin-6 (IL-6), that promote aromatase expression (28). 
Consequently, we next examined the impact of OB patient sera exposure on pre-
adipocyte production of aromatase-promoting factors. MCF-7 cells cultured in 
conditioned media (CM) from pre-adipocytes exposed to OB versus N patient sera 
expressed 74% more (p<0.01) aromatase (Figure 2.3a). While there was no 
difference in MCF-7 cell ER activity when the cells were exposed to OB versus 
N CM alone, the addition of testosterone to the CM resulted in a significant 
elevation in OB CM-induced ER activity. This suggests that the OB sera-induced 
elevation in MCF-7 cell aromatase expression can lead to greater estradiol 
production and ER activity. The significant suppression of OB CM-induced MCF-
7 cell ER activity with anastrozole treatment supports this conclusion (Figure 
2.3b). MCF-7 cell viability under the same conditions mirrored ER activity, with 
OB versus N CM producing similar levels of viability. The addition of testosterone 
led to elevated OB CM-induced viability in comparison to N CM (p<0.05), and 
30 
 
aromatase inhibition again significantly reduced viability in the OB CM condition, 
neutralizing the difference between OB and N CM (Figure 2.3c). To investigate 
whether this obesity-associated aromatase-promoting paracrine interaction is 
mediated by an increase in pre-adipocyte IL-6 production, the CM was depleted of 
IL-6 prior to use. IL-6 neutralization decreased OB CM-induced aromatase 
expression by 63% (p<0.05), eliminating the difference between OB and N CM 
(Figure 2.3d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
Figure 2.3 Breast cancer cell aromatase expression is enhanced by obesity-
induced pre-adipocyte interleukin-6 production. (a) Aromatase expression in 
MCF-7 cells cultured for 24 hours in pre-adipocyte conditioned media (CM) 
generated by exposure to obese (OB) or normal weight (N) patient sera (OB-CM, 
N-CM). (b) ER activity, assessed by ERE luciferase assay, in MCF-7 cells after 
a 48 hour incubation in pre-adipocyte OB-CM or N-CM +/- vehicle, testosterone, 
and anastrozole. (c) MCF-7 cell viability, measured by MTT assay, following a 48 
hour exposure to the same conditions as (b). (d) Aromatase expression in MCF-7 
cells cultured for 24 hours in OB-CM, N-CM or CM generated with sera depleted 
of IL-6 with a neutralizing antibody (OB+Ab-CM, N+Ab-CM). **, p<0.01; different 
letters indicate significant differences, p<0.05 
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2.4 Discussion 
 The role of aromatase expression and estradiol production in the obesity-breast 
cancer link has been the subject of numerous studies in recent years. Many have 
attributed the association between obesity and increased postmenopausal breast 
cancer risk and progression to an excess of aromatase-expressing adipose tissue. 
However, this theory fails to consider how obesity impacts estradiol production in 
the local breast tissue once a tumor has already formed, where both the pre-
adipocytes and malignant breast epithelial cells are significant sources of 
aromatase.  
 In the current study, we demonstrated that obesity-associated circulating 
factors directly and indirectly promote breast cancer cell aromatase expression. 
Sera from obese versus normal weight postmenopausal breast cancer patients 
stimulated greater MCF-7 breast cancer cell aromatase expression via Akt and 
MAPK-mediated signaling pathways. Obesity is associated with elevated levels of 
numerous circulating growth factors, adipokines, and inflammatory cytokines that 
can activate the Akt and MAPK signaling pathways, including insulin, IGF-1, leptin, 
and IL-6, and in vitro and animal studies have established that these obesity-
associated factors play a role in breast tumorigenesis (34, 38-39, 65-70, 87).  IGF-
1 has specifically been shown to regulate the expression and activity of aromatase 
in breast cancer epithelial cells.  Aromatase expression in both ER positive MCF-
7 and negative MDA-MB-231 breast cancer cells is increased by IGF-1 treatment 
(40).  In addition, IGF-1 enhances aromatase activity in the aromatase-
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overexpressing MCF-7aro and T47Daro cell lines via post-transcriptional 
mechanisms (88). While there was no difference in serum free IGF-1 levels 
between the obese and normal weight patients in our study population, insulin can 
also activate the IGF-1R, and there was a difference in serum insulin levels that 
approached significance. Leptin has also been shown to directly upregulate MCF-
7 cell aromatase expression via MAPK pathway activation of AP-1 (89). Given that 
serum leptin concentrations were significantly higher in our obese versus normal 
weight patients, it is possible that the effects of the obese patient sera on MCF-7 
cell aromatase expression are at least partly mediated by leptin. IL-6 signaling may 
also be playing a role, though, as the obese patients had significantly higher serum 
concentrations of this inflammatory cytokine, and it is known to stimulate breast 
cancer cell aromatase expression (28). In sum, the direct aromatase-inducing 
effects of the obese patient sera could be mediated by a number of obesity-
associated circulating factors, and it is likely that these effects are due to a 
combination of the various factors discussed above. 
 Intriguingly, inhibition of the PI3K, Akt, and MAPK pathways during normal 
weight sera exposure actually enhanced MCF-7 cell aromatase expression. This 
may be related to the inhibition of negative feedback loops that normally act to 
attenuate signaling via these pathways. For example, IGF-1R/insulin receptor-
mediated PI3K/Akt signaling is typically suppressed by a negative feedback loop 
in which S6K, following activation by mTOR, inhibits the insulin receptor substrate 
1/2 (IRS1/2) proteins located upstream of PI3K/Akt (90). Inhibition of PI3K or Akt 
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prevents activation of this loop, possibly resulting in continued stimulation of the 
aromatase-promoting pathway.  Similarly, inhibition of MAPK signaling has also 
been shown to upregulate PI3K/Akt signaling in several breast cancer cell lines 
(91). However, it remains unclear why these effects are only seen in the cells 
exposed to normal weight versus obese patient sera. 
 We have also demonstrated that the obese patient sera indirectly promotes 
breast cancer cell aromatase expression by stimulating pre-adipocyte IL-6 
production.  IL-6 is known to induce breast cancer cell aromatase expression (28). 
Pre-adipocytes, found in abundance within the tumor microenvironment and 
adjacent breast tissue, produce a number of inflammatory cytokines, including IL-
6 (92). Expression of the gene for IL-6 is regulated by tumor necrosis factor alpha 
(TNF), interleukin-1 (IL-1), and IL-6 itself, among other factors. We did not 
measure serum IL-1 levels in our patient population, but serum TNF and IL-6 
concentrations were both significantly greater in the obese patients. Consequently, 
one or both of these two cytokines may be responsible for the obese patient sera’s 
promotion of this aromatase-inducing paracrine interaction. 
 Obesity has been significantly and independently associated with 
postmenopausal breast cancer progression and a worse outcome, but the specific 
molecular mechanisms responsible for this link remain unclear.  As obesity rates 
among women continue to rise, improvements in breast cancer mortality rates 
could be compromised, suggesting that further research regarding the link 
between obesity and breast cancer is critical.  This study demonstrated that 
35 
 
obesity-associated circulating factors promote breast cancer cell aromatase 
expression via multiple pathways. Further elucidation of the mechanisms 
mediating these effects may inform the development of a more effective 
chemotherapeutic regimen for this high risk population.  
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Chapter 3: NSAID use reduces breast cancer recurrence in overweight and 
obese women: Role of prostaglandin-aromatase interactions 
 
3.1 Introduction 
Obesity has become a significant global public health problem in the past 30 
years (18).  More than 35% of Americans have a body mass index (BMI) of ≥30 
kg/m2 (17), an alarming percentage given obesity’s association with an increased 
incidence of and mortality from numerous chronic diseases, including breast 
cancer. Several studies have demonstrated a link between obesity and a worse 
breast cancer prognosis in both pre- and postmenopausal women, including a 
prospective study of almost 500,000 women that found a progressive escalation in 
the risk of breast cancer mortality with each successive increase in BMI category 
(19). Other studies have established positive correlations between obesity and 
breast cancer recurrence (20), a shorter disease-free survival and lower rates of 
overall survival, independent of tumor stage at diagnosis (21-23).   
Obesity is hypothesized to negatively impact outcomes in postmenopausal, 
hormone-responsive breast cancer patients by promoting adipose tissue 
expression of aromatase, the rate-limiting enzyme in estradiol production. This 
theory has been supported by the results of clinical studies with anastrazole and 
letrozole showing a reduction in the efficacy of these aromatase inhibitors with 
increasing BMI in postmenopausal breast cancer patients (48-49). Plasma 
estradiol and estrone sulfate levels in obese patients remain significantly elevated 
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in comparison to non-obese patients following letrozole treatment (51), suggesting 
that this reduced response rate is related to suboptimal inhibition of obesity-
associated aromatase activity. Recent findings by Dannenberg et al. confirm the 
presence of elevated aromatase expression in the breast tissue of overweight and 
obese women (52-53). Crucially, they have demonstrated high congruence 
between aromatase levels and local breast tissue inflammation, as measured by 
the number of crown-like structures (CLS-B). CLS-B is an inflammatory focus 
composed of a necrotic adipocyte surrounded by macrophages, which produce 
excess amounts of several pro-inflammatory mediators. These include COX-2 
derived prostaglandin E2 (PGE2), a potent stimulant of aromatase expression in 
pre-adipocytes, the predominant site of aromatase expression within adipose 
tissue (41-43).  This obesity-inflammation-aromatase axis may be a significant 
contributor to the reduced aromatase inhibitor response and increased mortality 
rate observed in obese postmenopausal patients.  Collectively, these studies 
suggest that obese postmenopausal women with estrogen receptor alpha (ER) 
positive breast cancer may benefit from combining hormone therapy with a drug 
targeting the COX-2 pathway. 
In this study, we retrospectively examined the association between non-
steroidal anti-inflammatory drug (NSAID) use and recurrence rate in a hormone-
responsive breast cancer patient population in order to determine whether this 
COX-2 pathway-targeting drug group improves prognosis. NSAID use reduced the 
recurrence rate by approximately 50% and extended the disease-free survival by 
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more than two years in our largely overweight/obese, postmenopausal population 
of women. Furthermore, to assess whether inflammation-associated pre-adipocyte 
aromatase expression may be responsible for this effect, we utilized an in vitro 
model of the obese patient’s tumor microenvironment. Here we demonstrated that 
obesity-associated circulating factors enhance macrophage-derived PGE2 
induction of pre-adipocyte aromatase expression and estradiol production, 
resulting in greater breast cancer cell ERα activity, proliferation and migration.    
 
3.2 Materials and Methods 
3.2.1 Subjects 
Review of medical records dated between 01/01/1987 and 1/12/2011 from 
the Cancer Therapy and Research Center (CTRC) at the University of Texas 
Health Science Center at San Antonio (UTHSCSA) and the START Center for 
Cancer Care clinic in San Antonio, Texas, yielded a patient population of 440 
women diagnosed with invasive, ER positive breast cancer. Exclusion criteria 
included diagnosis of carcinoma in situ, hormone therapy refusal or non-
compliance, unavailable treatment information, discontinuation of adjuvant therapy 
due to insurance issues or health problems, diagnosis of triple negative breast 
cancer, breast cancer metastasis at the time of diagnosis, unavailable diagnosis 
dates, and underweight status. The collection of patient data from these medical 
records was approved by the Institutional Review Boards (IRB) of UTHSCSA and 
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START and conducted in accordance with the Declaration of Helsinki and good 
clinical practice. Informed consent was obtained from all patients prior to 
participation.   
3.2.2 Study Design and Data Collection 
This exploratory study utilized retrospective data collected from patient 
charts.  Information regarding demographics, tumor stage, ER and progesterone 
receptor status, medications, baseline weight (or the earliest recorded weight), 
height, and menopausal status was extracted. Body mass index (BMI) was 
calculated and patients classified as normal weight (18.5-24.9 kg/m2), overweight 
(25.0-29.9 kg/m2), or obese (≥30.0 kg/m2). Perimenopausal women were classified 
as premenopausal because they receive tamoxifen as their first-line hormonal 
therapy (93-94). Patients were designated as NSAID users if progress notes 
described daily use of aspirin, ibuprofen, celecoxib, naproxen, meloxican or 
another COX-2 inhibitor in the list of medications. Use of analgesics that do not 
target COX-2, such as acetaminophen and hydrocodone, as well as prn COX-2 
inhibitor use did not qualify for inclusion in the NSAID user group. Recurrence was 
defined as any local, contralateral, distant tumor or metastasis of the primary 
breast cancer. Second primaries were not classified as recurrent breast cancer.  
3.2.3 Serum Samples 
Serum was collected from 25 postmenopausal breast cancer patients under 
an IRB approved biorepository collection protocol at the CTRC of UTHSCSA. The 
40 
 
collection and use of these biological samples was conducted in accordance with 
the Declaration of Helsinki and good clinical practice. Informed consent was 
obtained prior to participation, and all samples and data were deidentified prior to 
release to maintain patient confidentiality. Serum was pooled according to the BMI 
category of the patient (normal weight or obese). Serum from five normal weight 
and five obese postmenopausal women, who were ineligible control subjects in the 
Polish Women’s Health Study, was also utilized. The design of this study has been 
described elsewhere (95). The serum from these patients was not pooled.  
3.2.4 Cell Lines and Reagents 
The ER positive MCF-7 and T47D and ER negative MDA-MB-231 breast 
cancer cell lines (ATCC) were maintained in IMEM (GIBCO Life Technologies) 
supplemented with 10% fetal bovine serum (FBS). Pre-adipocytes isolated from 
women undergoing elective surgical procedures were a generous gift from Dr. 
Rong Li, UTHSCSA, and have been described previously (79). They were 
maintained in DMEM/F12 1:1 media (GIBCO Life Technologies) plus 10% FBS. 
U937 monocytes (ATCC) were cultured in RPMI supplemented with 10% FBS and 
matured to macrophages at the time of seeding for experimentation by incubating 
the cells in 10.0 ng/ml phorbol 12-myristate 13-acetate (TPA) for 48 hours. 
Testosterone, anastrozole, celecoxib, and TPA were purchased from Sigma-
Aldrich. 
3.2.5 Conditioned Media 
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Macrophage conditioned media (CM) was generated by seeding 4x105 U937 
monocytes per well in six-well plates, stimulating them to mature into macrophages 
with TPA, then serum-starving the cells for six hours. The macrophages were then 
exposed to a 2% concentration of the pooled or individual sera samples for one 
hour, the sera removed and cells washed once with phosphate buffered saline 
(PBS) followed by incubation in serum-free media (SFM) for 24 hours. Over the 
course of this 24 hours, the cells release various factors into the SFM, enriching it 
into CM, which was then collected and stored at -20°C for subsequent in vitro 
assays. To assess the impact of macrophage COX-2 inhibition, the macrophages 
were pre-treated with 30 uM celecoxib for one hour prior to as well as during sera 
exposure. Macrophage/pre-adipocyte co-culture CM was generated by first 
stimulating 2x105 U937 monocytes per well to mature into macrophages on top of 
confluent pre-adipocytes seeded in six-well plates. The co-culture was serum-
starved for six hours, exposed to a 2% concentration of the pooled sera for one 
hour, then washed once with PBS and incubated for 24 hours in SFM with or 
without the addition of testosterone (100 nM) and/or anastrozole (1 uM). The 
enriched SFM, now considered CM, was then collected and stored at -20° C for 
use in subsequent in vitro assays.   
3.2.6 Quantitative RT-PCR 
Macrophage PTGS2 (COX-2) mRNA levels were measured following a six-
hour serum-starvation period and a one-hour exposure to a 2% concentration of 
obese or normal weight pooled patient sera. To determine whether macrophage 
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COX-2 expression continued to change during the 24-hour SFM incubation period 
of CM generation, mRNA levels were also assessed after the six-hour serum-
starvation period to establish a baseline level (prior to sera exposure) and after 12 
and 24 hours in SFM (following the removal of the sera).    Pre-adipocyte CYP19A1 
(aromatase) mRNA levels were assessed following a 24-hour incubation in 
macrophage CM.  MCF-7 and T47D TFF1 (pS2) and CCND1 (cyclin D1) mRNA 
levels were measured after a 24-hour incubation in macrophage/pre-adipocyte co-
culture CM supplemented with 2% charcoal-stripped (CS)-FBS. All cells were 
serum-starved for six hours prior to exposure to sera or CM. Total RNA was 
isolated using TRIzol reagent (Invitrogen) and reverse transcribed with Promega’s 
ImProm II Reverse Transcription System. The primer sequences are as follows: 
PTGS2: forward, 5’-CCCTTGGGTGTCAAAGGTAA-3’; reverse, 5’-
GCCCTCGCTTATGATCT GTC-3’; CYP19A1: forward, 5’-
GCCGAATCGAGAGCTGTAAT-3’; reverse, 5’-GAGAATTCATGCGAGTCTGGA-
3’; TFF1: forward, 5’-GGTCGCCTTGGAGCAGA-3’; reverse, 5’-
GGGCGAAGATCACCTTGTT-3’; CCND1:  forward, 5’-TGGAGGTCTGCGA 
GGAACAGAA-3’; reverse, 5’-TGCAGGCGGCTCTTTTTCA-3’. The 
manufacturer’s recommended cycling conditions for the QuantiFast SYBR Green 
PCR kit (Qiagen) were used. Data shown represents the average of at least three 
independent experiments, with the exception of pre-adipocyte aromatase 
expression measured following culture in macrophage CM generated with the 
individual serum samples from the Polish Women’s Health Study.   
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3.2.7 Prostaglandin E2 and Estradiol Concentrations 
The concentration of prostaglandin E2 in macrophage CM was measured 
using the Prostaglandin E2 Parameter Assay Kit from R&D Systems (Minneapolis, 
MN). The estradiol concentration in macrophage/pre-adipocyte co-culture CM was 
analyzed with the Estradiol EIA Kit from Cayman Chemical (Ann Arbor, MI). 
3.2.8 ERE Luciferase Assay 
A luciferase reporter gene driven by a 3x ERE-tk promoter was utilized to 
measure ER transcriptional activity. Transient transfections were performed in 
triplicate wells three times. MCF-7 and T47D cell lines were seeded at a density of 
1.5 x 104 in 24 well plates and concurrently transfected with the ERE luciferase 
and renilla plasmids after 24 hours of growth using Fugene 6 from Promega 
(Madison, WI) at a 1:3 ratio. The cells were serum-starved for six hours the 
following day, then exposed for 48 hours to the macrophage/pre-adipocyte co-
culture CM supplemented with 2% CS-FBS. Luciferase activity was then measured 
using Promega’s Dual Luciferase Reporter Assay System, with the fluorescence 
read at 570 nm on a FLUOstar Omega Spectrometer (BMG Labtech, Offenberg, 
Germany). Relative ER activity was calculated by dividing the fluorescence value 
(standardized to renilla) from cells grown in each experimental condition by that 
from cells grown in CM generated with normal weight sera exposure followed by 
incubation in SFM plus testosterone. Data shown represents the average of at 
least three independent experiments.   
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3.2.9 Cell Proliferation and Migration 
MCF-7, T47D, and MDA-MB-231 cell proliferation was measured using cell 
counting by hemocytometer following a 48-hour incubation in macrophage/pre-
adipocyte co-culture CM supplemented with 2% CS-FBS. The cells were seeded 
in 24-well plates at a density of 1x104 cells/well for MCF-7 and MDA-MB-231 cells 
and 1.5x104 cells/well for T47D cells, then serum-starved for six hours the following 
day. For each cell line, the relative number of cells after 48 hours was calculated 
by dividing the cell number for each experimental condition by that for cells grown 
in CM generated with normal weight sera exposure followed by incubation in SFM 
plus testosterone, then multiplying that number by 1x105. Migration of these same 
cell lines was assessed using the wound healing assay after a 24-hour incubation 
in macrophage/pre-adipocyte co-culture CM supplemented with 2% CS-FBS. The 
cells were seeded in six-well plates and grown to 100% confluence, then serum-
starved for six hours. After adding the CM to the cells, a scratch was made down 
the center of each well and the baseline width of the scratch in three locations was 
measured using Spot Imaging software (Diagnostic Instruments, Sterling Heights, 
MI, USA). Images were captured with a Motic AE31 inverted microscope and Spot 
Idea 3cMP color digital camera (GMI, Minneapolis, MN, USA). At 24 hours, follow-
up measurements at the same locations were taken, and the percent wound 
closure was calculated by dividing the difference of the two measurements by the 
baseline and multiplying by 100. Data shown represents the average of at least 
three independent experiments.   
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3.2.10 Statistical analyses 
Patient data: The data was examined for normality. Duplicates were also 
analyzed to guarantee that one patient was not recorded twice in the event of 
referrals or transfer of medical care to the other clinic. Pearson’s chi-squared tests 
were used to analyze categorical variables of NSAID users and nonusers. 
Student’s t-test was used to examine mean differences in numerical variables. 
Time to recurrence in the NSAID users and nonusers that developed disease 
recurrence was assessed by Wilcox non-parametric test. Age at diagnosis and 
tumor stage were included as a priori confounding factors. Logistic regression was 
used to predict recurrence. A p value of <0.05 was considered significant. 
Statistical analyses were performed in R Foundation for Statistical Computing 
(version 2.10.1, Vienna, Austria, 2009). 
In vitro data: 
Differences between cells exposed to two different experimental 
conditions were measured using Student’s t test. One-way ANOVA was 
used to analyze differences between more than two experimental 
conditions. A p value of <0.05 was considered significant.    
 
3.3 Results 
3.3.1 Patient Characteristics 
The patient population consisted of 440 women with invasive, ER positive 
breast cancer. NSAID users did not significantly differ from nonusers by BMI 
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category, tumor stage, hormone receptor status, tumor type, race or type of 
surgery (lumpectomy versus mastectomy). Not surprisingly, NSAID users were 
more likely to be older, postmenopausal, and diabetic. The majority of patients in 
our population were overweight/obese (BMI≥25 kg/m2), such that the average BMI 
for both users and nonusers was >30 kg/m2 (Table 1).   
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Table 3.1 Descriptive characteristics of breast cancer patients (n=440) 
Characteristics    NSAID nonusers   NSAID users   p-value 
     (n=281)   (n=159) 
Age at diagnosis, years (mean±SD)  55.5 ± 10.3  60.7 ± 10.7  < 0.001 
BMI, kg/m2 (mean ± SD)   30.7 ± 6.21  31.9 ± 6.70  0.072 
Time to recurrence, months (median)a  50.6   78.5   0.464 
[-----------------------------N(%---)--------------------]     χ2, p-value for trend 
   
Recurrence 
Yes    34(12.1)   10(6.3)   0.050 
No    247(87.9)   149(93.7) 
BMI category 
 Normal    50(17.8)   25(15.7)   0.132 
 Overweight   94(33.4)   41((25.8) 
 Obese    137(48.8)   93(58.5) 
Menopausal status 
 Premenopausal   110(39.2)   32(20.1)   <0.001 
 Postmenopausal   171(60.8)   127(79.9) 
Race 
 Hispanic    134(47.7)   74(46.5)   0.135 
 White    111(39.5)   57(35.8) 
 African-American   5(1.8)   10(6.3) 
 Other    4(1.4)   1(0.7) 
 Missing/Unavailable   27(9.6)   17(10.7) 
Tumor stage 
 I    101(35.9)   60(37.8)   0.389 
 II    107(38.1)   64(40.2) 
 III    56(19.9)   23(14.5) 
 Missing/Unavailable   17(6.1)   12(7.5) 
Hormone receptor status 
 ER+/PR+    246(87.6)   133(83.6)   0.255 
 ER+/PR-    35(12.4)   26(16.4) 
Histological type 
 Ductal    218(77.6)   121(76.1)   0.156 
 Lobular    33(11.7)   21(13.2) 
 Mucinous    1(0.4)   2(1.2) 
 Missing/Unavailable   29(10.3)   15(9.5) 
Type of surgery 
 Lumpectomy   128(45.5)   72(45.3)   0.405 
 Mastectomy   122(43.4)   69(43.4) 
 Bilateral mastectomy  26(9.3)   12(7.5) 
 Other excisionb   5(1.8)   6(3.8) 
Adjuvant hormonal therapy 
 Aromatase inhibitor   171(60.9)   125(78.6)   <0.001 
 Tamoxifen   110(39.1)   34(21.4) 
Type of NSAIDc 
 Aspirin    -   129(81.1)    
 Other     -   30(18.9) 
Diabetes status 
 Diabetic    56(19.9)   57(35.9)   <0.001  
 Not diabetic   225(80.1)   102(64.1) 
Diabetes drug 
 Metformin   37(66.1)   33(57.9)   0.036 
 Other    19(33.9)   24(42.1) 
Omega-3 fatty acid use 
 Yes    32(11.4)   40(25.1)   <0.001 
 No    249(88.6)   119(74.9) 
Statin use 
 Yes    65(23.1)   67(42.1)   <0.001 
 No    216(76.9)   92(57.9) 
Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation; BMI, body mass index; ER, estrogen receptor; 
PR, progesterone receptor. a Wilcox non-parametric test used to analyze time to recurrence analysis in 44 patients who had a 
recurrence. b Other excision includes segmentectomy and quadrantectomy. c Calculations pertinent to the 159 patients classified as 
NSAID users. 
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3.3.2 NSAID use is associated with a reduced risk of recurrence and longer disease-
free survival  
The recurrence rate in NSAID users was 52% lower than non-NSAID users 
(OR, 0.48; 95% CI, 0.22-0.98) (Table 2).  NSAID users remained disease-free for 
an average of 78.5 months, while non-users averaged 50.6 months, a difference 
of more than two years (Table 1).  Overweight/obese patients had a 1.86-fold 
higher risk of recurrence versus normal weight when controlling for NSAID use and 
type of hormone therapy (OR, 1.86; 95% CI, 0.76-5.62), a trend that approached 
significance (Table 2). Unfortunately, the small number of normal-weight patients, 
combined with their low rate of recurrence, precluded our ability to examine 
whether NSAID use was more effective in preventing recurrence in patients with 
an elevated BMI. However, despite the small sample size, we found that NSAID 
was associated with a substantial reduction in recurrence rate in this predominantly 
overweight/obese postmenopausal patient population. Larger studies have 
observed more modest effects (96-98).  
Table 3.2 Logistic regression model to predict breast cancer recurrence 
Predictors    OR   95%CI   p-value 
NSAID use 
 Users    0.48   0.22-0.98  0.05 
 Nonusers   reference 
BMI category 
 Normal    reference 
 Overweight + Obese  1.86   0.76-5.62  0.11 
Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio; CI, confidence interval; BMI, body mass 
index 
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3.3.3 Obesity stimulates pre-adipocyte aromatase expression and estradiol 
production via elevated macrophage PGE2 production 
We next sought to determine whether the NSAID-associated reduction in 
recurrence rate observed in the overweight/obese patient population may be due 
to the effect of these drugs on local aromatase expression and estrogen 
production. To this end, we utilized an in vitro model in which cultured cells were 
exposed to pooled sera samples from obese (OB) or normal weight (N) 
postmenopausal breast cancer patients in order to mimic the tumor 
microenvironment of obese versus normal weight women. The characteristics of 
the serum donors, including serum concentrations of insulin-like growth factor 1 as 
well as various cytokines and adipokines, have been previously described (99). 
Following a one hour exposure to OB sera, COX-2 expression in cultured 
macrophages was a modest 24% higher than cells exposed to N sera (Figure 1a). 
However, exposure to OB sera for one hour increased macrophage PGE2 
production five-fold versus N sera in the 24 hours following sera removal (Figure 
1b). Consequently, we assessed whether COX-2 expression may continue to 
increase in macrophages exposed to OB sera during that 24-hour period following 
sera removal. While COX-2 expression rises in both OB and N sera-exposed 
macrophages during this period, after sera removal mRNA levels were 68% and 
92% greater in OB versus N sera-exposed cells at 12 and 24 hours, respectively. 
(Figure 1c). Pre-adipocytes cultured in conditioned media (CM) from macrophages 
exposed to OB versus N sera had 52% greater aromatase expression (OB-CM, N-
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CM) (Figure 1c). Treatment of the macrophages with celecoxib during sera 
exposure (OB+C-CM, N+C-CM) neutralized the difference in pre-adipocyte 
aromatase expression, indicating that OB sera-induced macrophage PGE2 
production is responsible for this effect. Pre-adipocyte aromatase expression was 
also measured following growth in CM from macrophages exposed to serum from 
ten individual OB or N postmenopausal women, allowing us to examine whether 
similar results are obtained using non-pooled serum with the data averaged by 
BMI category.  Serum from ineligible control subjects in the Polish Women’s Health 
Study, a breast cancer case-control study that has been described previously (95), 
was used, enabling us to additionally determine whether our results are unique to 
sera obtained from a specific patient population.  The average pre-adipocyte 
aromatase expression was over two-fold greater following culture in macrophage 
CM generated with OB versus N subjects’ sera (OB-CM, N-CM) (Figure 1d), 
supporting the findings obtained using pooled sera from the CTRC patients. 
Finally, the OB sera-induced increase in aromatase expression was correlated with 
a 16-fold amplification in pre-adipocyte estradiol production in the presence of 
exogenous testosterone, the substrate for aromatase (OB+T-CM, N+T-CM) 
(Figure 1e). The addition of the aromatase inhibitor anastrozole to the 
macrophage/pre-adipocyte co-culture following sera exposure (OB+T+AI-CM, 
N+T+AI-CM) completely nullified the difference between OB and N, demonstrating 
that the increase in estradiol production was solely due to the OB sera’s effect on 
aromatase expression.         
51 
 
 
  
Figure 3.1 Obesity stimulates macrophage PGE2 production, resulting in 
elevated pre-adipocyte aromatase expression and estradiol production. (a) 
COX-2 expression in U937 cells matured to macrophages following one hour 
exposure to obese (OB) versus normal weight (N) patient sera. (b) PGE2 
concentration in conditioned media (CM) from macrophages following exposure to 
OB or N patient sera. (c) COX-2 expression in U937 cells (matured to 
macrophages) after a six-hour serum-starvation period (Baseline), 12 hours after 
removal of the sera (OB and N, 12hr), and 24 hours after removal of the sera (OB 
and N, 24hr).  (d) Aromatase expression in pre-adipocytes incubated in 
macrophage CM generated following patient sera exposure (OB-CM, N-CM) with 
vehicle or celecoxib treatment. (e) The impact of macrophage CM on pre-adipocyte 
aromatase expression when individual patient serum samples were utilized for CM 
generation, with the results averaged according to patient BMI category. (f) 
Estradiol concentration in CM from macrophage/pre-adipocyte co-cultures 
exposed to patient sera, then incubated in serum-free media with vehicle, 
testosterone, and/or anastrozole. Data shown represents the average of at least 
three independent experiments, with the exception of (d).  *, p<0.05; **, p<0.01 in 
comparison to N or N-CM; different letters indicate significant differences, p<0.05.   
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3.3.4 Obesity-associated pre-adipocyte aromatase expression promotes 
greater breast cancer cell ERα activity 
After establishing that obesity-associated circulating factors stimulate pre-
adipocyte aromatase expression and estradiol production via their induction of 
macrophage PGE2 generation, we sought to determine whether this elevation in 
estradiol results in enhanced breast cancer cell ERα activity. ERα positive breast 
cancer cells cultured in CM from OB versus N sera-exposed macrophage/pre-
adipocyte co-cultures (OB+T-CM, N+T-CM) exhibited greater ERα activity, as 
measured by estrogen response element (ERE) luciferase assay, with 29% and 
42% differences in MCF-7 and T47D cells, respectively (Figures 2a and b). Co-
culture treatment with anastrozole after sera exposure (OB+T+AI-CM, N+T+AI-
CM) significantly decreased the OB-induced ERα activity in both cell lines, 
eliminating the difference between OB+T-CM versus N+T-CM-induced breast 
cancer cell ERα activity and mirroring the drug’s effect on sera-induced pre-
adipocyte estradiol production. OB and N co-culture CM produced without 
testosterone (OB-CM, N-CM) stimulated MCF-7 and T47D cell ERα activity that 
was statistically equivalent to that induced by CM from co-cultures treated with 
testosterone and anastrozole. Similar results were obtained when the CM was 
generated with anastrozole treatment but no testosterone (OB+AI-CM, N+AI-CM). 
This shows that the presence of testosterone during co-culture CM generation is 
required for the OB-induced elevation in breast cancer cell ERα activity, further 
demonstrating that this effect is due to pre-adipocyte aromatase activity. We 
53 
 
utilized pS2 and cyclin D1 expression as additional measures of ERα activity, 
obtaining analogous results. Following growth in OB+T-CM versus N+T-CM, pS2 
expression was 49% higher in MCF-7 cells and 63% greater in T47D cells (Figures 
2c and d) while cyclin D1 expression was elevated by 70% in MCF-7 cells and 
78% in T47D cells (Figures 2e and f). Co-culture treatment with anastrozole 
neutralized these differences in pS2 and cyclin D1 expression in both cell lines 
and, as seen with the ERE luciferase assays, CM generated without testosterone 
stimulated equivalent expression. Together, these results demonstrate that the 
obesity-associated, PGE2-induced increase in pre-adipocyte aromatase 
expression and estradiol production can enhance breast cancer cell ERα activity. 
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Figure 3.2 Obesity-associated pre-adipocyte aromatase expression 
promotes greater breast cancer cell ER activity. MCF-7 and T47D breast 
cancer cell ER activity after culture in macrophage/pre-adipocyte co-culture CM, 
as measured by ERE luciferase reporter (a, b) and qPCR analysis of pS2 (c, d) 
and cyclin D1 (e, f) expression. Experimental conditions include CM from co-
cultures exposed to obese (OB) or normal weight (N) patient sera (OB-CM, N-CM) 
followed by incubation in serum-free media with vehicle, testosterone, testosterone 
and/or anastrozole. Data shown represents the average of at least three 
independent experiments. Different letters indicate significant differences, p<0.05.   
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3.3.5 Breast cancer cell proliferation and migration are induced by obesity-
associated pre-adipocyte aromatase expression  
In order to determine whether the obesity-associated PGE2-induced 
elevation in pre-adipocyte aromatase expression and breast cancer cell ERα 
activity could result in enhanced disease progression, we assessed the impact of 
the macrophage/pre-adipocyte co-culture CM on breast cancer cell proliferation 
and migration. Culturing MCF-7 and T47D cells in OB+T-CM versus N+T-CM 
increased proliferation by 59% and 55%, respectively (Figures 3a and b). 
Treatment of the co-culture with anastrozole during CM generation (OB+T+AI-CM, 
N+T+AI-CM) eliminated the difference between OB and N, demonstrating that the 
OB+T-CM’s elevated estradiol concentration is responsible for its effect on cell 
proliferation. This conclusion is further supported by the lack of any difference in 
proliferation levels in MDA-MB-231 cells, an ERα negative breast cancer cell line, 
following culture in the four CM conditions (Figure 3c). A similar trend was seen 
when we examined the impact of the co-culture CM on ERα positive breast cancer 
cell migration. OB+T-CM stimulated 57% more MCF-7 and 46% greater T47D cell 
migration in comparison to N+T-CM (Figure 4a and b). This effect was neutralized 
in the T47D cells by treatment of the co-culture with anastrozole during CM 
production (OB+T+AI-CM, N+T+AI-CM). However, while aromatase inhibition 
significantly decreased OB-induced MCF-7 cell migration, these cells still migrated 
farther than those cultured in N+T+AI-CM. Intriguingly, the migration of MDA-MB-
231 cells was also significantly enhanced by culture in OB+T-CM versus N+T-CM 
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(Figure 4c). Consistent with this cell line’s ERα negative status, anastrozole 
treatment during CM generation did not affect the CM’s impact on migration. 
Overall, these findings strongly suggest that obesity-associated circulating factors 
may promote ERα positive breast cancer progression via stimulation of 
macrophage PGE2 production and the subsequent increase in pre-adipocyte 
aromatase expression.  
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Figure 3.3 ER positive breast cancer cell proliferation is induced by obesity-
associated pre-adipocyte aromatase expression. MCF-7 (a), T47D (b), and 
MDA-MB-231 (c) breast cancer cell proliferation in response to culture in 
macrophage/pre-adipocyte co-culture CM. Experimental conditions include CM 
from co-cultures exposed to obese (OB) or normal weight (N) patient sera (OB-
CM, N-CM) followed by incubation in serum-free media with vehicle, testosterone, 
and/or anastrozole. Data shown represents the average of at least three 
independent experiments. Different letters indicate significant differences, p<0.05.  
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Figure 3.4. Obesity-associated pre-adipocyte aromatase expression promotes 
breast cancer cell migration. MCF-7 (a), T47D (b), and MDA-MB-231 (c) breast cancer 
cell migration during incubation in macrophage/pre-adipocyte co-culture CM. Experimental 
conditions include CM from co-cultures exposed to obese (OB) or normal weight (N) 
patient sera (OB-CM, N-CM) followed by culture in serum-free media with vehicle, 
testosterone and/or anastrozole. Data shown represents the average of at least three 
independent experiments. Different letters indicate significant differences, p<0.05.   
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3.4 Discussion 
Suboptimal pharmacologic aromatase inhibition in postmenopausal patients 
with ERα positive breast cancer has detrimental consequences to clinical outcome. 
COX-2 is a critical node for the convergence of various upstream pathways of 
inflammation, including IL-1, IL-6, and TNF signaling (100-101), and it appears to 
be a key mediator of biologic processes affecting treatment failure, such as PGE2 
synthesis and the resulting aromatase expression and estrogen production. Our 
study is the first to specifically examine the molecular mechanisms that may 
mediate the impact of daily NSAID use on recurrence rate and time to disease 
progression in patients with invasive breast cancer receiving adjuvant endocrine 
therapy. We have demonstrated that the NSAID users in this patient population 
had a 48% lower recurrence rate. A similar trend was seen after controlling for 
patient age and tumor stage at diagnosis, though the strength of the association 
was reduced (data not shown).  This is not surprising given that late-stage tumors, 
as well as the aggressive tumors that disproportionately develop in younger 
women, seem less likely to significantly benefit from the modest effects of this drug 
group. NSAID users also remained disease-free for more than two years longer 
than non-users, a difference that was not statistically significant but may be a 
clinically relevant variance in outcome.   
Similar results have been obtained in some larger prospective studies 
examining NSAID use after breast cancer diagnosis. Holmes et al. (96) showed 
that aspirin use 6-7 days/week was associated with a significant reduction in the 
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risk of recurrence (RR, 0.57; 95% CI, 0.39-0.82). Utilizing the Nurses’ Health 
Study’s substantial pool of subjects, the authors found no change in these results 
after stratifying by BMI, menopausal status, and ER status. In an analysis of 
postmenopausal breast cancer patient outcomes, Blair and colleagues (98) 
observed that any amount of regular NSAID use was correlated with a lower risk 
of breast cancer death (HR, 0.64; 95% CI, 0.39-1.05). Adjustment for ERα status, 
but not BMI category, increased the HR and reduced the statistical significance of 
this association. In contrast with these studies, the recurrence rate in a population 
of pre and postmenopausal patients was not decreased by aspirin use ≥3 
days/week (RR, 1.09; 95% CI, 0.74-1.61), but was affected by use of ibuprofen 
(RR, 0.56; 95% CI, 0.32-0.98) (97). Controlling for BMI, menopausal status, and 
ERα did not alter these results.   
The variability in design and patient population among these studies makes 
any comparison with our results difficult. Cumulatively, they appear to indicate that 
NSAID use may be an effective addition to adjuvant breast cancer treatment, 
regardless of BMI, ERα, or menopausal status. However, the association between 
NSAID use and a 50% lower disease recurrence in our study, despite a relatively 
small patient population, led us to hypothesize that the overwhelming prevalence 
of overweight/obesity among this population may have increased the NSAID 
benefit. Our patient population was also largely postmenopausal and included only 
hormone responsive patients. Because obesity and overweight status are 
associated with higher PGE2-induced aromatase expression in female breast 
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tissue (41-42), it seems likely that the efficacy of COX-2 inhibitors in a 
postmenopausal, ERα positive patient population would increase with greater 
adiposity. Perhaps the lack of variation in effect among BMI categories in previous 
studies is due to their failure to stratify the data by BMI, ERα, and menopausal 
status simultaneously. This question could potentially be addressed by previous 
trials assessing the clinical benefit of a celecoxib/aromatase inhibitor combination 
treatment for postmenopausal, hormone-responsive breast cancer. Most of these 
studies showed a modest benefit with at least three months of combination 
treatment, including trends towards more clinical complete response, longer 
duration of clinical benefit, and greater progression-free survival (102-104). 
Unfortunately, none of these trials analyzed the treatment benefit by BMI category, 
so it is impossible to determine from this data whether overweight/obese women 
in this patient population are more likely to benefit from COX-2 inhibition.   
Given that obesity has been associated with a worse breast cancer prognosis 
(19-23) as well as a reduced response to aromatase inhibitor therapy among 
postmenopausal, ERα positive patients (48-49), determination of whether this 
specific population will benefit from COX-2 inhibition is an important question. 
Dannenberg et al. have demonstrated an obesity-associated, PGE2-induced 
elevation in pre-adipocyte aromatase expression using both pre-clinical models 
and patient breast tissue (41-43). Our aim was to confirm this phenomenon, using 
an in vitro model of the obese patient’s breast tumor microenvironment, as well as 
determine whether this increased pre-adipocyte aromatase expression can 
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promote greater epithelial cell ERactivity and subsequent proliferation and 
migration, two in vitro measures of cancer progression. We show that exposure to 
sera from obese postmenopausal women stimulates significantly greater 
macrophage COX-2 expression and a five-fold increase in PGE2 production. 
Saturated fatty acids can promote COX-2 expression and PGE2 production in 
cultured macrophages (43, 105),   and the increased lipolysis that accompanies 
obesity results in a higher concentration of circulating free fatty acids (106-108). 
Consequently, this difference in macrophage COX-2 expression and PGE2 
production may be due to elevated levels of free fatty acids in the obese patient 
sera. However, there is also some evidence that the inflammatory cytokines IL-6 
and TNF, found in higher concentrations in our obese patient serum samples 
(99), can induce COX-2 expression (36-37, 101). This suggests that more than 
one mechanism may be responsible for the obesity-associated upregulation of 
macrophage COX-2 expression and PGE2 production seen in this study. 
Taken together, our in vitro data provides compelling evidence that 
macrophage-derived PGE2 stimulates greater pre-adipocyte aromatase 
expression and estradiol production, resulting in an elevation in breast cancer cell 
ERα activity, proliferation, and migration. Neutralization of the obesity-induced 
elevation in ERα activity and cell proliferation by the addition of aromatase inhibitor 
treatment validates our hypothesis that these effects are due to pre-adipocyte 
aromatase expression and estradiol production. However, while incubation of the 
ERα negative MDA-MB-231 cells in OB versus N macrophage/pre-adipocyte co-
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culture CM did not differentially affect cell proliferation, it did stimulate significantly 
greater cell migration. In addition, OB CM continued to promote more extensive 
MCF-7 cell migration in comparison to N CM with aromatase inhibition during CM 
generation, though anastrozole did significantly decrease the OB CM-induced 
migration. These results indicate that, while locally produced estradiol clearly plays 
a role in mediating obesity-associated breast cancer cell migration, one or more 
additional signaling molecules produced by macrophages and/or pre-adipocytes is 
involved in this effect. Macrophage-derived PGE2 is one possibility, as it is known 
to promote breast cancer cell migration (109-110). Several studies have concluded 
that it also stimulates breast cancer cell proliferation based on the ability of COX-
2 inhibitors to hinder proliferation (111-112). However, we saw no differential 
proliferation in the MDA-MB-231 cells following incubation in OB versus N CM, and 
Robertson et al (113) demonstrated that treatment of MDA-MB-231 cells with 
exogenous PGE2 does not increase proliferation. The role of additional locally 
produced signaling molecules in the link between obesity-associated inflammation 
and breast cancer progression is an area that deserves further exploration in future 
studies.   
Our current investigation strongly suggests that PGE2-induced local estradiol 
production may be a key mediator in the link between obesity and 
postmenopausal, hormone-responsive breast cancer progression. This conclusion 
is supported by the clinical observation of a 50% lower recurrence rate and 28-
month extension in time to recurrence with NSAID use in a largely 
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overweight/obese and postmenopausal patient population with ERα positive 
disease. Collectively, our results provide a strong rationale for further studies 
regarding the clinical benefit of aromatase inhibitor/COX-2 inhibitor combination 
treatment for obese, postmenopausal breast cancer patients. 
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Chapter 4: Obesity promotes pre-adipocyte aromatase expression via breast 
cancer cell prostaglandin E2 production in an in vitro model of the breast tumor 
microenvironment 
 
4.1 Introduction 
The majority of breast cancer cases occur in postmenopausal women (1), 
though tumors in this population are typically less aggressive than those occurring 
in younger women (11). However, the obesity rate in women ≥60 years of age in 
the United States is currently 42.3%, the highest of any gender/age category (17), 
and this condition has been associated with a worse breast cancer prognosis. A 
2010 meta-analysis of 43 studies found that obesity at diagnosis is associated with 
poorer breast cancer specific and overall survival (23), and others have shown that 
the strength of the latter association increases with each successive increase in 
body mass index (BMI) category (19). Links between obesity and an increased risk 
of breast cancer recurrence and shorter disease-free survival (20, 22), 
independent of tumor stage at diagnosis (21), have also been established.  
Postmenopausal obesity is generally accompanied by an elevation in 
circulating estrogen levels because adipose tissue is the primary site of aromatase 
expression following menopause (25-27). Consequently, some researchers have 
hypothesized that this excess estrogen may link obesity with more aggressive 
estrogen receptor alpha (ER) positive breast tumors in postmenopausal women, 
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a theory supported by studies demonstrating a reduced response to aromatase 
inhibitor treatment in obese patients (48-49, 51). However, this explanation has 
been confounded by studies demonstrating that estrogen levels in breast tumor 
tissue can be up to 10-fold higher than serum concentrations (32). A corresponding 
5-fold elevation in aromatase expression in the tumor and associated adipose 
tissue in comparison to disease-free tissue (32) suggests that this estrogen is 
being produced locally, likely via a paracrine interaction between the adipose and 
tumor tissues. In support of this possibility, O’Neill et al. (33) demonstrated in their 
analysis of 12 breast samples that the highest aromatase activity is consistently 
found in the tumor-containing breast quadrant. Zhou et al. (30) later established 
that breast cancer cell-secreted prostaglandin E2 (PGE2), as well as other factors, 
stimulates aromatase expression in pre-adipocytes, the primary aromatase-
expressing fraction of the adipose tissue. These findings indicate that an elevation 
in systemic estrogen levels will probably not have a significant impact on breast 
tumor ER activity, given that a much larger local source of estrogen is available 
in the tumor microenvironment and adjacent adipose tissue. 
However, aromatase and estrogen may still be key factors in the link between 
obesity and poor prognosis in ER positive, postmenopausal breast cancer 
patients. Obesity is associated with increased circulating levels of several growth 
factors, cytokines, and adipokines that may enhance the paracrine interaction 
described above, resulting in a further elevation in local aromatase levels and 
estrogen production.  For example, serum concentrations of interleukin-6 (IL-6), 
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an inflammatory cytokine secreted by both immune cells and adipocytes, are 
generally increased with obesity (34), and this cytokine has been shown to 
promote PGE2 production in multiple cell types via its effects on cyclooxygenase-
2 (COX-2) (35-37).  In the current study, we utilized an in vitro model of obesity to 
investigate the impact of obesity-associated systemic factors on the aromatase-
promoting paracrine interaction between ER positive breast cancer cells and pre-
adipocytes. After establishing that obesity does enhance this interaction, we 
demonstrated that it results in greater breast cancer cell ER activity and 
proliferation, suggesting that it may be one mechanism by which obesity promotes 
a worse breast cancer prognosis.  
 
4.2 Materials and Methods 
4.2.1 Serum samples 
Serum was collected from 25 postmenopausal breast cancer patients under 
an IRB approved biorepository collection protocol at the CTRC of UTHSCSA. The 
collection and use of these biological samples was conducted in accordance with 
the Declaration of Helsinki and good clinical practice. Informed consent was 
obtained prior to participation, and all samples and data were de-identified prior to 
release to maintain patient confidentiality. BMI was calculated, and serum was 
pooled according to the BMI category of the patient (normal weight (18.5-24.9 
kg/m2) or obese (≥30.0 kg/m2).  
4.2.2 Cell lines and reagents 
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The ER positive MCF-7 and T47D breast cancer cell lines (ATCC) were 
maintained in IMEM (GIBCO Life Technologies) supplemented with 10% fetal 
bovine serum (FBS). Pre-adipocytes isolated from women undergoing elective 
surgical procedures were a generous gift from Dr. Rong Li, UTHSCSA, and have 
been described previously (79). They were maintained in DMEM/F12 1:1 media 
(GIBCO Life Technologies) plus 10% FBS. Celecoxib, human recombinant insulin, 
testosterone, and anastrozole were purchased from Sigma-Aldrich (St. Louis, MO) 
and human recombinant IL-6, tumor necrosis factor alpha (TNF-leptin, and 
insulin-like growth factor 1 (IGF-1) from R&D Systems (Minneapolis, MN). The IL-
6 depleting antibody was produced by EMD Millipore (Billerica, MA).   
4.2.3 MCF-7 cell conditioned media 
MCF-7 cell conditioned media (CM) was generated by seeding 2x105 MCF-7 
cells per well in 6-well plates, allowing them to grow for 24 hours, then serum-
starving the cells for 18 hours. The MCF-7 cells were then exposed to a 2% 
concentration of the pooled sera samples in serum-free media (SFM) for one hour, 
the sera removed and cells washed once with phosphate buffered saline (PBS) 
followed by incubation in SFM for 24 hours. Over the course of this 24 hours, the 
cells release various factors into the SFM, enriching it into CM, which was then 
collected and stored at -20°C for subsequent in vitro assays.  
4.2.4 MCF-7/pre-adipocyte conditioned media 
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MCF-7/pre-adipocyte co-culture CM was generated by first seeding 1x105 
MCF-7 cells on top of confluent pre-adipocytes seeded in six-well plates. After a 
24 hour incubation to allow the MCF-7 cells to adhere, the co-culture was serum-
starved for 18 hours, then exposed to a 2% concentration of the pooled sera in 
SFM for one hour. Following this, the cells were washed once with PBS and 
incubated for 24 hours in SFM + testosterone (100 nM) + anastrozole (1 uM) or 
vehicle. The enriched SFM, now considered CM, was then collected and stored at 
-20° C for use in subsequent in vitro assays.   
4.2.5 Quantitative RT-PCR 
MCF-7 cell PTGS2 (COX-2) mRNA levels were measured following a 18 hour 
serum-starvation period (baseline level) and a one-hour exposure to a 2% 
concentration of pooled patient sera in SFM. To determine whether MCF-7 cell 
COX-2 expression continued to change during the 24-hour SFM incubation period 
of CM generation, mRNA levels were also assessed after 12 and 24 hours in SFM 
(following the removal of the sera).    Pre-adipocyte CYP19A1 (aromatase) mRNA 
levels were assessed following a 24-hour incubation in MCF-7 CM.  To assess the 
impact of MCF-7 cell COX-2 inhibition on pre-adipocyte aromatase expression, the 
MCF-7 cells were pre-treated with 30 uM celecoxib for one hour prior to as well as 
during sera exposure when generating the MCF-7 CM. We previously measured 
the concentrations of several obesity-associated circulating factors, including IL-6, 
TNF-, leptin, insulin, and free IGF-1, in the obese versus normal weight patient 
sera samples (99). To examine whether these factors contribute to the aromatase-
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promoting paracrine interaction between breast cancer cells and pre-adipocytes, 
each factor was added back to the pooled normal weight patient sera. With the 
exception of IGF-1, the amount of each factor added was determined by the 
difference in average concentration between the obese and normal weight 
patients’ serum samples. There was no significant difference in free IGF-1 found 
in our samples, so it was added in an amount typically used in cell culture 
experiments (20 ng/ml) in order to examine whether IGF-1 could have an effect. 
Aromatase expression was then measured in pre-adipocytes exposed to MCF-7 
cell CM generated with this enhanced normal weight sera as well as MCF-7 CM 
generated with non-enhanced obese and normal weight patient sera. To further 
examine the role of serum IL-6, the pooled sera samples were incubated with or 
without an IL-6 depleting antibody (10 ug/ml) for one hour at room temperature 
prior to use of the sera for MCF-7 cell CM generation and subsequent aromatase 
expression measurement in pre-adipocytes exposed to this MCF-7 CM. MCF-7 
and T47D TFF1 (pS2) and CCND1 (cyclin D1) mRNA levels were measured after 
a 24-hour incubation in MCF-7/pre-adipocyte co-culture CM supplemented with 
2% charcoal-stripped (CS)-FBS. All cells were serum-starved for 18 hours prior to 
exposure to sera or CM. Total RNA was isolated using TRIzol reagent (Invitrogen) 
and reverse transcribed with Promega’s ImProm II Reverse Transcription System. 
The primer sequences are as follows: PTGS2: forward, 5’-
CCCTTGGGTGTCAAAGGTAA-3’; reverse, 5’-GCCCTCGCTTATGATCT GTC-3’; 
CYP19A1: forward, 5’-GCCGAATCGAGAGCTGTAAT-3’; reverse, 5’-
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GAGAATTCATGCGAGTCTGGA-3’; TFF1: forward, 5’-GGTCGCCTTGGAGC 
AGA-3’; reverse, 5’-GGGCGAAGATCACCTTGTT-3’; CCND1:  forward, 5’-TGG 
AGGTCTGCGA GGAACAGAA-3’; reverse, 5’-TGCAGGCGGCTCTTTTTCA-3’. 
The manufacturer’s recommended cycling conditions for the QuantiFast SYBR 
Green PCR kit (Qiagen) were used. Data shown represents the average of at least 
three independent experiments.  
4.2.6 Prostaglandin E2 and estradiol concentrations 
The concentration of prostaglandin E2 in MCF-7 CM was measured using the 
Prostaglandin E2 Parameter Assay Kit from R&D Systems (Minneapolis, MN). The 
estradiol concentration in macrophage/pre-adipocyte co-culture CM was analyzed 
with the Estradiol EIA Kit from Cayman Chemical (Ann Arbor, MI). 
4.2.7 Cell proliferation  
MCF-7 and T47D cell proliferation was measured using cell counting by 
hemocytometer following a 48-hour incubation in MCF-7/pre-adipocyte co-culture 
CM supplemented with 2% CS-FBS. The cells were seeded in 24-well plates at a 
density of 1x104 cells/well for MCF-7 cells and 1.5x104 cells/well for T47D cells, 
then serum-starved for six hours the following day. For each cell line, the relative 
number of cells after 48 hours was calculated by dividing the cell number for each 
experimental condition by that for cells grown in CM generated with normal weight 
sera exposure followed by incubation in SFM + testosterone, then multiplying that 
number by 1x105. 
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4.2.8 Statistical analysis 
Differences between cells exposed to two different experimental conditions 
were measured using Student’s t test. Two-way ANOVA was used to analyze 
experiments with two independent variables. A p value of <0.05 was considered 
significant.   
 
4.3 Results 
4.3.1 Pre-adipocyte aromatase expression is induced by obesity-associated 
circulating factors via stimulation of breast cancer cell PGE2 production 
Given that breast cancer cells are known to produce factors, including PGE2, 
that promote pre-adipocyte aromatase expression, we began by examining 
whether obesity-associating circulating factors could enhance this paracrine 
interaction.  To mimic the tumor microenvironment of an obese versus normal 
weight patient, we utilized an in vitro model in which cultured cells were exposed 
to postmenopausal breast cancer patient sera samples pooled according to BMI 
category (normal weight (N): 18.5-24.9 kg/m2; obese (OB): ≥30 kg/m2). The 
characteristics of the serum donors have been previously described (23). 
Conditioned media (CM) from MCF-7 breast cancer cells exposed to OB or N 
patient sera (OB-CM or N-CM, respectively) for one hour was generated. Pre-
adipocytes cultured in OB-CM had 89% higher aromatase expression in 
comparison to N-CM (p<0.05), demonstrating that OB patient sera promotes 
greater breast cancer cell production of factors that stimulate pre-adipocyte 
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aromatase expression (Figure 4.1a). One factor known to induce aromatase 
expression is PGE2, which is produced from arachidonic acid via a reaction 
catalyzed by COX-2.  Consequently, we next measured the impact of patient sera 
exposure on MCF-7 cell COX-2 expression and PGE2 production.  Following a 
one hour exposure to OB versus N patient sera, there was no significant difference 
in MCF-7 cell COX-2 expression between these conditions or in comparison to the 
baseline expression prior to sera exposure. However, COX-2 expression 
continued to increase during 24 hours of incubation in SFM following sera removal, 
with the expression in cells exposed to OB patient sera increasing to a greater 
degree.  At 24 hours, COX-2 expression in the MCF-7 cells that had been exposed 
to OB patient sera was 40% higher than N (p<0.05) (Figure 4.1b).  This 
methodology corresponds to the conditions under which the MCF-7 CM was 
generated, with the 24 hour time point reflecting COX-2 expression at the time of 
CM collection.  Intriguingly, the PGE2 concentration in MCF-7 cell OB-CM was 
almost 14-fold higher than N-CM (p<0.05) (Figure 4.1c). Celecoxib treatment was 
then used to determine whether the OB patient sera-induced COX-2 expression 
contributes to the OB-CM’s enhancement of pre-adipocyte aromatase expression.  
COX-2 inhibition in MCF-7 cells during CM generation significantly decreased the 
pre-adipocyte aromatase expression levels induced by both OB and N-CM 
(p<0.05), eliminating the difference between the two conditions (Figure 4.1d). This 
indicates that one or more obesity-associated circulating factors stimulate greater 
breast cancer cell PGE2 production, resulting in the promotion of higher pre-
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adipocyte aromatase expression through a paracrine interaction between the two 
cell types.  
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Figure 4.1 Obesity-associated circulating factors promote pre-adipocyte 
aromatase expression via stimulation of breast cancer cell COX-2 
expression and PGE2 production. (a) Aromatase expression in pre-adipocytes 
incubated in MCF-7 cell conditioned media (CM) generated following obese versus 
normal weight sera exposure (OB-CM and N-CM). (b) COX-2 expression in MCF-
7 cells after an 18-hour serum-starvation period (Baseline), 1 hr of sera exposure 
(OB and N, 1hr), 12 hr after removal of the sera (OB and N, 12hr), and 24 hr after 
removal of the sera (OB and N, 24hr). (c) Concentration of PGE2 produced by 
MCF-7 cells following exposure to OB or N sera. (d) Aromatase expression in pre-
adipocytes incubated in MCF-7 cell CM generated following sera exposure (OB-
CM, N-CM) with vehicle or celecoxib treatment. (e) Estradiol concentration in CM 
from MCF-7/pre-adipocyte co-culture exposed to sera (OB-CM, N-CM) followed by 
incubation in serum-free media with vehicle, testosterone, and/or anastrozole. 
Data shown represents the average of at least three independent experiments. 
Asterisks indicate significant differences in comparison to N or N-CM; different 
letters indicate significant differences, p<0.05. 
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4.3.2 Obesity-associated systemic IL-6 indirectly stimulates pre-adipocyte 
aromatase expression  
We have previously shown that the serum IL-6, TNF-, and leptin 
concentrations in our obese patient population were significantly elevated in 
comparison to normal weight patients. Serum insulin levels in the obese patients 
were also four-fold higher, a difference that approached significance, but there was 
no significant variance in free IGF-1 concentration (99).  Our next aim was to 
determine whether any of these obesity-associated systemic factors contribute to 
the promotion of the aromatase-enhancing paracrine interaction between breast 
cancer cells and pre-adipocytes.  To this end, we repeated our measurement of 
MCF-7 CM-stimulated pre-adipocyte aromatase expression with the addition of 
each factor to the pooled N patient sera during CM generation.  For IL-6, TNF-, 
leptin, and insulin, the amount of each factor added was determined by the 
difference in average concentration between the OB and N patients’ serum 
samples.  Though free IGF-1 was not elevated in our OB patient population, others 
have shown this growth factor to be increased with obesity (38-39), so we also 
included a condition with IGF-1 added to the N patient sera in an amount typically 
used for cell culture. Similar to our previous results, OB-CM stimulated 
approximately two-fold greater pre-adipocyte aromatase expression in comparison 
to N-CM (p<0.05). The addition of IL-6 or TNF- to the N patient sera during MCF-
7 CM generation significantly increased the resulting CM’s effect on pre-adipocyte 
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aromatase expression, with IL-6 having the greatest effect (p<0.05).  In fact, N-CM 
produced with IL-6 stimulated pre-adipocyte aromatase levels that were 
statistically equivalent to the OB-CM condition. The addition of both IL-6 and TNF-
 or all five factors to the N sera did not produce CM that further enhanced 
aromatase expression above the addition of IL-6 alone (Figure 4.2a). To confirm 
that IL-6 was the primary factor in the OB patient sera mediating its indirect 
enhancement of pre-adipocyte aromatase expression, we next added an IL-6 
depleting antibody to both the OB and N patient sera prior to their use, thereby 
neutralizing the variation in IL-6 content between the two.  This sera was then 
utilized to generate MCF-7 CM.  Aromatase expression in pre-adipocytes exposed 
to OB or N-CM produced with IL-6-depleted sera was significantly reduced in 
comparison to the OB or N-CM generated with untreated sera (p<0.05), and the 
IL-6 depletion eliminated the difference between the OB and N-CM conditions 
(Figure 4.2b). This demonstrates that IL-6, an inflammatory cytokine known to be 
systemically elevated with obesity, is the primary mediator of the OB patient sera’s 
aromatase enhancing effects. 
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Figure 4.2. Pre-adipocyte aromatase expression is indirectly stimulated by 
obesity-associated systemic IL-6. (a) Aromatase expression in pre-adipocytes 
exposed to MCF-7 cell CM generated following patient sera exposure (OB-CM and 
N-CM) +/- five obesity-associated circulating factors, including IL-6, TNF-, leptin, 
insulin, and IGF-1. (b) Aromatase expression in pre-adipocytes exposed to MCF-
7 cell CM generated following exposure to untreated patient sera (OB-CM and N-
CM) or patient sera pre-treated with an IL-6 depleting antibody (OB+AB-CM and 
N+AB-CM). Data shown represents the average of at least three independent 
experiments. Different letters indicate significant differences, p<0.05. 
 
4.3.3 Obesity-associated pre-adipocyte aromatase expression enhances 
breast cancer cell ER activity and proliferation 
To examine whether the observed obesity-associated increase in pre-
adipocyte aromatase expression could promote breast cancer progression, we first 
assessed whether it was associated with higher breast cancer cell ER activity. 
CM from a co-culture of MCF-7 cells and pre-adipocytes was generated by 
exposing the cells to either OB or N patient sera, then incubating them in SFM plus 
testosterone, the latter serving as the substrate for aromatase.  Expression of pS2, 
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a specific measure of ER activity, was 76% and 80% higher (p<0.05) in MCF-7 
and T47D breast cancer cells, respectively, cultured in the resulting OB versus N 
co-culture CM. Expression levels of cyclin D1, another ER target gene, were also 
elevated (p<0.05) in the same cell lines following exposure to OB-CM versus N-
CM (Figure 4.3a and b). Aromatase inhibition by anastrozole during CM generation 
reduced OB-CM-stimulated pS2 and cyclin D1 expression in the MCF-7 cells 
(p<0.05), neutralizing the difference between OB and N-CM in pS2, but not cyclin 
D1, expression. In the T47D cells, aromatase inhibition resulted in a similar 
decrease in the levels of OB-CM-induced pS2 and cyclin D1 expression (p<0.05), 
but the addition of anastrozole also significantly inhibited the N-CM’s effect on 
these ER target genes (p<0.05). Consequently, pS2 and cyclin D1 levels in the  
N-CM plus anastrozole condition were significantly lower than the levels in T47D 
cells exposed to either N-CM or OB-CM plus anastrozole, suggesting that 
aromatase inhibition may not be able to fully suppress the OB patient sera-induced 
estradiol production.  
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Figure 4.3. Obesity-associated pre-adipocyte aromatase expression 
enhances breast cancer cell ER activity. The impact of MCF-7/pre-adipocyte 
co-culture CM on ER activity in MCF-7 (a) and T47D (b) cells, as measured by 
qPCR analysis of pS2 and cyclin D1. Experimental conditions include CM from co-
cultures exposed to patient sera (OB-CM, N_CM) followed by incubation in serum-
free media with vehicle, testosterone, and/or anastrozole. Data shown represents 
the average of at least three independent experiments. Different letters indicate 
significant differences, p<0.05. 
 
These results closely correlated with the co-culture CM’s effect on breast 
cancer cell proliferation (Figure 4.4a and b).  MCF-7 and T47D cells cultured in OB 
versus N-CM demonstrated 45% and 68% greater proliferation levels (p<0.05).  
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The addition of anastrozole during CM generation reduced OB-CM-stimulated 
proliferation (p<0.05), but not to the level of N-CM without anastrozole. Aromatase 
inhibition was able to further decrease N-CM-stimulated cell proliferation (p<0.05).  
 
Figure 4.4. Breast cancer cell proliferation is increased by obesity-induced 
pre-adipocyte aromatase expression. MCF-7 (a) and T47D (b) breast cancer 
cell proliferation in response to culture in MCF-7/pre-adipocyte co-culture CM. 
Experimental conditions include CM from co-cultures exposed to patient sera (OB-
CM, N-CM) followed by incubation in serum-free media with vehicle, testosterone 
and/or anastrozole. Data shown represents the average of at least three 
independent experiments. Different letters indicate significant differences, p<0.05. 
 
4.4 Discussion 
Numerous studies have shown a positive association between obesity and a 
poor breast cancer prognosis, with the strongest effects frequently seen in 
postmenopausal, ER positive patients (19-24).  Obesity has also been linked to 
a reduced response to aromatase inhibitor therapy (48-49, 51), suggesting that it 
may promote breast cancer progression in this specific patient population via 
enhancement of local aromatase expression.  In the current study, we establish 
that an obesity-associated elevation in systemic levels of the pro-inflammatory 
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cytokine IL-6 promotes a PGE2-mediated paracrine interaction between breast 
cancer cells and pre-adipocytes, resulting in greater pre-adipocyte aromatase 
expression.  
Bulun et al. have previously demonstrated that pre-adipocyte aromatase 
expression is stimulated by a host of secretory products, including PGE2, found in 
MCF-7 breast cancer cell conditioned media. While PGE2 is known to be 
independently capable of stimulating aromatase expression in pre-adipocytes, the 
other breast cancer cell secretory products also make significant contributions to 
the conditioned media’s effect. In fact, stimulation of pre-adipocyte aromatase 
expression via MCF-7 cell conditioned media exposure persists with inhibition of 
breast cancer cell COX-2 activity, clearly showing that these other factors are 
involved in this paracrine interaction (30-31). Breast cancer cells also release 
TNF and interleukin-11 (IL-11), cytokines that inhibit the expression of adipogenic 
transcription factors and thereby prevent pre-adipocyte differentiation into mature 
adipocytes (114). Given that aromatase is expressed primarily in the 
undifferentiated fraction of adipose tissue (30, 115-116), this accrual of pre-
adipocytes in the tumor-adjacent breast tissue also enhances local aromatase 
expression.  
For this study, we focused on how obesity affects breast cancer cell 
production of secretory factors that directly stimulate pre-adipocyte aromatase 
expression. We were specifically interested in exploring whether obesity promotes 
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greater breast cancer cell PGE2 production because IL-6 has been shown to 
stimulate COX-2 expression in a number of cell types and concentrations of this 
cytokine were significantly elevated in our obese patient serum samples (35-37, 
99). In addition, the pathways by which PGE2 stimulates pre-adipocyte aromatase 
expression have been well-characterized (117-118), while other aromatase-
promoting breast cancer cell-derived factors remain largely unidentified.  
Consequently, we hypothesized that systemic factors known to be increased with 
obesity, including IL-6, stimulate greater MCF-7 cell COX-2 expression and PGE2 
production, resulting in higher pre-adipocyte aromatase expression and a 
subsequent increase in breast cancer cell ER activity and proliferation. 
Conditioned media from MCF-7 cells exposed to obese versus normal weight 
patient sera, which was shown to contain a higher concentration of PGE2, did 
stimulate greater pre-adipocyte aromatase expression. In support of an elevation 
in MCF-7 cell COX-2 expression and PGE2 production being responsible for this 
effect, we found that the difference in aromatase expression was eliminated by 
MCF-7 cell COX-2 inhibition during conditioned media generation. Thus, while 
other aromatase-promoting factors may be present in MCF-7 cell conditioned 
media, the production of these does not appear to vary with exposure to obese 
versus normal weight patient sera. In addition, our results indicate that an obesity-
associated elevation in serum IL-6 is primarily responsible for the difference 
between obese versus normal weight MCF-7 CM-induced pre-adipocyte 
aromatase expression, as depletion of IL-6 from the pooled sera also neutralized 
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this difference. Much of the excess systemic IL-6 found with obesity is produced 
by the adipose tissue (34), so local breast tissue IL-6 levels are likely also 
increased with obesity and contribute to this effect.  
Dannenberg et al. have also investigated the link between obesity and local 
aromatase expression, demonstrating that obesity is associated with elevated 
aromatase levels in the normal breast tissue of both disease-free women and 
breast cancer patients. Intriguingly, even stronger correlations were found 
between aromatase expression and levels of breast inflammation, defined by the 
number of macrophage-containing crown-like structures of the breast (CLS-B), as 
well as macrophage-secreted PGE2 (41-42).  In vitro experiments further defined 
the pathways mediating this effect, showing that macrophage COX-2 expression 
and PGE2 production promote pre-adipocyte aromatase expression and ER 
target gene expression (41, 43). The authors argue that this pathway may 
contribute to the increased breast cancer risk seen in obese postmenopausal 
women, but do not address how it might impact an established tumor.  
We have recently submitted a manuscript detailing findings that complement 
the work of Dannenberg et al. and additionally examine whether this 
macrophage/pre-adipocyte paracrine interaction may promote breast cancer 
progression. Using an in vitro model of the obese patient’s tumor 
microenvironment, we demonstrated that obesity-associated systemic factors 
further enhance macrophage COX-2 expression and PGE2 production, resulting 
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greater pre-adipocyte aromatase expression as well as higher breast cancer ER 
activity, proliferation, and migration (119).  However, while it is clear from our work 
and that of Dannenberg et al. that macrophages play a significant role in 
stimulating obesity-associated local aromatase expression, macrophages are not 
the only PGE2-producing cells within tumor-bearing breast tissue.  If obesity does 
enhance breast cancer cell PGE2 secretion in vivo, then this would likely result in 
greater aromatase expression in the adjacent adipose tissue and a subsequent 
increase in breast cancer cell ER activity and proliferation, as we have 
demonstrated here with our in vitro model. To confirm the relevance of our model, 
future studies of breast cancer patient tissue should examine whether correlations 
exist between the following: obesity, aromatase expression and IL-6 and PGE2 
levels in the tumor and tumor-adjacent adipose tissue, and tumor ER target gene 
levels. 
Our assessment of the impact of this aromatase-promoting paracrine 
interaction on ER target gene expression revealed a significant difference 
between the obese and normal weight conditions. While pre-adipocyte aromatase 
inhibition was able to significantly reduce the obese CM-induced ER activity, it 
only eliminated the difference between the obese and normal weight conditions for 
MCF-7 cell pS2 expression. In addition, aromatase inhibition was not able to 
decrease obese CM-induced MCF-7 or T47D cell proliferation to the level of the 
normal weight CM without anastrozole. These results suggest that anastrozole 
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alone is unable to reduce the obese CM-induced pre-adipocyte aromatase activity 
down to the same level as the normal weight condition, resulting in significantly 
decreased but still elevated breast cancer cell ER target gene and proliferation 
levels. Given that anastrozole was slightly more effective at inhibiting obese CM-
induced ER target gene expression versus proliferation, it is also possible that 
the obese patient sera promotes the production of additional proliferation-
stimulating factors in the pre-adipocytes and/or breast cancer cells. However, it 
seems clear that pre-adipocyte aromatase expression is playing a role in the 
variation between the obese and normal weight CM in ER activity and 
proliferation. Our findings reflect a possible mechanism to explain previous studies 
demonstrating a reduced response to aromatase inhibitors in obese women, as 
well as our recent study showing that obese and overweight ER positive women 
receiving endocrine therapy have a higher recurrence rate and shorter time to 
recurrence (119). They also indicate that obese postmenopausal breast cancer 
patients may benefit from an aromatase inhibitor/COX-2 inhibitor combination 
treatment, as celecoxib treatment of the MCF-7 cells was able to significantly 
decrease MCF-7 cell CM-induced pre-adipocyte aromatase expression and 
neutralize the difference between the obese and normal weight conditions.   
This study provides strong evidence that obesity may promote 
postmenopausal, hormone responsive breast cancer progression via an elevation 
in local aromatase expression. Obesity-associated IL-6 enhances breast cancer 
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cell COX-2 expression and PGE2 production, resulting in higher levels of pre-
adipocyte aromatase expression and a subsequent increase in breast cancer cell 
ER activity and proliferation. Based on these results, an assessment of the 
clinical benefit of an aromatase inhibitor/COX-2 inhibitor combination treatment for 
obese, postmenopausal breast cancer patients is warranted. 
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Chapter 5: Obesity enhances nongenomic estrogen receptor crosstalk with 
the PI3K/Akt and MAPK pathways to promote in vitro measures of breast 
cancer progression 
 
5.1 Introduction 
The prevalence of obesity in the United States has been climbing steadily for 
the past three decades, resulting in a current adult obesity rate of 35.7% (17).  A 
similar trend is evident in other nations around the world and is no longer unique 
to wealthy, industrialized countries (18).  This epidemic poses a dire threat to public 
health, as obesity can play a role in the pathogenesis of numerous diseases, 
including breast cancer.   In postmenopausal women, obesity increases breast 
cancer risk by approximately 40% (3-5).   A large body of evidence has also 
established that obesity is associated with a worse breast cancer prognosis for 
both pre- and postmenopausal women.  One prospective study that followed a 
population of more than 900,000 U.S. adults over a 16 year period found that the 
mortality rate due to breast cancer was amplified with each successive increase in 
body mass index (BMI) category (19).  Another study showed a significantly 
greater risk for disease recurrence within 10 years of diagnosis in breast cancer 
patients who were obese at the time of treatment in comparison to non-obese 
patients (20).  These effects could be due to later diagnosis in the obese 
population, resulting in more advanced disease at the time of diagnosis.  This 
hypothesis was initially supported by data from a large cohort of patients followed 
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for a 20 year period; Majed et al. (21) found that the obese patients presented with 
more advanced tumors, suggesting that diagnosis had been delayed.  However, 
the authors ultimately found that multivariate analysis demonstrated an 
independent effect of obesity on breast cancer prognosis, regardless of tumor 
stage at time of diagnosis.  Survival analysis revealed increased metastatic 
recurrence as well as decreased disease-free interval and overall survival in the 
obese patient population.  While obesity has been shown to negatively impact 
prognosis for both pre- and postmenopausal patients, the most prominent effects 
are seen in estrogen receptor alpha (ER) positive postmenopausal patients, a 
finding confirmed by a recent retrospective analysis of the German BRENDA-
cohort (24). 
Previous studies indicate that obesity may adversely impact prognosis in the 
ER positive postmenopausal patient population in part by promoting endocrine 
therapy resistance (22).  This theory is supported by an analysis of data from the 
ATAC trial by Sestak et al. (48), which found that obese breast cancer patients 
receiving anastrozole had a significantly greater risk of recurrence.   In agreement 
with these findings, Schmid et al. (49) demonstrated that obese patients have a 
significantly reduced response rate to letrozole in comparison to lean (11 vs 35%).  
The ATAC trial also showed that while anatrozole treatment resulted in significantly 
greater recurrence-free survival in comparison to tamoxifen, this benefit was lost 
in the obese cohort (48).  The primary site of aromatase expression and estrogen 
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production in postmenopausal women is the adipose tissue.  Due to an abundance 
of this aromatase-expressing tissue, obese postmenopausal women typically have 
higher levels of circulating estradiol (25-27), and researchers have posited that this 
may contribute to the observed increase in breast cancer risk and worse outcome 
in this population.  This hypothesis suggests that an adjustment of the aromatase 
inhibitor dosage may improve obese patient prognosis.  However, that conclusion 
is confounded by two phase III clinical trials of anastrozole that found no overall 
benefit from a 10 mg dose (versus 1 mg), indicating that an increased dosage may 
not be effective in overcoming obesity-induced resistance to aromatase inhibitors 
(52-53).  
The development of endocrine therapy resistance can be mediated by 
several mechanisms.  Frequently, aberrant signaling from growth factor receptors, 
particularly the insulin-like growth factor 1 receptor (IGF-1R) and the HER family 
of receptors, is responsible.  These receptors can engage in bidirectional crosstalk 
with ER, leading to increased nongenomic ER activity, ligand-independent 
activation of ER, and abnormal regulation of cell cycle and apoptotic signaling.  
Nongenomic ER activity results in the activation of the MAPK and PI3K/Akt 
signaling pathways, and these can in turn activate ER via phosphorylation, 
leading to enhanced genomic ER activity (54-55).  Obesity is typically 
accompanied by elevated circulating levels of insulin, bioavailable IGF-1 and 
leptin, as well as a series of pro-inflammatory cytokines (34, 38-39, 65).  All of 
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these obesity-associated circulating factors are able to activate the PI3K/Akt 
and/or MAPK pathways, potentially enhancing the ER crosstalk pathways 
described above and leading to endocrine resistance and breast cancer 
progression (66-70).  The metabolic alterations associated with obesity, including 
changes in insulin and insulin-like growth factor binding protein 1 (IGFBP-1) serum 
levels (which result in increased circulating free IGF-1 levels), are also significantly 
correlated with breast cancer recurrence and mortality (71).  High serum 
concentrations of pro-inflammatory cytokines and leptin have been similarly linked 
to a worse breast cancer outcome (72-74).  Overall, obesity creates a complex 
metabolic imbalance accompanied by chronic inflammation, enriching the blood 
with a number of signaling molecules that may promote breast cancer progression 
and adversely affect outcome.   
This study utilized an in vitro model of obesity in which ER positive breast 
cancer cells were exposed to pooled sera samples from normal weight or obese 
postmenopausal breast cancer patients.  This model enabled us to examine the 
molecular pathways by which obesity-associated circulating factors in the blood 
stimulate greater ER positive breast cancer cell viability and growth.  Here we 
provide evidence that these physiological effects are mediated by enhanced 
crosstalk between nongenomic ER signaling and the PI3K/Akt and MAPK 
pathways.  These studies provide insight into one potential mechanism by which 
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obesity may promote postmenopausal ER positive breast cancer progression 
and endocrine therapy resistance.   
 
5.2 Materials and Methods 
5.2.1 Serum Samples 
Serum was collected from postmenopausal breast cancer patients under an 
Institutional Review Board (IRB) approved biorepository collection protocol at the 
Cancer Therapy and Research Center of the University of Texas Health Science 
Center at San Antonio (UTHSCSA).  The collection and use of these biological 
samples was approved by the IRB of UTHSCSA (HSC20070684H) and conducted 
in accordance with the Declaration of Helsinki and good clinical practice.  Informed 
consent was obtained prior to participation, and all samples and data were 
deidentified prior to release to maintain patient confidentiality.  Serum was pooled 
according to the BMI category of the patient (normal weight (N): 18.5-24.9 kg/m2; 
obese (OB): ≥30 kg/m2).   
5.2.2 Cell Lines and Reagents 
ER positive MCF-7 and T47D cells (ATCC) were maintained in IMEM 
(GIBCO Life Technologies) supplemented with 10% fetal bovine serum (FBS).  3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent) was 
purchased from Sigma.  The drug treatments used in this study, which include PD 
98,059 (a MEK1 inhibitor), LY 294,002 (a PI3K inhibitor), and 4-hydroxytamoxifen 
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(a selective estrogen receptor modulator), were also obtained from Sigma.  The 
primary antibodies for pAkt (s473), tAkt, pERK1/2, tERK1/2, pER(s167), 
pER(s118), pIGF-1R(tyr1135/1136), and tIGF-1R were purchased from Cell 
Signaling (Beverly, MA).  The tER primary antibody was produced by Novacastra 
(Leica Microsystems, Buffalo Grove, IL).   
5.2.3 MTT Assay 
MCF-7 and T47D cells were seeded in IMEM supplemented with 10% FBS 
at a density of 8x103 in 96 well plates.  After 24 hours of growth in the 10% FBS 
media, the cells were exposed to 2% sera in serum-free media (SFM), with or 
without the addition of drug treatments, for 48 hours.  MTT reagent in PBS (5 
mg/ml) was then added to each well to a final concentration of 0.5 mg/ml.  After 
two hours of incubation at 37°C, the media was removed and 50 ul DMSO added 
to each well to lyse the cells.  Absorbance was read at 570 nm on a FLUOstar 
Omega Spectrometer (BMG Labtech, Offenberg, Germany).  Relative cell viability 
was calculated by dividing each absorbance value by the absorbance for cells 
grown in N patient sera.  Data shown represents the average of at least three 
independent experiments.   
5.2.4 Colony Formation Assay 
MCF-7 and T47D cells were seeded in IMEM supplemented with 10% FBS 
at a density of 500 and 1x103, respectively, in six well plates. After 24 hours of 
growth in the 10% FBS media, the cells were continuously exposed to 2% sera in 
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SFM, with or without drug treatments, for nine days.  On day five of the treatment 
period, the wells were aspirated and washed, and the media was replenished with 
the same concentration of sera and inhibitors.  On day nine, the colonies were 
fixed and stained with 1% crystal violet in 70% acetic acid for 30 minutes and then 
counted.  The relative number of colonies, a reflection of cell growth, was 
calculated by dividing each colony count by the count for cells grown in N patient 
sera and multiplying by 100.  Data shown represents the average of at least three 
independent experiments.   
5.2.5 Western Blot Analysis 
The cells were grown to 80% confluence in IMEM supplemented with 10% 
FBS, then the growth medium was aspirated, the wells were washed, and the 
medium replaced with SFM overnight.  After overnight serum-starvation to 
minimize the effect of growth factors and hormones in the growth medium, 2% OB 
or N patient sera was added directly to the overnight SFM with or without inhibitors 
for 15 minutes or one hour.  Kinase lysis buffer or RIPA buffer was used for protein 
extraction.  Protein content of the lysates was measured using the BCA Protein 
Assay kit from Thermo Scientific Pierce (Rockford, IL) or the Bio-Rad Protein 
Assay (Bio-Rad, Hercules, CA).  Images were acquired using a Syngene G:BOX 
Chemi (Frederick, MD).  Relative protein levels were calculated by first 
standardizing phosphorylated protein to total protein levels for each experimental 
condition, then dividing the standardized protein level for each condition by that of 
cells grown in N patient sera.  Data from at least three independent experiments 
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was compiled for each protein and cell line to calculate the average protein level, 
standard error of the mean and statistical significance, with one representative 
image for each protein shown.    
5.2.6 ERE Luciferase Assay 
A luciferase reporter gene driven by a 3X ERE-tk promoter was utilized to 
measure ER transcriptional activity.  Transient transfections were performed in 
triplicate wells three times.  MCF-7 and T47D cell lines were seeded in IMEM 
supplemented with 10% FBS at a density of 1.5 x 104 in 24 well plates and 
concurrently transfected with the ERE luciferase and renilla plasmids after 24 
hours of growth using Fugene 6 from Promega (Madison, WI) at a 1:3 ratio.  The 
cells were serum-starved for six hours the following day, then exposed for 48 hours 
to 2% OB or N patient sera, added directly to the SFM.  Luciferase activity was 
then measured using Promega’s Dual Luciferase Reporter Assay System, with the 
fluorescence read on a FLUOstar Omega Spectrometer (BMG Labtech, 
Offenberg, Germany).   Relative ER activity was calculated by dividing the 
fluorescence value (standardized to renilla) from cells grown in OB patient sera by 
that from cells grown in N patient sera.  Data shown represents the average of at 
least three independent experiments.   
5.2.7 Quantitative RT-PCR 
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse 
transcribed with Promega’s ImProm II Reverse Transcription System.  The primer 
96 
 
sequences are as follows: pS2: forward, 5’-GGTCGCCTTGGAGCAGA-3’; 
reverse, 5’-GGGCGAAGATCACCTTGTT-3’; cyclin D1:  forward, 5’-
TGGAGGTCTGCGAGGAACAGAA-3’; reverse, 5’-TGCAGGCGGCTCTTTTTCA-
3’.  The manufacturer’s recommended cycling conditions for the QuantiFast SYBR 
Green PCR kit (Quiagen) were used.  Data shown represents the average of at 
least three independent experiments.   
5.2.8 Statistics 
Differences between cells exposed to obese versus control sera were 
measured using Student’s t test.  One-way ANOVA was used to analyze 
differences between more than two experimental conditions.  A difference of 
p<0.05 was considered significant. 
 
5.3 Results 
5.3.1 Obesity-Associated Circulating Factors Enhance Breast Cancer Cell 
Viability and Growth 
In order to elucidate the potential mechanisms by which obesity promotes breast 
cancer progression, we first evaluated the effect of obesity-associated circulating 
factors on cell viability and growth, both in vitro parameters of cancer aggression.  
Viability of breast cancer cells in response to exposure to patient serum was 
measured by MTT assay.  MCF-7 cells grown in 2% OB sera in SFM for 48 hours 
displayed a 43% increase in viability in comparison to cells grown in N sera 
97 
 
(p<0.01).  OB sera also enhanced the viability of T47D cells by 32% versus N sera 
(p<0.01) (Figure 5.1a).  Colony formation assay was utilized to assess the effects 
of patient sera on breast cancer cell growth.  Both MCF-7 and T47D cells grew 
significantly better in OB sera, forming 63% (p<0.05) and 39% (p<0.01) more 
colonies, respectively, over a nine day exposure to the OB sera in comparison to 
N sera (Figure 5.1b).  These results demonstrate that one or more circulating 
factors in the obese patient sera directly induces higher levels of ER positive 
breast cancer cell viability and growth.  
    
Figure 5.1 Obesity-associated circulating factors promote greater breast 
cancer cell viability and growth. (a) MCF-7 and T47D breast cancer cells were 
exposed to 2% obese (OB) or normal weight (N) patient sera for 48 hours; viability 
was then measured by MTT assay. (b) Colony formation assay was utilized to 
assess MCF-7 and T47D cell growth following a nine day exposure to 2% OB or N 
patient sera.  Data shown represents the average of at least three independent 
experiments.  *, p<0.05; **, p<0.01 in comparison to N.   
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5.3.2 PI3K/Akt, MAPK, and IGF-1R Pathway Activation is Stimulated by 
Obesity-Associated Circulating Factors in Breast Cancer Cells 
The PI3K/Akt and MAPK pathways are both downstream targets common to 
many of the circulating factors typically upregulated with obesity (66-70).  They are 
also involved in the regulation of cell proliferation and survival and can crosstalk 
with and ultimately activate ER independent of estradiol (54-55).  Consequently, 
we assessed the effects of OB and N sera on Akt and ERK1/2 activation.  MCF-7 
cells exposed to 2% OB sera for 15 minutes and one hour had 100% (p<0.01) and 
55% (p<0.05) higher levels of pAkt (ser473), respectively, in comparison to cells 
exposed to N sera.  pERK1/2 levels following 2% OB sera exposure were 79% 
and 33% (p<0.05) greater at the same time points in comparison to N (Figures 
5.2a-b).  A similar effect was observed in T47D cells exposed to OB versus N sera 
at these time points.  OB sera exposure stimulated 53% and 64% (p<0.01) more 
Akt activation and 38% (p<0.05) and 72% (p<0.01) more ERK1/2 activation than 
N after 15 minute and 1 hour incubation periods (Figures 5.2c-d).  These results 
suggest that the PI3K/Akt and MAPK pathways may both play a role in obesity-
induced breast cancer progression.  Despite finding no difference between the two 
patient groups in average serum free IGF-1, MCF-7 cells exposed to the OB sera 
had 20% (p<0.01) higher pIGF-1R (tyr1135/1136) levels in comparison to N 
(Figures 5.2e-f).  This suggests that the OB sera-induced Akt and ERK1/2 
activation described above may be at least partly mediated by IGF-1R signaling 
that is upregulated by a mechanism independent of bioavailable IGF-1 levels.  
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Figure 5.2. Breast cancer cell Akt, ERK1/2, and IGF-1R activation are 
enhanced by obesity-associated circulating factors.  The effects of OB and N 
patient sera on Akt, ERK1/2, and IGF-1R activation were assessed by western 
blotting.  MCF-7 (a and b) and T47D (c and d) cells were exposed to 2% OB or N 
patient sera for 15 minutes and one hour; pAkt (ser473) and pERK1/2 protein 
levels were then measured and standardized to tAkt and tERK1/2 protein levels, 
respectively.  (e and f) pIGF-1R (tyr1135/1136) protein levels in MCF-7 cells were 
measured and standardized to tIGF-1R following a 15 minute incubation in 2% OB 
or N patient sera.  Densitometry data from at least three independent experiments 
was compiled for each protein and cell line to calculate the average protein level, 
standard error of the mean and statistical significance, with one representative 
image for each protein shown.  *, p<0.05; **, p<0.01 in comparison to N. 
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5.3.3 Genomic ER activity in breast cancer cells is not directly enhanced by 
obesity-associated circulating factors  
In addition to an elevation in circulating levels of growth factors, pro-
inflammatory cytokines, and leptin, obesity in postmenopausal women is typically 
accompanied by higher levels of circulating estrogens (120).  In ER positive 
breast cancer cells, estradiol can bind ER and activate its canonical signaling 
pathway, in which ER acts as a nuclear transcription factor or cofactor, 
modulating the expression of its target genes in a manner that promotes cell 
proliferation and growth.  This genomic ER activity can also be induced via ligand-
independent phosphorylation of the receptor’s AF-1 domain by Akt and ERK1/2 
(54-55, 121).   To assess the effect of OB and N sera on genomic ER activity, we 
measured relative ERE luciferase reporter activity in MCF-7 and T47D cells in 
response to these conditions.  No significant difference was detected in the 
luciferase activity, suggesting that the factors in OB sera do not directly enhance 
genomic ERα activity (Figure 5.a).  Expression of pS2, an ER target gene, was 
also measured as another indicator of ERα transcriptional activity.  qPCR analysis 
of the relative levels of pS2 mRNA showed no difference in pS2 expression in 
either the MCF-7 or T47D cell lines after growth in OB versus N sera (Figure 5.3b).  
In contrast, OB sera did induce significantly higher expression of cyclin D1, another 
ERα target gene, in both cell lines.  MCF-7 cells expressed 34% more cyclin D1 
following 24 hours of growth in OB sera versus N, while cyclin D1 mRNA levels 
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were 30% higher in T47D cells under these conditions (p<0.05) (Figure 5.3c).  
However, while pS2 expression is considered to be a very specific and reliable 
indicator of ER activity, cyclin D1 expression is regulated by many signaling 
pathways, including PI3K/Akt and MAPK.  Therefore, the upregulation of cyclin D1 
expression following OB sera exposure is likely related to increased activity in 
these upstream pathways.  Because cyclin D1 is involved in promoting progression 
through the cell cycle, these results are also supportive of our data demonstrating 
a significant difference in breast cancer cell growth following OB sera exposure.   
One potential critique of our study design is the use of sera from breast cancer 
patients.  Many of the patients that provided sera for this study were receiving 
aromatase inhibitor treatment at the time of serum collection, leading to a decrease 
in their circulating estradiol levels.  The lack of difference in genomic ER activity 
could be an artifact of the drug’s effects.  To address this issue, we repeated the 
ERE luciferase assay in MCF-7 cells with pooled sera from patients who had not 
been prescribed aromatase inhibitors (OB(-AI) versus N(-AI)) and again found no 
difference in genomic ER activity (Figure 5.3d).  Together, these studies strongly 
suggest that genomic ER activity plays a minimal role in mediating obese sera-
induced breast cancer cell viability and growth.   
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Figure 5.3. Genomic ER activity in breast cancer cells is not directly 
enhanced by obesity-associated circulating factors.  Genomic ER activity in 
response to 2% OB or N patient sera exposure was measured in MCF-7 and T47D 
cells with an ERE luciferase reporter (a) and qPCR analysis of pS2 expression (b). 
Expression of cyclin D1, which is regulated by both ER and the PI3K/Akt and 
MAPK pathways, was assessed by qPCR analysis in both cell lines following 
growth in 2% OB or N patient sera (c).  The effect of 2% OB(-AI) and N(-AI) patient 
sera on genomic ER activity in MCF-7 cells was also measured by ERE luciferase 
reporter (d).  This pooled sera excluded breast cancer patients receiving 
aromatase inhibitors at the time of collection.  Data shown represents the average 
of at least three independent experiments. *, p<0.05 in comparison to N. 
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5.3.4 Combined PI3K and ER inhibition attenuates effects of obese patient 
sera on breast cancer cell viability and growth  
After demonstrating that OB sera exposure directly increases PI3K/Akt and 
MAPK pathway activation, but not genomic ER activity, we examined the 
contribution of these pathways to OB sera-induced MCF-7 cell viability and growth.  
Using the targeted inhibitors LY 294,002 (LY, a PI3K inhibitor), PD 98,059 (PD, a 
MEK1 inhibitor), and 4-hydroxytamoxifen (Tam, a selective estrogen receptor 
modulator), we established which factors were essential for the observed increase 
in viability and growth.  While each drug was able to significantly decrease the 
viability of MCF-7 cells exposed to OB sera (p<0.05), LY/Tam inhibited viability by 
54% and was the only treatment able to inhibit it to a level significantly less than 
cells grown in N sera (p<0.05).  In addition, cells exposed to N sera and LY/Tam 
had a significantly lower viability level in comparison to all N sera-exposed cells 
(p<0.05) except those also treated with LY/Tam, suggesting that this drug 
combination is the most effective at neutralizing obesity-induced viability (Figure 
5.4a).  OB sera-induced MCF-7 cell growth was significantly decreased by all drug 
treatments except PD.  However, the LY/Tam combination again proved to be the 
most effective inhibitor; it decreased OB sera-induced growth by 87%, inhibiting it 
to a level significantly lower than that produced by all other drug treatments 
(p<0.01).  Intriguingly, PD alone significantly increased the number of colonies 
formed by MCF-7 cells grown in OB or N sera, but also inhibited OB sera-induced 
growth when administered in combination with Tam (p<0.01) (Figure 5.4b).  These 
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results suggest that signaling from all three pathways, as well as enhanced 
crosstalk between them, contributes to the upregulation of breast cancer cell 
viability and growth by OB patient sera.  However, because the most effective drug 
combination was LY/Tam, the data also indicates that the PI3K/Akt pathway and 
its interactions with ER may play a more critical role than the MAPK pathway in 
mediating these effects.  
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Figure 5.4. Combined PI3K/ER inhibition attenuates effects of obesity on 
breast cancer cell viability and growth.  The contribution of the PI3K/Akt, MAPK, 
and ER pathways to Ob patient sera-induced cell viability and growth was 
examined via treatment of MCF-7 cells with the following inhibitors during sera 
exposure: LY 294,002 (LY, a PI3K inhibitor, 10uM), PD 98,059 (PD, a MEK1 
inhibitor, 10uM), and 4-hydroxytamoxifen (Tam, a selective estrogen receptor 
modulator, 100nM).  (A) MCF-7 cell viability was measured by MTT assay following 
a 48 hour exposure to 2% OB or N patient sera, with or without drug treatment.  
(B) Colony formation assay was used to assess MCF-7 cell growth over a nine day 
exposure to 2% OB or N patient sera, with or without drug treatment.  Data shown 
represents the average of at least three independent experiments, and different 
letters indicate significant differences (p<0.05). 
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5.3.5 Obesity-Associated Circulating Factors Enhance Akt-mediated 
Activation of ER and Nongenomic ER activity 
In addition to its transcriptional activity, ER signaling also occurs at the 
plasma membrane and in the cytoplasm.  Here, ER can activate the PI3K/Akt 
and MAPK pathways when it forms complexes with other signaling molecules, 
including the IGF-1R and the regulatory subunit of PI3K, p85.  Akt and ERK1/2 can 
in turn activate ER in a ligand-independent manner by phosphorylation (54-55).  
Although there was no difference in genomic ER activity following OB versus N 
sera exposure, our data demonstrated that LY/Tam is the most effective drug 
combination for the inhibition of OB sera-induced breast cancer cell viability and 
growth, indicating that ER is indeed a critical player in mediating these effects.  
Consequently, we next examined whether nongenomic ER activity is enhanced 
by obesity-associated circulating factors.  We found that OB sera, in comparison 
to N, promotes 53% (p<0.01) and 52% (p<0.05) higher levels of ER 
phosphorylation at the Akt target site (s167) in MCF-7 cells following a 15 minute 
or one hour exposure, respectively (p<0.05).  No difference between OB and N 
was seen at the ERK1/2 target site (ser118) under the same conditions (Figures 
5.5a and 5.5b).  OB sera also stimulated an increase in Akt and ERK1/2 
phosphorylation via ER activity in the cytoplasm.  This is demonstrated by the 
ability of Tam to inhibit OB sera-induced Akt and ERK1/2 activation in MCF-7 cells 
by 36% (p<0.01) and 33% (p<0.05), respectively.  In contrast, Tam had no effect 
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on N sera-induced Akt and ERK1/2 activation (Figures 5.5c and 5.5d).  ER 
inhibition also eliminated the difference in Akt and ERK1/2 activation levels 
stimulated by OB and N sera exposure alone, suggesting that obesity-associated 
circulating factors are promoting greater nongenomic ER activity.  This enhanced 
crosstalk explains why the addition of Tam to either LY or PD results in greater 
inhibition of OB sera-induced breast cancer cell viability and growth in comparison 
to either drug alone.   
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Figure 5.5 Obesity-associated circulating factors promote greater Akt-
mediated ER phosphorylation and nongenomic ER activity.  
Phosphorylation of ER at two different sites (ser167 and ser118, the Akt and 
MAPK target sites, respectively) following a 15 minute and one hour exposure to 
2% OB or N patient sera was assessed in MCF-7 cells by western blot and 
standardized to tER protein levels (a and b).   The effect of tamoxifen (T) 
treatment on Akt and ERK1/2 activation in MCF-7 cells following a 15 minute 
exposure to 2% OB or N patient serum was also measured by western blot (c and 
d). Densitometry data from at least three independent experiments was compiled 
for each protein to calculate the average protein level, standard error of the mean 
and statistical significance, with one representative image for each protein shown.  
*, p<0.05; **, p<0.01 in comparison to N, and different letters indicate significant 
differences (p<0.05). 
 
5.4 Discussion 
Growth factor signaling is known to promote the development of endocrine 
resistance in breast cancer.  However, while obesity has been shown to modulate 
growth factor signaling pathways, its impact on hormone independence remains 
relatively unexplored.  We have previously reported that obese ovariectomized 
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mice implanted with syngeneic mouse mammary tumor cells displayed enhanced 
mammary tumor development and progression, and this was associated with 
elevated levels of bioavailable IGF-1 and downstream PI3K/Akt/mTOR signaling 
(122-123).  Because elevated growth factor signaling can stimulate cytoplasmic 
ER localization and nongenomic ER activity (54), we investigated the role of 
bidirectional crosstalk among various growth factor pathways and ER.  Based on 
our current findings, we propose that obesity-induced systemic factors promote 
breast cancer progression and may increase resistance to aromatase inhibitor 
therapy by initiating crosstalk between nongenomic ERactivity and the IGF-1R, 
PI3K/Akt and MAPK signaling pathways.   
Here we demonstrate that circulating factors associated with postmenopausal 
obesity increased ER positive breast cancer cell viability and growth (Figure 5.1).  
This was coupled with greater breast cancer cell Akt and ERK1/2 phosphorylation, 
as well as enhanced IGF-1R activation (Figure 5.2).  Intriguingly, we previously 
found that there was no difference between the obese and control patients in 
average serum free IGF-1 concentration.  However, average insulin levels were 
non-significantly higher in the obese group, and insulin can also bind and activate 
the IGF-1R (Table 2.1).  The lack of significant differences in these hormones may 
be due to the non-fasting status of the patients, as other studies examining their 
association with obesity have assessed fasting serum samples (38-39).  Obese 
postmenopausal women are also known to have, on average, higher levels of 
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circulating estradiol (25-27).  Consequently, we were surprised to find no difference 
in the genomic ER activity of breast cancer cells grown in obese versus control 
patient sera, even with the exclusion of patients on aromatase inhibitors at the time 
of serum collection, suggesting that obesity-related circulating factors promote 
ERα positive breast cancer cell viability and growth independent of ERα 
transcriptional activity.   
However, previous studies have demonstrated that ER, in addition to its 
canonical genomic signaling pathway, is active outside the nucleus.  Over the past 
decade, a number of researchers have successfully characterized several 
interactions between ER and other signaling molecules that occur in the 
cytoplasm.  For example, Song et al. (56-57) discovered that, in the presence of 
estradiol, ER undergoes translocation to the plasma membrane and complexes 
with IGF-1R and the adaptor protein Shc, resulting in MAPK pathway activation.  
Down-regulation of IGF-1R prevents ER translocation to the membrane, 
suggesting that IGF-1R signaling is necessary for nongenomic ER activity.  
Ligand-bound ER can also directly bind Src as well as p85, the regulatory subunit 
of PI3K, resulting in Akt activation downstream (58-59).  In addition, p85 can bind 
IGF-1R, leading to speculation that ER may complex with both of these molecules 
upon activation by estradiol (60-61).    The receptor for leptin, an obesity-
associated adipokine that was significantly elevated in our obese patient group 
(Table 2.1), has also been shown to crosstalk with IGF-1R, resulting in greater 
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IGF-1R activation and an upregulation of Akt and ERK1/2 phosphorylation (62).  
This interaction could potentially enhance IGF-1R/ER crosstalk.  Activated Akt 
and ERK1/2 can in turn activate ER via phosphorylation at serine 167 and 118, 
respectively, within the receptor’s AF-1 domain, leading to enhanced genomic ER 
activity (63-64).   Illustration 5.1 summarizes the different mechanisms of ER 
activity.  Because PI3K/Akt, MAPK, and IGF-1R activity were all upregulated with 
obese patient sera exposure, we next explored the effects of obesity-associated 
factors on nongenomic ER activity. 
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Illustration 5.1. Breast cancer cell estrogen receptor activity. Three general 
mechanisms of ER signaling are depicted.  First, ER can bind estradiol (E2) and 
enter the nucleus, where it forms complexes with co-activators (CoAs) and 
regulates gene transcription by binding directly to estrogen response elements 
(EREs) specific to ER or via interaction with other transcription factors (A).  This 
genomic ER activity can also be stimulated by Akt or MAPK-mediated 
phosphorylation of the receptor (B).  Ligand-bound ER can also remain outside 
the nucleus, where it complexes with the IGF-1R at the cell membrane or with 
other signaling molecules in the cytoplasm to activate the PI3K/Akt and MAPK 
pathways (C).  IGF-1R crosstalk with the leptin receptor (OB-R) is also depicted 
(D).  Each mechanism ultimately leads to the transcription of target genes that 
promote breast cancer cell growth. 
 
To determine whether obese patient sera promotes this nongenomic ER 
activity and cross-talk with growth factor signaling pathways, we first examined the 
contribution of the PI3K/Akt, MAPK, and ER pathways to obese patient sera-
induced breast cancer cell viability and growth.  Intriguingly, we found that a 
combination of the PI3K inhibitor LY 294,002 (LY) with the ER inhibitor tamoxifen 
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(Tam) most effectively mitigated the pro-growth effects of obese patient sera in the 
MCF-7 cells.  The combination of PD 98,059 (PD) and Tam also demonstrated an 
attenuating effect on MCF-7 cell growth, so we were surprised that PD treatment 
alone stimulated significantly more cell growth than sera alone (Figure 5.4).  This 
may be due to feedback upregulation of the PI3K/Akt pathway in response to MEK 
inhibition, as Hoeflich, et al. (91) has demonstrated that the selective MEK inhibitor 
PD0325901 enhances PI3K/Akt signaling in several breast cancer cell lines.  
Together, these data support the possibility that crosstalk between both the 
PI3K/Akt and MAPK pathways and nongenomic ER signaling may be playing a 
role in obesity-induced postmenopausal breast cancer progression, though the 
PI3K/Akt pathway may be the more important mediator of these effects.  Additional 
evidence to support this conclusion includes the observation that Tam alone is 
sufficient to decrease obese patient sera-induced Akt and ERK1/2 activation to the 
levels observed in breast cancer cells grown in control patient serum (Figure 5).   
In addition to demonstrating that obesity-associated circulating factors 
increase ER-mediated Akt and MAPK activation, we also found that they 
stimulated greater Akt-mediated phosphorylation of ER at serine 167 in MCF-7 
cells (Figure 5.5).   In contrast, exposure to obese patient sera did not upregulate 
ER phosphorylation at the MAPK target site (serine 118), but researchers have 
found that breast cancer cell MAPK activity does not always correlate with 
phosphorylation at this site (124).  This ligand-independent activation of ER via 
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its AF-1 domain is a purported mechanism by which endocrine resistance can 
develop (54-55).  However, ligand-independent ER activity is thought to be limited 
to the nucleus, where phosphorylated ER acts as a transcription factor or co-
factor (Illustration 5.1B).  As we did not detect a difference in ERα genomic activity, 
it is unclear whether the obese patient sera-induced increase in pER(s167) has 
any biological significance. 
Given the lack of any detectable effect on genomic ERα activity, it is possible 
that the obese sera-induced breast cancer cell viability and growth may be 
independent of circulating estrogen levels.  If this hypothesis is confirmed, it would 
suggest one mechanism by which obesity may contribute to the development of 
resistance to aromatase inhibitor therapy, a finding with potential clinical 
implications.  This conjecture, as well as the proposed importance of the 
PI3K/Akt/mTOR pathway in mediating the effects of obesity-associated systemic 
factors, is supported by the literature on endocrine resistance.  For example, Miller 
et al. (125) found that induction of hormone independence via long-term estrogen 
deprivation of ER positive breast cancer cells was accompanied by an 
amplification of PI3K/Akt/mTor signaling linked to upstream IGF-1R/insulin 
receptor hyperactivation, similar to the effects of obese patient sera exposure.  
PI3K signaling was required for the induction of hormone independence, 
illustrating the key role this pathway plays in the development of endocrine 
resistance.  An earlier study by Beeram et al. (126) demonstrated that MCF-7 cells 
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expressing a constitutively active Akt were refractory to treatment with letrozole, 
fulvestrant, and tamoxifen, providing further basis for our conclusions.  Results 
indicated that the Akt-induced resistance was mediated by both ER-dependent 
and independent mechanisms and that response to endocrine therapy in these 
cells was achieved only by combining letrozole with the mTOR inhibitor RAD001.  
Similarly, Cavazzoni et al. (127) found that letrozole-resistant, aromatase-
overexpressing MCF-7/AROM cells displayed greater PI3K/Akt/mTOR and MAPK 
pathway activity.  Further, mTOR inhibition with RAD001 was able to completely 
inhibit proliferation in this cell line.  The authors correlated these results with an 
analysis of pathway activation in breast cancer patients that had progressed on 
letrozole, finding an upregulation of PI3KA, pAkt, and p-mTOR after three months 
on treatment in comparison to the patients’ pre-treatment baseline.  All of these 
studies suggest that the PI3K/Akt/mTOR pathway and its interaction with ER are 
key mediators in the development of resistance to aromatase inhibitors.  
Consequently, it is probable that an upregulation of the crosstalk between these 
pathways, as seen in ER positive breast cancer cells grown in obese patient sera, 
will lead to aromatase inhibitor resistance and disease progression. 
The continuous rise in obesity rates around the world underscores the 
importance of identifying the molecular pathways by which obesity contributes to 
the pathogenesis and progression of numerous chronic diseases, including breast 
cancer.  This study provides evidence that postmenopausal obesity enhances ER 
positive breast cancer cell viability and growth via crosstalk between the ER, 
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PI3K/Akt, and MAPK signaling pathways, suggesting that the addition of a 
PI3K/Akt/mTOR pathway inhibitor to aromatase inhibitor therapy may improve the 
clinical outcome of obese postmenopausal patients.  Additional clarification of the 
crosstalk mechanisms responsible for the effects of obesity on postmenopausal 
breast cancer progression will be the goal of future studies.    
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Chapter 6: Obesity suppresses estrogen receptor beta expression in breast 
cancer cells via a HER2-mediated pathway 
 
6.1 Introduction 
The National Cancer Institute estimates that one in eight women born in the 
United States today will develop breast cancer at some point in their lives (1). A 
multitude of factors have been shown to affect an individual’s risk of developing 
breast cancer as well as her breast cancer prognosis. One modifiable lifestyle 
factor that impacts both disease risk and outcome is obesity. In postmenopausal 
women, obesity has consistently been associated with an increased risk of breast 
cancer (3-5). A number of studies have also demonstrated that obesity negatively 
affects breast cancer prognosis for both pre- and postmenopausal women. Obese 
patients do not respond as well to chemotherapy and aromatase inhibitor 
treatment, and an elevated body mass index (BMI) has been associated with 
increased metastatic recurrence and decreased disease-free interval and overall 
survival (19-23, 48-50, 128-130). Our understanding of the mechanisms mediating 
this link between obesity and poor breast cancer outcome remains incomplete, 
hindering efforts to develop new chemotherapeutic regimens that may improve 
prognosis in the obese patient population. 
In addition to modifiable lifestyle factors like obesity, breast cancer outcome 
is significantly affected by the non-modifiable intrinsic characteristics of a given 
tumor, including tumor expression of estrogen receptor alpha (ER), progesterone 
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receptor (PR), and human epidermal growth factor receptor 2 (HER2). The 
presence or absence of these three protein receptors defines the four major breast 
cancer subtypes, listed here in increasing order of aggressiveness: luminal A 
(ER+, PR+, HER2-), luminal B (ER+, PR-, HER2-), HER2-overexpressing 
(ER+/-, PR+/-, HER2+), and triple-negative (ER-, PR-, HER2-) (13). While ER 
expression is generally considered to be a positive prognostic marker (131), ER 
activity does promote breast cancer cell proliferation, survival, and motility (132-
133). This is in contrast with the activity of estrogen receptor beta (ER), a second 
estrogen receptor that was first identified in 1995. Multiple studies have 
demonstrated that higher tumor expression of ER is correlated with an improved 
prognosis in all breast cancer subtypes (134-140), suggesting that ER may act 
as a tumor suppressor. These findings are supported by in vitro models that show 
ectopic expression of ER in ER positive breast cancer cells results in decreased 
growth, motility, and invasion (141-145). In addition, tumor formation and 
angiogenesis in mouse xenografts was reduced with ER overexpression (142, 
146). Finally, the protective effect of ER expression is further evidenced by its 
decreased expression in breast cancer cells, particularly in higher versus lower-
grade tumors (143, 146-150). In normal mammary tissue, ER is the predominant 
ER, but its expression is inhibited via promoter hypermethylation in breast cancer 
cells (151-152). However, approximately 76% of breast tumors still express ER, 
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leading a number of researchers to explore its potential as a therapeutic target 
(153). 
While many studies have been devoted to the examination of whether 
increased ER activity can improve breast cancer outcome, relatively little 
attention has been paid to expanding our understanding of the factors affecting 
ER expression. In fact, the effects of obesity on breast cancer cell ER expression 
remain completely unknown, though a reduced ER expression may be a 
potentially targetable mechanism by which obesity promotes a worse breast 
cancer prognosis. In the current study, we utilized an in vitro model of obesity to 
investigate how obesity-associated circulating factors affect ER expression in 
multiple cell lines representing the four major breast cancer subtypes. We 
demonstrate that exposure to obesity-associated circulating factors reduces ER 
expression in HER2-overexpressing breast cancer cell lines via a HER2-mediated 
signaling pathway. 
 
6.2 Materials and Methods 
6.2.1 Serum samples 
Serum was collected from 25 postmenopausal breast cancer patients under 
an IRB approved bio-repository collection protocol at the CTRC of UTHSCSA. The 
collection and use of these biological samples was conducted in accordance with 
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the Declaration of Helsinki and good clinical practice. Informed consent was 
obtained prior to participation, and all samples and data were de-identified prior to 
release to maintain patient confidentiality. Body mass index (BMI) was calculated, 
and serum was pooled according to the BMI category of the patient (normal weight 
(18.5-24.9 kg/m2) or obese (≥30.0 kg/m2).  
6.2.2 Cell lines and reagents 
SKBR3, MCF-7, ZR75, and MDA-MB-231 human breast cancer cell lines 
(ATCC) were maintained in IMEM (GIBCO Life Technologies) supplemented with 
10% fetal bovine serum (FBS). Mammary tumor cells isolated from MMTV-neu 
transgenic mice were cultured in DMEM (GIBCO Life Technologies) plus 10% 
FBS. Herceptin is manufactured by Genentech Inc. (San Francisco, CA). ON-
TARGETplus SMARTpool siRNA to ERBB2 and scrambled siRNA were 
purchased from Thermo Fisher Scientific (Waltham, MA).   
6.2.3 Quantitative RT-PCR 
ER mRNA levels in all cell lines were measured following an 18 hour serum-
starvation period and a one-hour exposure to a 2% concentration of pooled patient 
sera in serum-free media (SFM). To assess the role of HER2 receptor signaling, 
SKBR3 cells were pre-treated for one hour with Herceptin (1.0 ug/ml) prior to sera 
exposure. HER2 receptor expression was also silenced using siRNA (25 nM). 
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcribed 
with Promega’s ImProm II Reverse Transcription System. The primer sequences 
are as follows: human ER: forward, 5’-ATGGAGTCTGGTCGTGTGAAGG-3’; 
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reverse, 5’-TAACACTTCCGAAGTCG GAGG-3’; mouse ER: forward, 5’-
GACTGTAGAACGGTGTGGTCATCAA-3’; reverse, 5’-CTGTGAGGTAGGAATG 
CGAAAC-3’; HER2: forward, 5’-GGAGCCGCGAGCACCGA AGT-3’; reverse, 5’-
CGGCCAGGGCATAGTTGTCC-3’. The manufacturer’s recommended cycling 
conditions for the QuantiFast SYBR Green PCR kit (Qiagen) were used. Data 
shown represents the average of at least three independent experiments. 
6.2.4 Statistical Analyses 
Differences between cells exposed to two different experimental 
conditions were measured using Student’s t test. One-way ANOVA was 
used to analyze differences between more than two experimental 
conditions. A p value of <0.05 was considered significant.   
 
6.3 Results 
6.3.1 Obesity-associated circulating factors suppress ER expression levels 
in HER2/neu-overexpressing breast cancer cell lines 
This project was initiated in order to further explore the mechanism(s) 
mediating the effects seen in a currently unpublished study that examined the 
impact of energy balance modification on ER expression in the mammary tissue 
of MMTV-neu transgenic mice. This study demonstrated that mice placed on a 
diet-induced obesity regimen had lower mammary tumor ER expression levels in 
comparison to mice receiving a calorie-restricted diet (Stephen Hursting, personal 
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communication). Consequently, we first measured the impact of patient sera 
exposure on mammary tumor cells isolated from MMTV-neu mice and found that 
ER expression was 67% higher (p<0.05) in cells exposed to normal weight (N) 
versus obese (OB) patient sera. Similarly, ER expression in the human HER2-
overexpressing SKBR3 cell line was 41% greater (p<0.05) following incubation in 
N versus OB patient sera (Figure 6.1a). In contrast, there was no significant 
difference in ER expression in MCF-7, ZR75, or MDA-MB-231 cells after 
exposure to N versus OB patient sera (Figure 6.1b). These human cell lines are 
representative of the luminal A, luminal B, and triple negative breast cancer 
subtypes, respectively, and all express low levels of HER2. 
  
Figure 6.1 ER levels are suppressed by obesity-associated systemic factors 
in HER2-overexpressing breast cancer cells. (a) ER expression, measured by 
quantitative RT-PCR, in SKBR3 breast cancer cells and mammary carcinoma cells 
isolated from MMTV-neu mice following a 1 hr exposure to obese (OB) or normal 
weight (N) patient sera. (b) ER expression measured by quantitative RT-PCR, in 
MCF-7, ZR75, and MDA-MB-231 breast cancer cells following a 1 hr exposure to 
OB or N patient sera. Data shown represents the average of at least three 
independent experiments. **, p<0.01 relative to OB 
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6.3.2 Inhibition of HER2 signaling attenuates obesity-induced suppression 
of SKBR3 cell ER expression 
Given that a difference in ER expression following N versus OB patient sera 
exposure was only observed in HER2-overexpressing cell lines, we next examined 
whether the effects of the OB sera may be mediated by HER2 signaling by utilizing 
the HER2-targeting monoclonal antibody Herceptin. SKBR3 cell ER expression 
increased by 2.79-fold with Herceptin treatment prior to and during OB sera 
exposure in comparison to OB sera alone (p<0.05). In contrast, HER2 inhibition in 
SKBR3 cells exposed to N patient sera resulted in a non-significant 39% increase 
in ER expression over N sera alone. Consequently, ER expression was 42% 
higher (p<0.05) in OB versus N sera-exposed SKBR3 cells when HER2 signaling 
was suppressed with Herceptin (Figure 6.2a). These results strongly suggest that 
the HER2 receptor plays a role in mediating the effects of OB patient sera on breast 
cancer cell ER expression. 
6.3.3 HER2 receptor silencing reverses obesity-induced suppression of 
SKBR3 cell ER expression 
To further assess the role of HER2 signaling in the OB patient sera-induced 
suppression of SKBR3 cell ER expression, we next silenced the HER2 receptor 
using siRNA. Transfection of SKBR3 cells with HER2-targeting siRNA resulted in 
a 52% decrease (p<0.05) in HER2 expression, while transfection with a scrambled 
siRNA sequence did not significantly alter HER2 expression (Figure 6.2b). HER2 
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silencing prior to OB patient sera exposure led to a 2.32-fold increase (p<0.05) in 
SKBR3 cell ER expression in comparison to non-transfected SKBR3 cells.  
However, in SKBR3 cells exposed to N patient sera, there was no significant 
change in ER expression with HER2 silencing (Figure 6.2c). This data provides 
additional evidence in support of the hypothesis that obesity-associated systemic 
factors suppress breast cancer cell ER expression via a HER2-mediated 
signaling pathway.   
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Figure 6.2 Obesity-associated suppression of ER expression is mediated 
by HER2 signaling. (a) ER expression, measured by quantitative RT-PCR, in 
SKBR3 cells exposed to obese (OB) or normal weight (N) patient sera for 1 hr +/- 
Herceptin (H). (b) HER2 expression, measured by quantitative RT-PCR, in SKBR3 
cells without transfection (None) or following transfection with HER2 or Scramble 
siRNA (siR). (c) ER expression, measured by quantitative RT-PCR, in SKBR3 
cells without siRNA (siR) transfection or following transfection with HER2 or 
Scramble siR, exposed to OB or N patient sera. Data shown represents the 
average of at least three independent experiments. Different letters indicate 
statistically significant differences, p<0.05. 
 
 
6.4 Discussion 
 In the years following the discovery of ER, researchers have devoted 
substantial resources to exploring the functions of this second ER, with many 
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focused on defining how ER activity impacts breast cancer prognosis. The 
consensus among most investigators of this subject is that greater ER expression 
and activity is generally associated with an improved disease outcome, especially 
in patients with ER positive disease (134-140). In contrast, few studies have 
examined the mechanisms by which ER expression is regulated. Human ER 
gene transcription is known to be controlled by at least two promoters, 0N and 0K, 
with transcripts from 0N predominating in both normal and transformed breast 
epithelial cells (154-155). Promoter 0N, cloned in 2000, was shown to have 
silencer elements in a region containing a putative AP-1 binding site (156). We 
have demonstrated in the current study that exposure to obesity-associated 
circulating factors suppresses ER expression in HER2-overexpressing breast 
cancer cells, and this effect is reversed by HER2 inhibition or silencing. Given that 
HER2 signaling is known to activate AP-1 (157), this binding site is a potential 
mechanistic link between elevated HER2 activity and a reduction in ER 
expression.  
 However, it is still unclear how obesity-associated circulating factors might 
activate this HER2-mediated ER-suppressing pathway. One possibility is via 
stimulation of the insulin-like growth factor-1 receptor (IGF-1R). Serum levels of 
insulin and free IGF-1 are typically elevated with obesity, and both of these factors 
can promote IGF-1R activation (38-39). Several studies have demonstrated cross-
talk between HER2 and IGF-1R (158-160), suggesting that obesity-induced IGF-
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1R signaling may further enhance HER2 activity. IGF-1R signaling may also 
independently impact ER expression, as silencing of this receptor in MCF-7 
breast cancer cells has been shown to increase ER levels (161). Greater IGF-1R 
activity has not been linked to a reduction in ER, though, and an ER-IGF-1R link 
that is independent of HER2 would conflict with our results. 
 In conclusion, the current study demonstrates that obesity-associated 
circulating factors suppress ER expression in breast cancer cells that 
overexpress HER2. While HER2 inhibition and silencing were definitively shown 
to reverse this effect, the precise molecular mechanism(s) connecting obesity, 
HER2, and ER expression remains unclear. Elucidation of this signaling pathway, 
as well as an assessment of the biological relevance of the observed obesity-
induced inhibition of ER levels for breast cancer progression, will be the focus of 
our future studies. 
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Chapter 7: Obesity Promotes Chemotherapy Resistance in Triple-Negative 
Breast Cancer Cells 
 
7.1 Introduction 
Based on current incidence rates, the National Cancer Institute estimates 
that one in eight women born in the United States will develop breast cancer at 
some point in their lives (1). Among those with invasive breast cancer, 
approximately 10-20% are diagnosed with the triple negative subtype of tumor 
(162), characterized by low expression of the estrogen receptor alpha (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) (13). Triple-negative tumors, which have a 1.5 to 2-fold higher risk of 
mortality in comparison to those that express ER/PR, are typically the most 
aggressive of the four major breast cancer subtypes (14). They are also the most 
difficult to treat because they lack the three receptors listed above, which makes 
them insensitive to endocrine and HER2-targeted therapies. Consequently, 
combination cytotoxic chemotherapy remains the standard of care for these 
patients (163). 
Unfortunately, some patients are also resistant to these chemotherapeutic 
agents, and a number of factors can contribute to an individual’s risk of 
chemotherapy resistance, including obesity. Several studies have linked an 
elevated body mass index (BMI) with a poor response to chemotherapy. For 
example, Fabbro et al (128) found that overweight (BMI≥25 kg/m2) patients 
receiving neoadjuvant chemotherapy had a lower pathological complete response 
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(pCR) and shorter progression-free survival in comparison to normal weight 
patients. Others have demonstrated a similar correlation between overweight 
status and a decreased chance of achieving pCR with neoadjuvant chemotherapy 
(129-130). These results are supported by reports that obesity is associated with 
a worse breast cancer outcome, including lower disease-free survival and overall 
survival, for all breast cancer subtypes treated with taxane agents (164-165) and 
specifically for triple-negative breast cancer (12).  
In the current study, we have demonstrated that obesity-induced 
chemotherapy resistance can be modeled in cell culture by growing triple-negative 
breast cancer cells in serum from breast cancer patients that has been pooled by 
BMI category. The chemotherapy drug docetaxel, a taxane agent, was less 
effective in its inhibition of cell viability when the cells were cultured in obese versus 
normal weight patient sera. Possible mechanisms mediating this effect have been 
explored, with preliminary data indicating that upregulation of the Akt/mTOR 
pathway by obesity-associated circulating factors may be the key mediator. Given 
that more than a third of adult women in the United States are currently obese (17), 
a greater understanding of this mechanism is imperative to improving breast 
cancer outcomes. 
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7.2 Materials and Methods 
7.2.1 Serum samples 
Serum was collected from postmenopausal breast cancer patients under an 
Institutional Review Board (IRB) approved biorepository collection protocol at the 
Cancer Therapy and Research Center of the University of Texas Health Science 
Center at San Antonio (UTHSCSA).  The collection and use of these biological 
samples was approved by the IRB of UTHSCSA (HSC20070684H) and conducted 
in accordance with the Declaration of Helsinki and good clinical practice.  Informed 
consent was obtained prior to participation, and all samples and data were 
deidentified prior to release to maintain patient confidentiality.  Serum was pooled 
according to the BMI category of the patient (normal weight (N): 18.5-24.9 kg/m2; 
obese (OB): ≥30 kg/m2).   
7.2.2 Cell lines and Reagents 
Triple-negative MDA-MB-231 breast cancer cells (ATCC) were maintained in 
IMEM (GIBCO Life Technologies) supplemented with 10% fetal bovine serum 
(FBS).  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT 
reagent) was purchased from Sigma.  The drug treatments used in this study, 
which include docetaxel, celecoxib, and rapamycin, were also obtained from 
Sigma.  The primary antibodies for Bcl-2 and actin were purchased from Santa 
Cruz Biotechnology, Inc. (Dallas, TX).   
7.2.3 MTT Assay 
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MDA-MB-231 cells were seeded in IMEM supplemented with 10% FBS at a 
density of 5x103 in 96 well plates.  After 24 hours of growth in the 10% FBS media, 
the cells were exposed to serum-free media (SF), 2% FBS, 2% OB, or 2% N sera 
(all sera was diluted in SF), with or without the addition of docetaxel (25 nM), for 
24, 48, 72, or 96 hours.  MTT reagent in PBS (5 mg/ml) was then added to each 
well to a final concentration of 0.5 mg/ml.  After two hours of incubation at 37°C, 
the media was removed and 50 ul DMSO added to each well to lyse the cells.  
Absorbance was read at 570 nm on a FLUOstar Omega Spectrometer (BMG 
Labtech, Offenberg, Germany).  This process was also done for an untreated plate 
of cells at the time the other plates were treated in order to establish a baseline 
absorbance value. Relative cell viability for each treatment condition was 
calculated by dividing the absorbance values for a given treatment at the different 
time points by the baseline absorbance value. Percent inhibition of cell viability 
achieved with docetaxel treatment of cells grown in each of the three sera 
conditions was also calculated for each time point. This experiment was repeated 
with celecoxib (30 uM) or rapamycin (10 nM) treatment, alone or in combination 
with docetaxel, for a 96 hour period only, and percent inhibition with each drug or 
drug combination under the different sera conditions was calculated.   
7.2.4 Quantitative RT-PCR   
Macrophage PTGS2 (COX-2) mRNA levels were measured following a six-hour 
serum-starvation period and a 24-hour exposure to a 2% concentration of obese 
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or normal weight pooled patient sera in SF. Total RNA was isolated using TRIzol 
reagent (Invitrogen) and reverse transcribed with Promega’s ImProm II Reverse 
Transcription System. The primer sequences are as follows: PTGS2: forward, 5’-
CCCTTGGGTGTCAAAGGTAA-3’; reverse, 5’-GCCCTCGCTTATGATCT GTC-3’; 
The manufacturer’s recommended cycling conditions for the QuantiFast SYBR 
Green PCR kit (Qiagen) were used. Data shown represents the average of at least 
three independent experiments.    
7.2.5 Western Blot Analysis 
The cells were grown to 50% confluence in IMEM supplemented with 10% 
FBS, then the growth medium was aspirated, the wells were washed, and the 
medium replaced with SF overnight.  After overnight serum-starvation to minimize 
the effect of growth factors and hormones in the growth medium, the cells were 
either left in SF or 2% FBS, OB or N patient sera was added directly to the 
overnight SF. The cells were incubated in these conditions for 72 or 96 hours. 
Laemli lysis buffer was used for protein extraction.  Protein content of the lysates 
was measured using the BCA Protein Assay kit from Thermo Scientific Pierce 
(Rockford, IL).  Images were acquired using a Syngene G:BOX Chemi (Frederick, 
MD).  
4.2.8 Statistical analysis 
Differences between cells exposed to two different experimental conditions 
were measured using Student’s t test. Two-way ANOVA was used to analyze 
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differences in experiments with two independent variables. A p value of <0.05 was 
considered significant. 
  
7.3 Results 
7.3.1 Obesity-associated circulating factors induce docetaxel resistance 
To examine the impact of obesity on breast cancer cell response to the 
chemotherapeutic agent docetaxel, we utilized an in vitro model of obesity in which 
MDA-MB-231 cells, a triple-negative breast cancer cell line, were exposed to sera 
from breast cancer patients that had been pooled by BMI category (obese (OB): 
≥30 kg/m2; normal weight (N): 18.5-24.9 kg/m2). During incubation in SFM or 2% 
FBS, OB or N sera in SFM, the cells were treated with a vehicle or docetaxel. After 
a 72 hour incubation in N sera, the viability of cells exposed to the vehicle was 
significantly higher (p<0.05) than those treated with docetaxel. This difference also 
approached significance (p=0.01) at the 96 hour time point, and docetaxel 
significantly suppressed (p<0.05) the viability of cells grown in FBS at both time 
points. In contrast, docetaxel did not significantly inhibit the viability of cells grown 
in OB sera at any time point, suggesting that obesity-associated circulating factors 
may promote resistance to docetaxel treatment (Figure 7.1a). This conclusion is 
supported by the fact that there is a significant difference in the percent inhibition 
of cell viability achieved by docetaxel treatment of MDA-MB-231 cells grown for 96 
hours in OB sera versus FBS or N sera (Figure 7.1b). 
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Figure 7.1 Obesity-associated circulating factors induce docetaxel 
resistance. The impact of obese (OB) versus normal weight (N) patient sera 
exposure on MDA-MB-231 cell response to docetaxel was measured via MTT 
assay assessment of cell viability. Serum-free media (SF) and fetal bovine sera 
(FBS) were utilized as controls. (a) Relative MDA-MB-231 cell viability following a 
24, 48, 72, or 96 hour exposure to SF, FBS, OB, or N sera in the presence of a 
vehicle or docetaxel (D). (b) Percent inhibition of MDA-MB-231 cell viability 
achieved by docetaxel treatment while the cells were grown in FBS, OB, or N sera 
for 24, 48, 72, or 96 hours. *Indicates a significant difference from each other; 
different letters indicate significant differences, p<0.05.  
 
7.3.2 Obesity-induced resistance to docetaxel is not mediated by COX-2 or 
Bcl-2 
Resistance to chemotherapy has previously been shown to be mediated by 
upregulation of COX-2 and Bcl-2 signaling (166-174). Consequently, we next 
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examined whether either of these pathways may be responsible for the obesity-
induced docetaxel resistance we observed. To assess whether COX-2 may be 
playing a role in this effect, we first measured the impact of OB versus N sera 
exposure on COX-2 expression in MDA-MB-231 cells. A 24 hour incubation in OB 
sera resulted in COX-2 mRNA levels that were two-fold (p<0.05) the level seen in 
cells grown in N sera (Figure 7.2a). We next inhibited COX-2 activity with celecoxib 
during a 96 hour sera exposure, with a vehicle or docetaxel treatment, to see if the 
drug combination could resolve the resistance and produce an additive or 
synergistic effect. We found that the celecoxib plus docetaxel combination did not 
result in a greater suppression of cell viability in comparison to either drug plus 
vehicle for any of the three sera conditions, indicating that COX-2 is not 
responsible for mediating obesity-induced docetaxel resistance (Figure 7.2b). To 
measure whether exposure to OB versus N sera increases MDA-MB-231 cell Bcl-
2 expression, which would suggest that this protein could be involved in promoting 
obesity-associated docetaxel resistance, we utilized western blotting. Incubation 
in 2% OB sera for 72 and 96 hours did not stimulate greater Bcl-2 expression in 
comparison to N sera (Figure 7.2c). Consequently, we did not pursue any further 
investigation of this pathway.  
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Figure 7.2 Obesity-induced resistance to docetaxel is not mediated by COX-
2 or Bcl-2. (a) The effects of obese (OB) versus normal weight (N) sera exposure 
on MDA-MB-231 cell COX-2 expression were measured by qPCR. (b) The impact 
of COX-2 inhibition using celecoxib (C) on response to docetaxel (D) in MDA-MB-
231 cells grown for 96 hours in the presence of 2% fetal bovine sera (FBS), OB, 
or N sera was assessed by MTT measurement of cell viability. (c) Bcl-2 protein 
expression following a 72 or 96 hour exposure to serum-free media (SF) or 2% 
FBS, OB, or N sera was measured by western blot. *, p<0.05 
 
7.3.3 The Akt/mTOR pathway is a potential mediator of obesity-induced 
docetaxel resistance in triple-negative breast cancer  
 Several researchers have demonstrated that increased Akt/mTOR 
signaling confers resistance to chemotherapeutic agents, including docetaxel and 
other taxane agents (175-178).  Numerous obesity-associated circulating factors, 
including interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1), can activate 
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the Akt-mTOR pathway (34, 38-39, 68-69), and we have shown that exposure to 
OB patient sera promotes Akt activation in the ER positive MCF-7 and T47D cells 
lines (Figure 5.2a-d). Consequently, we next utilized the mTOR inhibitor rapamycin 
to examine whether Akt/mTOR signaling may be mediating the observed obesity-
induced docetaxel resistance. Preliminary data indicate that a combined docetaxel 
plus rapamycin treatment synergistically inhibits the viability of MDA-MB-231 cells 
grown in OB patient sera. That is, the combined treatment resulted in a 61% 
decrease in cell viability, while docetaxel and rapamycin plus vehicle suppressed 
cell viability by only 34% and 11%, respectively. The drug combination produced 
an additive, but not synergistic, effect in cells cultured in N sera. Unfortunately, 
there was no difference in the effect of docetaxel alone on the viability of cells 
grown in OB versus N sera in this preliminary experiment. However, our results 
suggest that Akt/mTOR signaling may be mediating the previously observed obese 
sera-induced docetaxel resistance.  
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Figure 7.3 Akt/mTOR may mediate obesity-induced docetaxel resistance in 
triple-negative breast cancer. Percent inhibition of MDA-MB-231 cell viability 
was measured by MTT assay. Cells were exposed to 2% fetal bovine sera (FBS, 
used as a control), obese (OB), or normal weight (N) sera for 96 hours and treated 
with a vehicle, docetaxel (D), rapamycin (R), or a combination of the two drugs 
(D+R). 
 
7.4 Discussion 
Docetaxel is one of the most frequently prescribed chemotherapy drugs for 
the treatment of invasive breast cancer. This cytotoxic agent, like other members 
of the taxane family of drugs, triggers cell apoptosis by preventing cell cycle 
progression via impairment of the centrosome during mitosis. More specifically, it 
stabilizes the microtubules, causing the cells to be frozen in metaphase (179). 
Several studies have demonstrated that obesity is associated with a reduced 
response rate to chemotherapy drugs, including taxanes, leading to a worse 
disease outcome (12, 128-130, 164-165). However, while there has been ample 
research investigating the mechanisms mediating general chemotherapy 
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resistance, little attention has been paid to how obesity may specifically reduce 
patients’ chemotherapy response rate.  
The study described here is still ongoing, but we have shown that exposure 
to sera from obese versus normal weight breast cancer patients induces docetaxel 
resistance in a triple-negative breast cancer cell line, mimicking the effects of 
obesity in vivo. We have explored three possible mechanisms for this effect: 
upregulation of COX-2, Bcl-2, and Akt/mTOR signaling. While obese patient sera 
exposure did increase MDA-MB-231 cell COX-2 expression, suppression of COX-
2 activity with celecoxib did not improve docetaxel response in cells grown in obese 
patient sera. Studies have previously linked increased COX-2 expression with a 
reduced response to various chemotherapies, including taxanes, and a worse 
disease outcome in breast, ovarian, and cervical cancer patients (167-170). Some 
researchers have attributed this association to COX-2-mediated enhancement of 
the MDR1 gene and its product, p-glycoprotein, which actively pumps substrates 
like chemotherapy drugs out of cells. Consequently, overexpression of MDR1 can 
lead to multi-drug resistance (167-168). However, despite the upregulation of 
MDA-MB-231 cell COX-2 expression with obese patient sera exposure, this 
mechanism does not appear to be mediating the obesity-associated docetaxel 
resistance seen here. Neither is Bcl-2, as obese patient sera does not modulate 
its expression in MDA-MB-231 cells. Overexpression of Bcl-2 can block taxane-
induced apoptosis, resulting in resistance to these drugs, and Bcl-2 expression 
has been correlated with outcome in patients receiving taxanes (172, 174). 
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However, based on the results from our in vitro model, Bcl-2 cannot be mediating 
the effects of the obese patient sera on docetaxel response in the MDA-MB-231 
cells. 
We have previously demonstrated that breast cancer cell Akt activation is 
stimulated by exposure to obese patient sera (99), while pS6K1 levels have been 
shown to predict breast cancer patient response to neoadjuvant chemotherapy 
(175). In addition, mTOR inhibition with rapamycin has been shown to 
synergistically enhance the growth inhibitory effects of taxane treatment on breast 
cancer cells in vitro and in vivo. Researchers have speculated that activated mTOR 
may promote cell survival via its downstream targets, so inhibition of the mTOR 
pathway improves chemotherapy response by allowing apoptosis to proceed (23).  
Consequently, we recently began investigating whether the addition of rapamycin 
to docetaxel treatment would improve the taxane agent’s inhibition of MDA-MB-
231 cell viability. Preliminary data suggests that rapamycin synergistically 
enhances the inhibitory effects of docetaxel on the viability of cells grown in obese 
patient sera. Further experimentation will be necessary to confirm these results 
and explore the mechanism by which mTOR inhibition improves docetaxel 
response in the context of obesity. To demonstrate the biological relevance of our 
findings, it will then be necessary to conduct animal studies assessing whether 
obesity-induced docetaxel resistance occurs in a mouse model of TN breast 
cancer and, if so, does the addition of rapamycin improve docetaxel response. The 
results of these studies could provide highly relevant translational data to inform 
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the development of a more effective chemotherapeutic regimen for obese women 
with triple-negative breast cancer. 
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Chapter 8: The Impact of Obesity on Tumor Incidence and Characteristics 
in the MMTV-Wnt1 Mouse Model of Mammary Carcinogenesis 
 
8.1 Introduction 
Currently, 35.7% of adult women in the United States are obese, defined as 
a body mass index (BMI) of ≥30 kg/m2. Among women aged 40-59 years, the time 
period in which menopause typically occurs, the obesity rate is 38.2% (17). These 
numbers are a significant public health concern given the association between 
both obesity and increasing age and an elevated risk of developing and dying from 
numerous diseases, including breast cancer. A large body of evidence has 
demonstrated that obesity is correlated with an increased risk of breast cancer in 
postmenopausal women (3-5) and enhanced breast cancer progression in both 
pre- and postmenopausal women. Studies have shown that obesity is associated 
with a higher breast cancer recurrence rate and lower disease-free interval (20-
21). In addition, the breast cancer mortality rate escalates with each increase in 
BMI category (19). While obesity has been linked to a worse prognosis in patients 
of all ages and across breast cancer subtypes, the most prominent effects have 
been seen in postmenopausal, estrogen receptor alpha (ER) patients (24). 
The MMTV-Wnt-1 (Wnt-1) transgenic mouse model is predisposed to the 
development of mammary adenocarcinoma. The proto-oncogene Wnt-1 encodes 
a cysteine-rich glycosylated secretory protein that is normally expressed during 
mouse embryonic development but not expressed in the normal mammary gland 
(180). Extensive ductal hyperplasia occurs early in the life of Wnt-1 female mice, 
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and approximately 50% develop mammary tumors by six months of age (181-182). 
The tumors are heterogenous in ER positive/negative status, but exhibit an ER 
negative phenotype (183). In fact, ER positive tumors arising in this model have 
been shown to be refractory to ovariectomy and tamoxifen treatment, suggesting 
that estrogen signaling is unnecessary for tumor growth in Wnt-1 mice, despite the 
presence of ER (184). However, ovariectomy did delay tumor growth in C57BL/6 
mice implanted subcutaneously with syngeneic Wnt-1 mouse mammary tumor 
cells, indicating that these cells may be estrogen-responsive. In addition, diet 
induced obesity (DIO) enhanced tumor growth in this syngeneic mouse model of 
breast cancer, but only in the absence of ovarian hormones (185). While the impact 
of obesity on Wnt-1 tumor progression in ovariectomized mice has been previously 
explored in several studies using this orthotopic transplant model, no one has 
analyzed how obesity affects tumor development and characteristics in the 
spontaneous Wnt-1 mouse model. 
In the current study, we found that DIO enhances tumor incidence and 
growth rate, but does not decrease tumor latency or survival, in ovariectomized 
Wnt-1 mice. When examining possible mechanisms mediating these effects, we 
focused on how DIO impacts ER expression and signaling at multiple time points 
in normal mammary fat pad (MFP) and tumor tissue. In addition, we measured 
ER expression, as estradiol also activates this second ER, and ER signaling can 
counteract the pro-growth effects of ER. The ultimate goal of this study was to 
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improve our understanding of how obesity impacts tumor development and 
characteristics in the spontaneous Wnt-1 mouse model. With this enhanced 
knowledge, we will be better able to move forward with intervention studies 
designed to counteract the negative effects of obesity on postmenopausal breast 
cancer risk and progression. 
 
8.2 Materials and Methods 
8.2.1 Animals and Diets 
 Fifty female MMTV-Wnt-1 (Wnt-1) mice, a transgenic mouse model 
predisposed to the development of mammary carcinoma, were bred. Our Wnt-1 
mouse strain was developed on a pure C57BL/6 background, resulting in a greater 
susceptibility to obesity versus the original mixed background strain. To model the 
postmenopausal state, the mice were ovariectomized at 12 weeks of age.  
Ovariectomized mice exhibit characteristics of the postmenopausal state in human 
females, including decreased levels of circulating estrogen, loss of bone mineral 
density, and cessation of estrous cycles (186). The mice were housed singly and 
allowed to recover for one week following ovariectomy.   
To assess the effects of obesity on tumor development and characteristics 
in this mouse model, the mice were randomized at 13 weeks of age to a diet-
induced obesity (DIO) or control (Con) regimen (n=25 in each group) consisting of 
ad libitum access to a 60% or 10% kcal from fat diet, respectively (D12492 or 
D12450B; Research Diets, Inc, New Brunswick, NJ).  The DIO and Con diets were 
145 
 
stored at -20°C and thawed in aliquots sufficient for 3-4 days to prevent rancidity. 
The mice were further randomized to three diet time groups: 2 months (n=5/diet 
group), 4 months, (n=10/diet group), and 6 months (n=10/diet group) on diet. Body 
weights were measured weekly, and feed intake was measured biweekly. All 
animal protocols were approved by the University of Texas at Austin Institutional 
Animal Care and Use Committee. 
8.2.2 Tumor Assessment and Tissue Collection 
Mice were palpitated for tumors twice a week. Using calipers, the length and 
width of the tumors were measured.  Mice were euthanized when a tumor reached 
a 1.5 cm diameter or, if no tumor developed, following the assigned number of 
months on diet. On the day of sacrifice, the mice were fasted for four to six hours. 
Mice were euthanized using carbon dioxide inhalation followed by cervical 
dislocation. Tumors and MFP were excised, with some of each tissue preserved 
for paraffin embedding and some flash frozen in liquid nitrogen. Lungs and liver 
were also removed and preserved for paraffin embedding in order to assess for 
metastases. Whole blood was collected by cardiac puncture and allowed to clot at 
room temperature for 30 minutes prior to centrifugation at 1000 x g for 10 minutes. 
The serum was removed and stored at -80◦ C for analyses.  After euthanasia, 
carcasses were stored at -20◦ C for future body composition analysis.  
8.2.3 Body Composition Analysis 
Percent body fat was assessed on each mouse carcass by dual-energy X-
ray absorptiometry (DEXA) (GE Lunar PIXImus II, Madison, WI) as described in 
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(187).  The head of each mouse was eliminated from the scan by using the region 
of interest exclusion option provided in the software. 
8.2.4 Quantitative RT-PCR 
 Gene expression in tumor and MFP was assessed by quantitative RT-PCR. 
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcribed 
with Promega’s ImProm II Reverse Transcription System.  The primer sequences 
are as follows: ER: forward, 5’-TGCACCATTGACAAGAACCGGA-3’; reverse, 5’-
AGCACCCATTTCATTTCGGCCT-3’; ER: forward, 5’-GACTGTAGAACGGTG 
TGGTCATCAA-3’; reverse, 5’-CTGTGAGGTAGGAATGCGAAAC-3’; pS2: 
forward, 5’-CCACAATTTATCCTCTCCCG-3’; reverse, 5’-AAGGTGATCTGT 
GTCCTCGC-3’; progesterone receptor: forward, 5’-AGGTGATTCTCTCTGGCT 
CAGG-3’; reverse, 5’-ATGGTCCTTGGAGGTCGTAA-3’; cyclin D1: forward, 5’-
GGGTGGGTTGGAAATGAACT-3’; reverse, 5’-CTTCCTCTCCAAAATGCCAG-3’; 
Bcl-2: forward, 5’-TTCTCTCGTCGCTACCGTCGTGACT-3’; reverse, 5’-AGAGAC 
AGCCAGGAGAAATCAAACA-3’. The manufacturer’s recommended cycling 
conditions for the QuantiFast SYBR Green PCR kit (Qiagen) were used.  
8.2.5 Statistical Analysis 
Values are presented as mean ± standard error of the mean (SEM). Statistical 
analysis of the tumor-free survival curves was conducted using the Mantel-COX 
test. Comparisons between the DIO and control groups were analyzed using 
Student’s t test. Two-way analysis of variance (ANOVA) was used to assess the 
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effects of diet type and time on diet on normal mammary tissue and tumor gene 
expression. A p value of <0.05 was considered significant.   
 
8.3 Results 
8.3.1 Obesity promotes greater tumor incidence and growth rate in Wnt-1 
mice, but did not affect tumor latency or survival 
Among the mice that were not euthanized due to tumor burden prior to the end the 
study, mean body mass was significantly higher (p<0.05) in the DIO versus Con 
group for all diet time groups (Figure 8.1a-c). For all mice, mean body mass (data 
not shown) and body fat percentage (Figure 8.1d) at the time of euthanization was 
also significantly greater (p<0.05) in the DIO versus Con group for all diet time 
groups. There was no difference in tumor latency between the DIO and Con diet 
groups for any of the three diet time points. In both the two-month (2mo) and four-
month (4mo) groups, tumor incidence was higher among the DIO mice. The growth 
rate was faster in DIO mice in the 4mo and 6mo groups, but the differences did not 
reach statistical significance (Table 8.1). There was no statistically significant 
variance in the survival curves of the DIO versus Con groups for any diet time point 
(Figure 8.2) 
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Figure 8.1 DIO diet promotes elevated body mass and body fat percentage 
in Wnt-1 mice. Change in body mass (grams) in Wnt-1 mice over 2 (a), 4 (b), and 
6 (c) months on a high-fat diet-induced obesity (DIO) or low-fat Control diet is 
shown. Significant differences indicated are between DIO and Control mice that 
were not euthanized prior to the end of the diet time point due to tumor burden. (d) 
Percent body fat at the time of euthanization in Wnt-1 mice on a DIO or Control 
(Con) diet for 2, 4 , or 6 months. **, p<0.01; *, p<0.05 in comparison to Control. 
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Table 8.1 Impact of obesity on tumor formation in Wnt-1 mice 
 2 Month 4 Month 6 Month 
DIO Con DIO Con DIO Con 
Tumor 
Incidence 
2 0 5 2 4 4 
Tumor Latency 
in days 
119 
(17.0) 
NA 172 
(18.4) 
182 (7.0) 157 
(24.1) 
168 
(34.8) 
Growth Rate in 
mm/day 
1.75 
(0.39) 
NA 2.19 
(0.51) 
1.16 
(0.09) 
3.93 
(1.43) 
0.75 
(0.09) 
Numbers for Tumor Latency and Growth Rate indicate mean (standard error of the mean). 
DIO (diet-induced obesity), Con (control).  
 
 
 
 
 
Figure 8.2 Obesity does not adversely impact tumor survival in Wnt-1 mice. 
The effect of DIO vs Control diet on survival in Wnt-1 mice receiving diet for 2 (a), 
4 (b), or 6 (c) months. 
 
 
 
c 
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8.3.2 Obesity is associated with higher Wnt-1 mouse tumor ER expression, 
but not ER activity 
 After menopause and the cessation of ovarian estrogen synthesis, the 
primary site of estrogen production becomes the adipose tissue, where the 
aromatase enzyme catalyzes the conversion of testosterone to estradiol (25-27). 
Due to an abundance of this aromatase-expressing tissue, obesity is associated 
with increased circulating levels of estradiol in postmenopausal women (28). It has 
also been correlated with higher mammary tissue aromatase expression (41-42). 
Given that DIO enhanced tumor incidence and growth rate in our Wnt-1 mice, we 
next examined whether these effects may be mediated by an obesity-induced 
increase in tumor ER expression and/or activity. Obesity resulted in 2.27-fold 
higher (p<0.05) tumor ER expression (Figure 8.3a). There was a trend towards 
higher ER levels specifically in the six month (6mo) DIO group, but this variance 
did not reach statistical significance (Figure 8.3b). There was no difference 
between DIO and Con in tumor expression levels of four ER target genes, 
including pS2, PR, cyclin D1, and Bcl-2 (Figure 8.3c). Stratifying the data by diet 
and diet time point groups did not change this result or reveal any clear trend in 
the expression of the four genes (data not shown). 
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Figure 8.3 Diet-induced obesity promotes elevated tumor ER expression 
levels in Wnt-1 mice. (a) ER expression in the tumors of Wnt-1 mice maintained 
on a high-fat diet-induced obesity (DIO) or low-fat Control (Con) diet. (b) Wnt-1 
mouse tumor ER expression, stratified by diet (DIO or Con) and months on diet 
(2mo, 4mo, or 6mo). (c) Tumor expression of four ER target genes (pS2, 
progesterone receptor (PR), Cyclin D1, and Bcl-2) in Wnt-1 mice maintained on 
the DIO or Con diet. *, p<0.05  
 
8.3.3 Wnt-1 mouse mammary fat pad (MFP) ER expression and activity 
decrease over time and have variable associations with obesity and tumor 
development 
While obesity did not appear to be promoting greater tumor ER activity in the 
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promoting greater tumor incidence. Consequently, we next assessed the impact 
of diet-induced obesity on ER expression and activity in Wnt-1 mouse MFP. At 
each diet time point, levels of ER expression were similar between the DIO and 
Con groups, but they clearly decreased over time in mice on both diets. In mice 
receiving the DIO diet, there was a 71% decrease (p<0.05) between the 2mo and 
6mo groups, while ER expression decreased by 65% (p<0.05) in the Con group 
(Figure 8.4a). In the 2mo DIO group, there was a trend towards higher 
ERexpression in the mice that developed a tumor, but the 2mo Con group had 
zero tumor incidence while also having relatively high ER expression (Figure 
8.4b). The expression of pS2, an ER target gene, also seemed to decrease over 
time, but only for the DIO group. In addition, expression was highest in the 2mo 
DIO group, but not statistically different from the levels in the other groups (Figure 
8.4c). When we stratified the data further by tumor incidence, pS2 expression was 
greatest in the 2mo DIO with tumor group, and may be higher among the Con mice 
that developed tumors (Figure 8.4d). Finally, the expression of another ER target 
gene, PR, was highest in the 2mo Con group and appeared to decrease over time, 
with levels significantly lower at 6mo versus 2mo for the Con group (Figure 8.4e). 
In the Con group, higher PR expression was associated with a lack of tumor 
development, though the differences between groups were not statistically 
significant (Figure 8.4f). There was no clear pattern of PR expression in the DIO 
group by time point or tumor incidence. 
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Figure 8.4 MFP ER expression and activity in Wnt-1 mice decreases over 
time. ER (a), pS2 (c), and PR (e) expression in the MFP of Wnt-1 mice 
maintained on a high-fat diet-induced obesity (DIO) diet or low-fat Control (Con) 
diet for different time periods (2mo, 4mo, or 6mo). Data from a, c, and e was further 
stratified by tumor incidence (b, d, f). Mice were classified as tumor-bearing 
(Tumor) or lacking any tumor formation (None) during their prescribed time on 
experimental diet. Different letters indicate significant differences, p<0.05.  
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8.3.4 ER expression decreases over time in Wnt-1 mouse MFP and is 
associated with lower tumor incidence in lean mice 
As there was no clear association between MFP ER expression or activity and 
obesity-induced tumor incidence in the Wnt-1 mice, we next examined whether 
tumor or MFP ER expression or the ratio of ER/ER may be playing a role in 
the effects of obesity in this model. ER is typically considered to be anti-
proliferative and protective against tumor formation (142-145, 149-152). Obesity 
had no effect on tumor ER levels (Figure 8.5a), and this did not change when the 
data was further stratified by diet time point (data not shown). The tumor ER:ER 
expression level ratio was over two-fold higher in the DIO versus Con group 
(Figure 8.5b), but this was entirely due to the difference in ER expression 
between the two groups (Figure 8.3a). When the data was stratified by diet time 
point, the ER:ER also largely followed the same pattern as ER expression 
(data not shown). Intriguingly, ER expression in the MFP of the 2mo DIO Wnt-1 
mice was 3.5-fold greater (p<0.05) than 2mo Con mice. In both the DIO and Con 
groups, ER expression decreased over time, and there was no significant 
difference between the two groups at the 4mo and 6mo time points (Figure 8.6a). 
ER expression in the DIO mice did not vary by tumor incidence within the three 
time point groups, but there was a non-significant trend towards higher ER 
expression in the 2mo and 4mo Con mice that did not develop tumors (Figure 
8.6b). The ER:ER expression level ratio in MFP increased over time for both the 
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DIO and Con diet groups. This was largely due to the steep decline in ER levels 
over time, as ER also decreases with time but to a smaller degree. At the 4mo 
and 6mo time points, the ratio in the DIO group was higher in comparison to Con, 
which could contribute to tumor development in the DIO mice (Figure 8.6c). 
However, when we stratified the data by tumor incidence, the ER:ER ratio in the 
DIO tumor bearing mice was greater only in the 6mo group (Figure 8.6d). 
 
Figure 8.5 Diet-induced obesity does not modulate tumor ER expression in 
Wnt-1 mice. (a) ER expression in tumors from Wnt-1 mice maintained on a high-
fat diet-induced obesity (DIO) or low-fat Control (Con) diet. (b) The ratio of ER to 
ER expression in tumors from Wnt-1 mice fed a DIO or Con diet.  
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Figure 8.6 Obesity promotes elevated early MFP ER expression and a high 
MFP ER:ER ratio is associated with increased late tumor development in 
DIO mice. (a) ER expression in the mammary fat pad (MFP) of Wnt-1 mice 
receiving a high-fat diet-induced obesity (DIO) or low-fat Control (Con) diet for one 
of three time periods (2mo, 4mo, or 6mo). (b) Data from (a) further stratified by 
tumor incidence. Mice were classified as tumor-bearing (Tumor) or lacking any 
tumor formation (None) during their prescribed time on experimental diet.  (c) Ratio 
of ER to ER expression in the MFP of Wnt-1 mice maintained on the DIO or Con 
diet for the three different time points. (d) Data from (c) further stratified by tumor 
incidence as described above. Different letters indicate significant differences, 
p<0.05.  
 
8.4 Discussion 
The majority of breast cancer patients, particularly in the postmenopausal 
population, have ER positive tumors. These tumors tend to be less aggressive 
and such patients generally have a better prognosis in comparison to those lacking 
ER (13-14). However, there is still a subset of patients that have an intrinsic or 
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acquired resistance to endocrine therapies targeting estrogen signaling due to a 
number of factors, including obesity, and this negatively affects their prognosis (48-
49, 54-55). Consequently, it is imperative that we develop animal and cell culture 
models of ER positive breast cancer that can be used to examine how factors 
like obesity promote a more aggressive and drug-resistant disease in these 
patients. 
 The MMTV-Wnt-1 transgenic murine model of mammary carcinogenesis 
develops tumors that are heterogenous in their ER status (183) and is thus not 
the ideal model for the study of ER positive disease. However, there are very few 
widely available mouse models that develop ER positive tumors. Other ER 
positive models also tend to have a relatively lower tumor incidence and/or longer 
tumor latency (188), making studies more expensive and time-consuming. For 
these reasons we chose to examine the impact of obesity on ER positive tumor 
development and characteristics in the Wnt-1 model. To our knowledge, this is the 
first study to investigate the effects of obesity on the spontaneous Wnt-1 model. 
We found that obesity promoted an increase in tumor incidence and growth rate, 
but no decrease in tumor latency or survival. Previous studies have assessed the 
effects of obesity on Wnt-1 tumor growth and characteristics, but they have used 
an orthotopic transplant model in which cells isolated from a Wnt-1 tumor were 
subcutaneously injected into mouse MFPs. The results from these studies differ 
slightly from our findings. While they demonstrated a similar increase in growth 
rate with obesity (123, 185, 189-190), two also reported a reduction in tumor 
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latency (123, 189). This suggests that there may be differences in how the 
spontaneous model responds to obesity, perhaps due to the heterogeneity of the 
tumors that develop in this model in comparison to those that arise from orthotopic 
injection of cells derived from a single Wnt-1 tumor.  
Because we were primarily interested in improving our understanding of 
how obesity promotes postmenopausal, ER positive tumor risk and progression, 
we initially focused on the impact of obesity on ER and ER expression and ER 
signaling in the Wnt-1 tumor and MFP tissue. Intriguingly, we found that obesity 
was associated with increased tumor ER expression, but not ER activity. We 
actually expected to find the opposite result, given that obesity is known to promote 
greater estrogen production both systematically and locally in the breast via an 
increase in adipose tissue aromatase expression in humans (25-27, 41-42). These 
results are also in contrast with a previous report that obesity suppresses tumor 
ER expression in orthotopically injected Wnt-1 cells (189). However, in addition 
to the differences in the animal model methodology used, the study by Ford et al 
(189) measured ER expression by immunohistochemistry (IHC), while we used 
qPCR. IHC is the more accepted method for examination of tumor ER levels, and 
we plan to measure tumor and MFP ER and ER expression by IHC in the future 
to validate our qPCR results. Using qPCR, we found no difference between the 
DIO and Con groups in tumor ER expression. 
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We next investigated whether obesity may be modulating ER expression 
and activity as well as ER expression in the Wnt-1 mouse MFP, as this could play 
a role in the observed obesity-induced increase in tumor incidence. There was a 
trend towards greater tumor incidence with increased MFP pS2 expression (a 
measure of ER activity) in the 2mo DIO group, which had the highest pS2 
expression overall. However, pS2 did not seem to correlate with tumor incidence 
in the other groups, particularly at the 6mo time point, suggesting that ER activity 
may promote early but not later tumor growth. PR expression, typically used as 
another measure of ER activity, was actually higher in the Con group and seemed 
to be associated with reduced incidence of early tumors. The literature regarding 
the impact of progesterone on postmenopausal breast cancer risk is mixed, with 
some studies indicating no effect and others suggesting an increase in risk (191-
194).  However, we did not find any studies supporting a protective effect of 
increased PR expression.  
While there were no clear trends in the MFP expression of ERbetween 
diet groups, the 2mo DIO group had significantly greater MFP ER expression in 
comparison to all other groups. MFP ER expression decreased precipitously in 
the DIO mice at later time points, though, and did not correlate with tumor 
development in any of the DIO groups. In contrast, there was a trend towards a 
protective effect with higher MFP ER expression in the 2mo and 4mo Con groups. 
This suggests that obesity may confer resistance to the protective effects of ER 
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expression. Since ER expression is often considered in the context of ER levels 
due to their opposing effects on cell proliferation and other tumor-promoting factors 
(132-133, 138, 140-146), we also calculated the ER:ER ratios for each group.  
The 6mo DIO group, followed by the 6mo Con group, had the highest ER:ER 
ratios, likely due to the very low ER levels found in these groups. When stratified 
by tumor incidence, a higher ratio was associated with tumor incidence in the 6mo 
DIO group and 4mo Con group. These results suggest that obesity may promote 
a higher ER:ER ratio that contributes to increased late tumor incidence. 
However, the 6mo time point was the only one at which the DIO group did not have 
a greater tumor incidence in comparison to Con, making the biological relevance 
of ER and the ER:ER ratio in this model questionable. 
In sum, ER activity and ER expression do not appear to be playing a role 
in the obesity-induced elevation in tumor growth rate in the Wnt-1 model.  An 
increase in MFP ER activity may be contributing to the obesity-associated 
increase in tumor incidence, though. Obesity may also be somehow conferring 
resistance to the protective effects of MFP ER expression. Further 
experimentation will be necessary to provide a better characterization of the 
mechanisms by which obesity promotes tumor incidence and growth in this model. 
This will include measurement of ER and ER expression by IHC and 
examination of additional factors known to mediate the pro-carcinogenic effects of 
obesity, including growth factor and inflammatory cytokine signaling pathways. 
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Others have demonstrated that mTOR signaling clearly plays a role in obesity’s 
promotion of tumor growth in the Wnt-1 orthotopic injection model (123, 190). In 
addition, characterization of cells isolated from Wnt-1 tumors have demonstrated 
that these tumors contain both basal-like and claudin-low subtype cell populations 
(195). Given that claudin-low breast cancer cells are known to be more aggressive 
than the other breast cancer subtypes, obesity could also be promoting tumor 
growth in the Wnt-1 model via an escalation in the claudin-low cell population. 
Consequently, we will also be measuring the tumors for markers of these subtypes. 
With an enhanced understanding of the mechanisms by which obesity promotes 
tumor incidence and growth in the Wnt-1 spontaneous model, we hope to be better 
equipped to design future intervention studies that target the identified signaling 
pathways to prevent and improve the treatment of breast cancer in obese 
postmenopausal women. 
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Chapter 9: Concluding Remarks 
 
9.1 Conclusions 
Over the past 30-40 years, a growing epidemic of obesity that began in the 
United States and other Western countries has now spread across the globe (18).  
In the United States, over a third of the adult population is now obese, defined as 
a body mass index (BMI) of ≥30 kg/m2 (17). The rise in obesity rates has had 
alarming effects on public health, as the metabolic abnormalities that accompany 
excess adiposity can increase individuals’ risk of and mortality from numerous 
diseases, including breast cancer. Obesity has been shown to enhance the risk of 
postmenopausal breast cancer and also promote breast cancer progression in 
women of all ages (3-5, 19-21). However, an elevated BMI is most strongly 
associated with a worse prognosis in postmenopausal, estrogen receptor alpha 
(ER) positive breast cancer (24). Obese women in this patient population do not 
respond as well to aromatase inhibitors (48-49), the standard endocrine therapy 
for postmenopausal patients. Consequently, the studies detailed here, which 
examine the mechanisms by which obesity promotes breast cancer progression, 
have primarily focused on investigating the role of increased aromatase expression 
in the link between obesity and postmenopausal, ER positive breast cancer. Our 
goal has been to identify relevant signaling pathways that may be targeted in order 
to develop a more effective chemotherapeutic regimen for this patient population. 
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Building on previous studies from Dannenberg et al that demonstrated a 
correlation between obesity, elevated breast tissue inflammation, and higher levels 
of aromatase expression in the breast (41-43), we utilized an in vitro model of 
obesity to determine whether this local aromatase expression could be contributing 
to obesity-associated breast cancer progression via its production of excess 
estrogen. To model obesity in vitro, we used serum collected from postmenopausal 
breast cancer patients and pooled by BMI category (normal weight: 18.5-24.9 
kg/m2; obese: ≥30 kg/m2). Breast cancer cells exposed directly to the obese versus 
normal weight patient sera had higher aromatase expression levels as well as ER 
activity and viability in the presence of testosterone, the substrate for aromatase. 
These effects were mediated by an increase in Akt and MAPK pathway signaling. 
Exposure to the obese patient serum also caused pre-adipocytes to produce more 
interleukin 6 (IL-6), which led to greater breast cancer cell aromatase expression, 
ER activity, and viability. We did not pursue further investigation of obesity’s 
impact on breast cancer cell aromatase expression, though, because we found 
that the pre-adipocytes themselves were actually a substantially greater source of 
aromatase expression. Given that pre-adipocytes are found in abundance in the 
breast tumor microenvironment and tumor-adjacent tissue (28), exploration of how 
obesity impacts pre-adipocyte aromatase expression seemed to be the more 
biologically relevant question. 
Direct exposure to obese versus normal weight serum had no differential 
effect on pre-adipocyte aromatase expression. However, macrophages and breast 
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cancer cells both express cyclooxygenase 2 (COX-2), which catalyzes the 
production of the aromatase-stimulating eicosanoid prostaglandin E2 (PGE2) from 
arachidonic acid (30, 43). Consequently, we next conducted a retrospective 
analysis of the medical records of ER positive breast cancer patients that 
received endocrine therapy to determine whether recurrence rates differed 
according to patient use of COX-2-targeting non-steroidal anti-inflammatory drugs 
(NSAIDs). We found that daily NSAID use decreased recurrence by approximately 
50% and delayed time to recurrence by over two years. The fact that the vast 
majority of the patients in this pilot study were overweight or obese and had a 
higher risk of recurrence suggested that perhaps the strong effect of NSAID use in 
this patient population was due to the predominance of excess adiposity. 
Unfortunately, we did not have adequate power in this study to test this hypothesis.  
Based on these results and other researchers’ (41-43), we next examined 
whether obese patient sera exposure enhanced macrophage and breast cancer 
cell PGE2 production. We found that obese patient sera did increase these cells’ 
COX-2 expression and PGE2 secretion, leading to greater pre-adipocyte 
aromatase expression and estradiol production. This estradiol stimulated greater 
breast cancer cell ER activity and proliferation, suggesting that targeting 
macrophage and breast cancer cell COX-2 expression and PGE2 production may 
improve obese patients’ response to aromatase inhibitor therapy. 
Another possible mechanism mediating obesity-induced aromatase inhibitor 
resistance and breast cancer progression in postmenopausal women is an 
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enhancement of the cross-talk between cytoplasmic ER and the PI3K/Akt and 
MAPK signaling pathways. This cross-talk has been associated with resistance to 
endocrine therapy (54-55), and obesity is typically accompanied by increased 
circulating insulin, insulin-like growth factor 1 (IGF-1), leptin, and inflammatory 
cytokines that can all activate the PI3K/Akt and MAPK pathways (34, 38-39. 65, 
68-70). We found that breast cancer cells grown in obese versus normal weight 
patient sera demonstrated higher cell viability and growth, effects mediated by 
PI3K/Akt, MAPK, and nongenomic ER signaling. Combined inhibition of PI3K and 
ER produced the greatest reduction in obesity-induced breast cancer cell viability 
and growth, while ER inhibition significantly reduced the Akt activation stimulated 
by obese patient sera exposure. These results suggest that obesity-associated 
circulating factors may promote postmenopausal breast cancer progression, and 
perhaps aromatase inhibitor resistance, by enhancing PI3K/Akt and MAPK 
signaling and their cross-talk with cytoplasmic ER. 
The last three studies described here are still ongoing, but have produced 
promising initial results. We assessed the effects of obesity on estrogen receptor 
beta (ER) expression in breast cancer cells because activation of this second ER 
counterbalances the pro-growth effects of ER, and higher ER expression has 
been associated with an improved prognosis (137-146). We have demonstrated 
that exposure to obese versus normal weight patient sera suppresses ER 
expression in HER2 overexpressing breast cancer cells, but not in cells 
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representative of the other three breast cancer subtypes. Further experimentation 
revealed that the obese patient sera’s effects on ER expression are mediated by 
HER2 signaling. In agreement with clinical data indicating that obesity is 
associated with a reduced response to chemotherapy treatment (128-130, 164-
165), we have also shown that obese patient sera exposure confers resistance to 
docetaxel treatment in triple-negative breast cancer cells. Preliminary data 
suggests that this effect may be mediated by activation of the Akt/mTOR pathway. 
Finally, we have initiated an analysis of obesity’s effects on tumor development 
and characteristics in the MMTV-Wnt-1 transgenic mouse model, which is 
predisposed to the spontaneous development of mammary adenocarcinoma 
(181). Diet-induced obesity promotes tumor incidence and faster tumor growth in 
this model, but no decrease in tumor latency or survival. Assessment of tumor and 
mammary fat pad (MFP) ERexpression and activity as well as ER expression 
suggests that an obesity-induced increase in MFP ER activity could be playing a 
role in promoting tumor incidence. However, ER and ER signaling do not appear 
to be substantial contributors to obesity’s promotion of mammary tumorigenesis in 
this model.  
 
9.2 Future Directions 
 The aromatase-focused studies described here produced some compelling 
results suggesting that obesity may promote postmenopausal, ER positive breast 
cancer progression and aromatase inhibitor resistance via an increase in PGE2-
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induced pre-adipocyte aromatase expression. However, the biological relevance 
of our data remains uncertain without in vivo studies to support these findings. 
Consequently, the next step should be to utilize a transgenic mouse model of 
mammary carcinogenesis to test whether COX-2 inhibition improves response to 
aromatase inhibitor therapy in the context of obesity. Our preliminary data from the 
MMTV-Wnt-1 mouse study suggests that this model is probably not a good choice 
for the study of ER positive breast cancer. Another option is the Pik3caH1047R 
transgenic mouse, which has a conditional knock-in of this common activating 
mutation of the PIK3CA gene that results in 100% penetrance of ER positive 
tumors by approximately 12 months of age (196). Due to the long tumor latency in 
this model, an orthotopic injection model in which cells isolated from one of these 
tumors are subcutaneously injected into the MFP of non-transgenic mice of the 
same background strain could also be utilized. Because we have not previously 
used this mouse model, a pilot study to assess whether obesity promotes tumor 
development and mammary tissue aromatase expression will be necessary prior 
to proceeding with any drug intervention studies. If this proves to be a suitable 
model for further studies, the next step would be to choose the most appropriate 
COX-2 targeting drug. While we employed the selective COX-2 inhibitor celecoxib 
for our in vitro studies, this drug has been linked to an increase in major vascular 
events in humans (197). Thus, an over-the-counter NSAID, like aspirin, or an 
omega-3 fatty acid supplement, which can shift COX-2 activity away from PGE2 
production and towards the production of anti-inflammatory eicosanoids (198), 
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should be used for this study. Based on the animal study results, a pilot clinical 
trial examining the efficacy of this drug combination in obese postmenopausal ER 
positive breast cancer patients could follow. 
 Confirmation of the essential role that we believe increased aromatase 
expression plays in obesity-induced postmenopausal ER positive breast cancer 
progression will also require an animal study. Researchers at the University of 
Texas Health Science Center at San Antonio have developed a Cre-inducible 
aromatase knock-out transgenic mouse. This mouse could be bred with the 
Pik3caH1047R transgenic mouse, then a mouse line with inducible, Cre-dependent 
recombination in adipocytes to ultimately produce a triple-transgenic mouse with 
inducible aromatase knock-out in the adipocytes and a predisposition for ER 
positive mammary carcinogenesis. The impact of diet-induced obesity on tumor 
development in mice with and without the aromatase knock-out induced would 
then be assessed to determine whether aromatase over-expression is an 
important mediator of obesity’s effects. 
 Based on our determination that exposure to obesity-associated circulating 
factors enhances cross-talk between ER and the PI3K/Akt and MAPK signaling 
pathways in breast cancer cells, further investigation into the importance of this 
effect in obesity-induced breast cancer progression is warranted. The focus of 
future studies regarding this effect should be an assessment of the role of PI3K/Akt 
activation and cross-talk with cytoplasmic ER in obesity-related aromatase 
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inhibitor resistance, as inhibition of these two pathways produced the greatest 
suppression of obese patient sera-mediated breast cancer cell viability and growth. 
Such an assessment could best be accomplishment with another animal study in 
which aromatase inhibitor therapy is combined with a PI3K inhibitor in the context 
of diet-induced obesity to determine if this improves aromatase inhibitor response. 
Given its activating PIK3CA mutation, the Pik3caH1047R transgenic mouse model 
would not be a good choice for this study, so another transgenic mouse model of 
ER positive mammary carcinogenesis would have to be utilized. 
 The final three studies described here remain in progress. To complete our 
analysis of the impact of obesity on breast cancer cell ER expression, the 
biological relevance of obesity-induced ER suppression must first be assessed. 
We will transfect the cells with an ER-overexpressing plasmid to prevent this 
suppression, then measure whether the obese patient sera is still able to promote 
greater breast cancer cell viability. If ER suppression does appear to be 
biologically relevant, studies designed to further define the HER2-mediated 
pathway by which obesity inhibits ER expression should be planned. In addition, 
the efficacy of an ER agonist in counteracting the effects of the obese patient 
sera on breast cancer cell viability could be tested. Finally, depending on the 
results of the above in vitro experiments, an in vivo study utilizing the MMTV-neu 
transgenic mouse model of HER2-overexpressing breast cancer could be 
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designed to determine whether an ER agonist can counteract the negative effects 
of obesity on tumor progression in this breast cancer subtype. 
 Our analysis of how obesity promotes resistance to docetaxel treatment in 
triple-negative breast cancer cells should continue by first confirming our finding 
that mTOR inhibition is able to reverse this resistance. If this result holds up, the 
next steps should include an exploration of how obesity confers docetaxel 
resistance and why the addition of the mTOR inhibitor rapamycin results in 
synergistic inhibition of cell viability. One possibility is that obesity is promoting cell 
survival via mTOR activation, so an analysis of the induction of cell apoptosis 
under these different treatment conditions should be conducted. Future studies 
should also include confirmation of these effects in an animal model of triple-
negative breast cancer, like the C3(1)/SV40 T-antigen transgenic mouse model. 
Positive results from an animal study would provide a strong rationale for the 
development of a pilot clinical trial testing a docetaxel/rapamycin combination 
treatment in obese women with triple-negative breast cancer. 
 Finally, our characterization of how obesity impacts tumor development in 
the MMTV-Wnt-1 mouse model will continue with measurement of ER and ER 
expression by IHC and examination of additional factors known to mediate the pro-
carcinogenic effects of obesity, including growth factor and inflammatory cytokine 
signaling pathways. In addition, given that Wnt-1 mouse tumors have been shown 
to contain populations of cells representative of both the basal-like and claudin-low 
breast cancer subtypes (195), we will also examine whether obesity affects tumor 
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expression of the various subtype markers. This will demonstrate whether obesity 
may be promoting tumor growth in the Wnt-1 model via an escalation in the highly 
aggressive claudin-low cell population.  
All of these studies have enhanced our understanding of the mechanisms 
by which obesity promotes breast cancer progression. Hopefully, this improved 
knowledge will lead to the development of future studies in our laboratory and 
others’ that build on the findings reported here in order to achieve the overall goal 
of this project. That goal has been to identify relevant, targetable obesity-induced 
signaling pathways that will inform the design of improved chemotherapeutic 
regimens for the treatment of breast cancer in obese women. 
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